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Thesis Abstract 
The daily transition we take in and out of sleep is ancient and occurs in all known mammals. 
Ancient also is human manipulation of this transition – across cultures there have been herbal 
remedies to prolong wake, shorten latency to sleep and induce a state of reversible 
unconsciousness known as anaesthesia.  While we have discovered specific brain structures 
necessary for maintenance of sleep and wake and protein channels targeted by anaesthetics, 
much still remains unknown. This study aimed to elucidate which neuronal pathways are 
recruited in sleep, wake and anaesthesia by studying the EEG and behaviour of genetically 
manipulated mice. Study of TASK-3 potassium channel knockout mice, which are less 
sensitive to anaesthetics, revealed increased wakefulness, resistance to stress and normal 
sensitivity to wake-promoting compounds. These mice also unexpectedly revealed an 
inability to return to normal temperature after drug-induced hypothermia. Meanwhile, study 
of mice in which the wake-active locus coeruleus (LC) was selectively manipulated using 
adeno-associated viral vectors revealed that LC suppression increases rapid-eye-movement 
sleep. Conversely, selective activation of the LC via designer drug receptors maintained wake 
but paradoxically produced behavioural arrest. Both studies reveal that the neuronal 
mechanisms that control sleep and anaesthesia are complex. Manipulation of crucial channels 
(TASK-3) and crucial regions (LC) change sensitivity to specific anaesthetics and produce 
distinct changes in sleep-wake that cannot be generalized to all anaesthetics or all aspects of 
sleep architecture. Nevertheless, these findings contribute novel insights into individual 
components of the ancient and complex neural circuits that orchestrate sleep, wake and 
anaesthesia. 
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General Introduction 
Rationale and study outline 
Doctors often refer to a patient being put to “sleep” when undergoing anaesthesia and 
indeed these two states of reversible unconsciousness share physiological traits. Both sleep 
and anaesthesia are states of diminished responsiveness to external stimuli and inhibition of 
voluntary movement, the former is actively and cyclically orchestrated by the central nervous 
system while the latter is induced by drugs. Sleep is clearly not identical to anaesthesia nor 
would that be desirable – sensitivity to pain is essential in one and prohibitive in the other, for 
example, but nevertheless their neural substrates may be shared. By dissecting the neural 
mechanisms behind each process and monitoring for overlap, we can not only shed light on 
fundamental aspects of animal behaviour but uncover physiological processes that are 
relevant to the clinic. Understanding the mechanisms behind sleep may bring us closer to 
understanding its function in all living mammals, vital despite the vulnerability to predation 
sleep has incurred through millennia of evolution. We know most of the main molecular 
binding targets of anaesthetics [1] but are still unclear on what network activity these drugs 
set in motion and how this activity may change and switch to different networks as 
anaesthesia deepens. The varied classes of general anaesthetics (halogenated anaesthetics, 
nitric oxide, ketamine, GABAergic drugs such as propofol, etc.) act on different molecular 
targets but all produce reversible unconsciousness. It is still unknown whether a common 
network is activated by all of these and whether this network hijacks those involved in sleep. 
Finally, wakefulness and the quality of wake is becoming increasingly pressing in our 24 
hour society, disorders of sleep-wake often dull cognitive function, affect emotional control 
and motivation so are as much a disorder of wake as of sleep. In order to understand and 
remedy primary and secondary sleep-wake disorders, a three-pronged research approach is 
required: 1) better understanding of the aetiology of sleep-wake disorders, 2) development or 
improved application of sedatives (these may be found by studying anaesthetics) and 3) 
development of cognitive enhancers or wake-promoters.  
Tackling all these questions is beyond the scope of this thesis but I have addressed 
two questions. Firstly, I investigated what the effects of genetically silencing a wake-active 
nucleus in the ascending arousal network, the locus coeruleus (LC), were on sleep 
architecture, behaviour and sensitivity to dexmedetomidine; an anaesthetic used in low doses 
for sedation in intensive care units as well as at higher doses in veterinary, paediatric and 
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adult anaesthesia [2]. Dexmedetomidine has been proposed to chiefly act through silencing 
the LC [3] but since then other regions such as the hypothalamus have been implicated [1, 4] 
so we have chronically silenced the LC to determine its role in dexmedetomidine anaesthesia 
as well as monitoring sleep-wake during normal activity and after sleep deprivation. In 
addition, I introduced designer drug activated receptors into the LC to investigate what effect 
acute activation of the LC would have on behaviour during wakefulness (Chapters 1 and 2). 
Secondly, I investigated whether a tandem two pore potassium channel, TASK-3, found in 
the LC and in a number of sleep-wake regions of the brain and opened by certain anaesthetics 
was also inhibited by wake-promoting compounds and thus involved in a common sleep-
wake switch pathway. The rationale for this hypothesis came from research on TASK-3 
knockout mice and the effects of a novel TASK-3 antagonist on rodents. The TASK-3 
antagonist ‘C23’ causes prolonged wake [5] and several other wake-promoting compounds 
act at receptors coupled to Gq/11 protein, which in turn inhibit TASK-3 [6]. In addition, 
TASK-3 knockout mice exhibit increased wakefulness [7], all of which together suggested 
TASK-3 inhibition or genetic ablation promotes wakefulness while opening promotes 
unconsciousness. I tested a number of wake-promoting compounds on TASK-3 knockout 
mice and wild-type littermates to investigate whether TASK-3 was a necessary common 
target for wake promotion (Chapters 3 and 5). Unexpectedly, whilst recording temperature in 
TASK-3 knockout and wild-type animals, I found that TASK-3 knockout mice were less 
sensitive to stress-induced increases in body temperature and simultaneously that TASK-3 
antagonist C23 produces significant hypothermia, despite also promoting wake. This novel 
role for TASK-3 in temperature regulation is described separately in Chapter 4. 
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Studying sleep and anaesthesia using EEG 
Much of what we understand about the science of sleep in mammals relies on 
recordings of spontaneous brain activity via an electroencephalogram (EEG), first developed 
by psychiatrist Hans Berger in 1924 to detect telepathy, which he was convinced existed 
between him and his sister. Sadly, his electrodes could only pick up brain activity if located 
very near the scalp, disproving the possibility of long-range brain waves but inadvertently 
inventing an invaluable tool for neuroscientists [8]. In human studies, EEG is recorded from 
the scalp using a cap with multiple electrodes, meanwhile in rodent studies of EEG we 
technically record an encephalocorticogram (referred to here as EEG) via steel electrodes 
embedded in the skull and recording from the surface of the brain. Sleep, wake and 
anaesthesia are each accompanied by distinct patterns of spontaneous brain activity that we 
can detect in the EEG. The EEG signatures are so different that most rodent sleep studies rely 
on EEG and muscle tone (electromyogram; EMG) recording alone to determine which 
behavioural state the animal is in, without the need for additional information such as video. 
By the 1960s, human sleep researchers Allan Rechstschaffen and Anthony Kales identified 
and formalised the key EEG/EMG hallmarks of wake and two types of sleep; rapid eye 
movement sleep (REM) and non-rapid eye movement sleep (NREM) [9] that have been 
adapted to score EEG and concurrent EMG recordings in rodents [10]. 
Wake is a characterised by a number of behaviours such as eating, purposeful 
movement and communication and, crucially, it is a state of engagement with the external 
environment. A waking EEG is typically a low amplitude mixture of different frequencies, 
elevated muscle tone and, during locomotion; ‘theta’ range (6-10 Hz) EEG activity 
predominates. Strikingly, we can rapidly transition out of this state if compelled to sleep or 
anaesthetised. Typically, within a minute of a rodent falling asleep  [11], voluntary movement 
is abolished, muscle tone diminishes and the EEG is dominated by high amplitude low 
frequency activity in the ‘delta’ range (1-4 Hz). This slow wave activity state, referred to as 
NREM or slow wave sleep, makes up the majority of the sleeping time of humans and mice 
[12]. Despite a more synchronous low frequency EEG, a lower proportion of theta activity 
persists in NREM in addition to two periodic events; bursts of waxing and waning activity 
(10-13 Hz) activity called spindles and brief low-frequency, high amplitude events called K-
complexes [13]. Meanwhile, the amplitude of the ‘delta’ activity seen in NREM has been 
positively correlated with sleep depth, i.e. higher amplitude delta activity associates with 
diminished arousability [14], and increases with sleep drive so NREM sleep at the beginning 
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of the night is typically higher amplitude than before waking and higher still if sleep 
deprivation preceded it [15]. 
Few mammals sleep in one consolidated period the way that humans do (the slow 
loris joins humans in the short list [16]) most, including rodents, experience multiple cycles 
in and out of sleep but still experience a larger proportion of sleep during a consistent portion 
of the 24 hour cycle, e.g. rodents are predisposed to sleeping more during the day[12]. Within 
the rodent sleep period, delta-dominated NREM switches to REM sleep every 5 to 10 
minutes [12] while in humans, the NREM-REM cycle lasts approximately 90 minutes [11]. 
REM sleep, also called paradoxical sleep, is accompanied by rapid eye movements behind 
closed lids in humans and drastic loss of muscle tone (atonia) but strangely wake-like EEG; a 
mixture of low amplitude mixed frequency activity, predominantly in the theta range.  Vivid 
dreaming is thought to occur during this phase although dreaming occurs throughout sleep 
[11]. While all known mammals experience slow wave NREM sleep, it remains controversial 
whether cetaceans experience REM sleep; dolphins have not been recorded experiencing 
conclusively REM-like activity [17] which may be related to their need to keep moving to 
breathe (incompatible with the muscle atonia that accompanies REM sleep).  
Compared to sleep researchers, anaesthetists have been far less confident in the use of 
EEG as sole predictor of the depth of anaesthesia [18]. Nonetheless, during general 
anaesthesia, the different stages of anaesthetic states managed by clinicians each have their 
own typical EEG activity. Induction or initial sedation appears to resemble the early stages of 
NREM sleep; there is a global shift to lower frequency activity and, in the more spatially 
precise EEG recorded from human patients, alpha range activity (7.5-12.5 Hz) associated 
with closed eyes can be detected near the occipital lobe [19]. Following induction, 
paradoxical neural excitation can follow, accompanied by beta range activity (13-15 Hz), 
irregularity of breathing, loss of affective control and abnormal movements [20]. After this 
paradoxical beta range activity, the global EEG frequency slows back down to delta activity 
and decreases in amplitude [21].Very deep surgical anaesthesia can see the EEG amplitude 
fall to an isoelectric state (an EEG flat line) which is interrupted by periodic bursts of alpha 
and beta activity [19]. Brown et al., describe how deep surgical anaesthesia approximates 
brain stem death; reflexes are depressed, there is no response to nociceptive stimuli, there is 
no apneic drive and cardiorespiratory and thermoregulatory support is required [19]. Indeed, 
without this support very deep anaesthesia can veer into anaesthetic overdose and eventually 
death. Sleep, meanwhile, while characterised by typical reductions in cardiac output and a 
  
16 
 
drop of around one degree Celsius in body temperature, sustains reflexes, nociceptive 
sensitivity and apneic drive and, crucially, responds to a number of cues (homeostatic, 
circadian or arousal cues) that return us back to wakefulness. A key question is therefore 
whether the delta EEG activity experienced under deep sedation/mild anaesthesia and NREM 
sleep share common mechanisms distinct from the processes through which apneic drive, 
pain sensation and anaesthetic reflexes are lost. 
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 Neural mechanisms of sleep and anaesthesia 
An ancient and vital activity, it seems almost inevitable that the sleep-wake 
machinery has multiple components and redundancy in case of insult to the system. Hijacking 
of sleep networks by anaesthesia may therefore initiate network activity through a number of 
components, although dissociation of the cortex from external inputs by deactivation of the 
thalamus appears necessary to induce unconsciousness [1, 22]. In addition to known neural 
networks that switch between wake, NREM or REM, there are additional components that 
help maintain each state and also sleep and wake ‘drivers’, each of which will be briefly 
described. Sleep must be regained if lost; prolonged wakefulness results in increasing sleep 
drive but the external environment experienced during wake (ambient light levels, meal 
times, acute stressors) strongly influence the timing, duration and structure of subsequent 
sleep periods. These two key interacting drivers are described as the ‘homeostatic’ drive to 
sleep as a result of waking/sleep loss (also called Process S) and the ‘circadian’ drive to sleep 
and wake at certain times of the day (also called Process C), e.g. the drive to sleep during the 
light period in nocturnal rodents such as mice. These two drivers work largely in tandem 
while we remain in the same environment and stick to a consistent routine but become 
dysregulated during jet lag or shift work when Process S continues to increase sleep drive 
according to time spent awake but the countering drives for arousal and accompanying 
changes in body temperature and appetite are shifted out of sync by light and behaviour cues 
driving Process C [23].   
While many cell types are now known to possess molecular clocks that maintain 
rhythmic activity, Process C, our circadian rhythm, is orchestrated largely by a tiny sub-
region of the hypothalamus called the suprachiasmatic nucleus (SCN), strongly entrained by 
input from specialised blue light receptors in the eye [24]. Meanwhile, it is still unclear 
whether the homeostatic drive for sleep occurs as a diffuse set of cues like accumulation of 
extracellular products of wake activity (such as adenosine) or local EEG activity [25, 26] or 
whether various cues converge on a specific neuronal subset, mirroring the way that multiple 
circadian cues are processed by the SCN. It is notable that the SCN is not implicated in the 
execution of sleep-wake transitions or state maintenance; loss of SCN leads to a profound 
loss of sleep rhythm but does not abolish sleep or wake or, to my knowledge, drastically 
affect anaesthetic sensitivity. Strikingly, despite the rapid transitions between sleep and wake, 
individual human sleep cycles remain a consistent length and I have repeatedly observed 
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regularly replicable sleep patterns in individual mice, demonstrating tightly regulated neural 
network activity.  
A model for this stable state with rapid transitions based on the last few decades of 
research has been proposed by Clifford Saper [27]. In its most basic version – wakefulness is 
sustained by an ascending arousal network, located in the mesopontine junction, which is 
largely monoaminergic and cholinergic. The ascending arousal network reciprocally inhibits 
NREM-active neurons in and around the ventrolateral preoptic area (VLPO) of the anterior 
hypothalamus, which are largely GABAergic and galaninergic. Through largely unknown 
mechanisms, the VLPO and other nearby sleep structures are gradually disinhibited, at which 
point they inhibit the ascending arousal system and the brain transitions into sleep. During 
NREM sleep, both the cholinergic and monoaminergic ascending arousal networks are 
minimally active due to VLPO inhibition but during REM cholinergic cells become active 
again, driving EEG activity, until monoaminergic cells inhibit them and therefore terminate 
the REM period. A population of orexinergic neurons in the lateral posterior hypothalamus 
innervates the ascending arousal system, including strong connections to the LC, and helps 
maintain wakefulness and inhibit REM, acting as a state stabiliser. Damage to orexinergic 
neurons results in narcolepsy [28]; a condition characterised by sudden attacks of sleep, 
excessive daytime sleepiness, sleep fragmentation and intrusion of a REM-like state (with 
accompanying paralysis) into wakefulness [11]. In addition to the stabilising role of orexin 
neurons, the mutual inhibition of both wake-NREM networks and the REM-on-REM-off 
network mean that once one ‘side’ of the circuit begins to gain an advantage, it rapidly 
silences the other and so achieves a stable state. In this ‘flip-flop’ model of mutual inhibition, 
Saper’s model of the mechanism for sleep and wake consists of prolonged stable states 
interspersed with rapid transitions between them. 
TASK-3 channels, studied here, are expressed in a number of sleep-related regions 
including the LC and the thalamus [29], their opening generally promotes hyperpolarisation 
and so anaesthetics may inactivate arousal nuclei via TASK channels as part of their 
mechanism. This ascending network of arousal-associated wake-active nuclei has been 
identified in the region spanning the rostral pons and the caudal midbrain (also called the 
mesopontine junction) since pioneering work by Moruzzi, Magoun and colleagues in 1949 
[30]. These nuclei comprise monoaminergic cells (located in the noradrenergic LC, the 
serotoninergic dorsal raphe and dopaminergic nuclei adjacent to the dorsal raphe) and 
cholinergic cells (located in the pedunculopontine and laterodorsal tegmental nuclei); 
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together these nuclei project mainly to the forebrain which includes the cerebral hemispheres, 
thalamus and hypothalamus. The monoaminergic cell populations of the mesopontine 
junction, in addition to another group of monoaminergic (histamine) neurons in the posterior 
hypothalamus (tuberomammillary nucleus (TMN)), fire most during wakefulness, reduce 
their firing during NREM sleep and are virtually silent during REM, suggesting their activity 
drives arousal and vigilance. Meanwhile, the cholinergic populations fire most during wake 
and REM, suggesting that their activity drives the cortical activation and higher frequency 
EEG activity that is typical of both states [11]. The ascending arousal system appears to 
strongly influence forebrain arousal and wakefulness but lesioning damage to this system can 
be compensated by structures found in the forebrain itself, particularly in the posterior 
hypothalamus, which includes histaminergic, orexinergic and glutamatergic populations. 
Indeed the posterior hypothalamus was the first seat for wakefulness proposed by Romanian 
psychiatrist Baron Constantin von Economo in the 1920s who noticed this region was 
frequently damaged in encephalitis lethargica sufferers (symptoms of which included 
excessive sleepiness and even coma).  
Baron von Economo studied patients affected by the European influenza epidemic, 
some of which presented with encephalitis lethargica but others of whom were insomniacs. 
In these insomniac patients, the damaged brain regions often included the anterior 
hypothalamus, which he concluded was a region that actively generated sleep. The 
ventrolateral preoptic area (VLPO), located in the anterior hypothalamus, presents a plausible 
candidate for orchestrating sleep. As well as projecting to the ascending arousal system and 
nearby TMN, it also receives reciprocal noradrenergic, serotoninergic, dopaminergic, 
cholinergic projections as well as endorphin projections from the TMN. However, while 
ablation of the VLPO causes insomnia in laboratory animals and humans, it does not fully 
abolish sleep [11, 31], which suggests, much like the wakefulness network, that multiple sites 
are involved in NREM sleep promotion.  
During wake, the monoaminergic and cholinergic nuclei appear to work in concert but 
McCarley and Hobson proposed that in REM their roles become opposed with cholinergic 
cell signalling driving REM until their increased firing eventually activates monoaminergic 
cells, particularly those in the LC, that then fire to terminate the process [32]. Since then, 
additional REM generating regions have been located caudally in the vicinity of the 
originally identified pedunculopontine and laterodorsal tegmentum cholinergic regions [27]; 
in particular the sublaterodorsal nucleus, precoeruleus region and medial parabrachial nucleus 
  
20 
 
(the latter two regions neighbour the LC and thus could have suffered collateral damage in 
older lesioning studies of the role of the LC in sleep). In addition, orexinergic cells in the 
lateral hypothalamus, which strongly innervate the LC, dorsal raphe as well as the TMN, 
appear to stabilise the REM-off state and inhibit atonia. Saper and colleagues suggest that 
monoaminergic tone, such as that coming from the LC, supports muscle tone, and the 
inhibition of LC activity by the cholinergic system during REM or in disorders of the orexin 
system like narcolepsy lead to sporadic bouts of cataplexy [27].   
We don’t fully understand if sleep pressure accumulates and causes the switch to 
sleep in a “top-down” model, i.e. from the accumulation of factors or local EEG activity in 
the cortex or whether it is initiated in subcortical structures. In much the same way, we don’t 
understand whether anaesthetics act “top-down” or by inhibiting subcortical structures that 
then inactivate the cortex and cause the transition into slow EEG activity [22]. It is apparent 
that during sleep and anaesthesia, the cerebral cortex becomes dissociated from incoming 
sensory information. The thalamus, a central brain structure spanning the region between the 
hypothalamus and the cortex, has strong reciprocal connectivity with the cortex and acts as a 
gate between peripheral sensory information and the higher cortical structures [33]. It has two 
modes of firing activity; high frequency tonic activity that permits the flow of sensory 
activity to the cortex and low frequency burst firing that drive slow wave activity in the 
cortex and dissociate it from external input [1]. Shifting firing mode from tonic firing to low 
frequency burst firing can be achieved by hyperpolarising the thalamus, which includes 
hyperpolarisation through opening of TASK channels [34].  
During wake, the ascending arousal system from the mesopontine junction, posterior 
hypothalamus and basal forebrain directly innervates the thalamus to inhibit low frequency 
burst firing and promotes higher frequency tonic activity [33]. In human imaging studies of 
sleep and anaesthesia, deactivation of the thalamus is almost always observed around the time 
of loss of consciousness or deep sleep. Because the cortex and the thalamus are reciprocally 
connected, it is has long been controversial whether the transition into unconsciousness in 
both sleep and anaesthesia is brought about by “top-down” inhibition of the thalamus by the 
cortex or “bottom-up” dissociation of the thalamus from the cortex. Recent work by in our 
lab [22] that monitored both regions simultaneously during sleep and anaesthesia in the rat 
has found that the switch in firing pattern around unconsciousness occurs first in the thalamus 
and then in the cortex in both sleep and anaesthesia. This finding suggests that the thalamus 
may be a necessary common neural pathway through which both sleep and anaesthesia are 
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achieved. In this thesis, I have attempted to address the following key questions to contribute 
to our understanding of how sleep, wake and anaesthesia are orchestrated: 
1. What contribution the LC, a component of the ascending arousal system, makes in 
the regulation of sleep and wakefulness  
2. Whether chronic LC silence detrimentally affects animal behaviour or sensitivity to 
the anaesthetic dexmedetomidine 
3. Whether wake promoting compounds acting through Gq/11 pathway require TASK-
3, a potassium channel targeted found in the LC and multiple other sleep-wake regions, for 
their mechanism of action 
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Chapter 1  
The locus coeruleus: a controversial role in sleep and 
anaesthesia 
The blue spot 
Like the other monoamines dopamine, serotonin and histamine, noradrenaline is one of the 
classic neuromodulators that allows neuronal circuitry to go beyond the simple “yes” and 
“no” commands of glutamate and gamma-aminobutyric acid (GABA). We still do not fully 
understand the complex phenomenon of neuromodulation. The simplest way to look at this is 
that neuromodulators, such as noradrenaline, provide “context” to sensory and internally-
generated information and allow complex behaviors to emerge. A common feature of all 
monoamine-based modulation is that the compounds, because of volume transmission, 
influence the properties of many target neurons simultaneously.  
Noradrenaline is synthesized in a number of brain nuclei, referred to collectively as the ‘A’ 
group.  The nucleus I will focus on in this thesis is the locus coeruleus (LC); one of the main 
CNS sources of noradrenaline. The mouse LC (also known as A6) is a small unmyelinated 
pontine region that contains large noradrenergic neurons, non-noradrenergic glia and 
interneuron populations [35-39]. In addition to noradrenaline, LC neurons use the co-
transmitters neuropeptide Y, glutamate, enkephalin, and, crucially for my study, the 
neuropeptide galanin [40-44]. In humans, the LC can be identified in unstained tissue due its 
distinctive blue colour that gets more intense with age [45]; hence the Latin name locus 
coeruleus, or “blue spot” This colouring comes from neuromelanin granules, a product of 
noradrenaline oxidation. For poorly understood reasons, this colorant is absent in rodents, 
whilst being present in higher primates and is maximally found in humans [45, 46]. In mice, 
in the absence of its namesake blue colour, I identified the LC as a catecholaminergic, 
pontine region with a distinctive tear-drop shape and typically large cell morphology. This 
was done by immunostaining the mouse pons around the floor of the fourth ventricle (the 
location of the nucleus proper is estimated at 5.5 mm behind Bregma [47] with more diffuse 
cells spreading rostrally) for tyrosine hydroxylase, the rate-limiting enzyme in noradrenaline 
synthesis (Fig. 1.1).   
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Figure 1.1. Tyrosine hydroxylase expression identifies locus coeruleus in mouse pons 
Throughout this study, the LC was identified by tyrosine hydroxylase immunoreactivity and 
the stereotaxic coordinates of Paxinos and Franklin 2004 [48] An example, visualised at 10x 
magnification with AlexaFluor® 594 conjugated secondary antibody (Molecular Probes) is 
shown here. Images show the left and right LC in the same coronal section. (E. Steinberg, 
unpublished) 
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LC projects widely and distributes noradrenaline by volume and wiring transmission 
Despite its small size, the LC provides the majority of brain noradrenaline through its 
extensive, widely-divergent, ipsilateral projections which span the basal forebrain, limbic 
system, diencephalon, hypothalamus and brainstem and are the sole source of cortical 
noradrenaline [49-52]. Noradrenaline is released from both LC boutons and axonal 
varicosities [53, 54], thus contributing to both ‘wiring’ and ‘volume’ transmission of 
noradrenaline throughout the brain [55]. These qualities do not necessarily mean that firing in 
the LC results in uniform noradrenergic signaling at all its projection sites and varicosity 
locations [56, 57]. This can be illustrated by discussing a key projection target of the LC, the 
neocortex. 
Firstly, although LC cells have widely divergent projections, there is some topographical 
organization in the ‘wiring’ of this nucleus. Projections from the LC have five major tracts: 
three to the forebrain, one to the cerebellum and one to the spinal cord [58]. In general, rostral 
and dorsal LC cells innervate the forebrain and cerebral cortical structures, whereas the 
caudal and ventral LC cells innervate the cerebellum and spinal cord [56, 59]. The LC cells 
that project to the neocortex do not innervate functionally distinct regions simultaneously. In 
a recent anatomical study of LC projections to the rat cortex by retrograde tracing, Chandler 
and Waterhouse found three distinct populations of LC cells projecting to either the medial 
prefrontal cortex or the orbitofrontal or the anterior cingulate cortex. Just 4.3% of labelled 
cells projected to two regions at once and none supplied all three [60]. In their subsequent 
paper, they found that LC cells projecting to the medial prefrontal cortex were also more 
excitable and more likely to fire spontaneously than cells projecting to the adjacent motor 
cortex [57].   
Secondly, varicosity density varies in the neocortex and so ‘volume’ transmission is not 
necessarily uniform. Noradrenergic innervation of the neocortex, which stems solely from the 
LC, varies with modality. The frontal cortex has higher varicosity density than sensory or 
motor regions. In addition, varicosity varies by depth: varicosity density increases in 
superficial layers and in the mediolateral axis while decreasing in the medial to lateral 
direction [61]. Thus, the LC organizes and differentially regulates nearby neocortical regions 
by its wiring patterns and electrophysiology of projecting neurons.  At each target region the 
distribution of noradrenergic receptors, transporters and reuptake proteins also results in 
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distinct regional responses to noradrenaline levels. The importance of knowing ambient 
levels of noradrenaline is crucial in the interpretation of our findings. 
In this study, we injected adeno-associated viral vector (AAV) capsids containing Cre 
recombinase-dependent transgenes into the LC of transgenic mice to selectively manipulate 
the LC. In this mouse line, Cre recombinase expression is driven by the regulatory elements 
of  the mouse galanin gene (Tg(Gal-cre)KI87Gsat/Mmucd, abbreviated to Gal-Cre) [62]. 
Galanin is co-expressed with noradrenaline in 80-100% LC neurons [40, 63-65] along with 
galanin receptors that negatively regulate LC activity [66, 67]. As part of the Brain 
Connectivity project conducted at the Allen Institute for Brain Science, this Gal-Cre mouse 
line was stereotaxically injected in the LC with AAV containing a FLEX-revEGFP transgene.  
The AAV transduced all neurons, but only cells expressing Cre recombinase, in this case the 
galanin-expressing LC neurons, activated the EGFP expression. This resulted in anterograde 
transport of EGFP in the axons of the galanin-LC neurons [68]. The resulting pattern of 
expression is shown in Fig. 1.2. The left panel is a still from a 3D topography map made from 
serial two-photon tomography through the entire injected brain.  Notably, this galaninergic-
LC projection map appears to be missing the cerebellar projections expected from LC 
transduction. This may be a product of a more rostral injection transducing only forward-
projecting cells or, more significantly, this could mean that the cell population we will be 
transducing, primarily projects rostrally and to regions neighbouring the LC in the pons. 
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Figure 1.2. Allen Mouse Brain Connectivity Atlas for the Gal-Cre mouse line injected 
with recombinant adeno-associated viral tracer in the LC 
Sagittal section from adult female mouse (Tg(Gal-cre)KI87Gsat/Mmucd) injected with AAV-
FLEX-revEGFP at post-natal day 56, unilaterally 5.52 mm behind Bregma into the LC 
region. Main projection sites composed 69.6% of total projections. Diffuse projections were 
seen in the frontal cortex (FCtx), hypothalamus (Hyp) and hippocampus (HPC). Chart 
composed using data from “Quantified Injection Summary” which can be found at 
http://connectivity.brain-map.org/projection/experiment/301210208 
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Projections to the LC reflect feedback from projection sites and strong autoregulation 
LC activity regulates arousal and autonomic function [69, 70] and many of the projection 
regions, such as the cortex, thalamus, brainstem, intermediate zone of the spinal cord and 
limbic system, feed back to the LC [56, 71]. The noradrenergic/adrenergic network strongly 
regulates LC activity. The LC core receives two main adrenergic medullary inputs from the 
nucleus paragigantocellularis and the nucleus prepositus hypoglossi – retrograde labelling 
from the LC directly labels these [72]. The contralateral LC region and other noradrenergic 
regions (A1, A2, A4 and A5) provide inhibitory input [47]. Finally, extracellular 
noradrenaline levels feedback to the LC via autoreceptors and heteroreceptors in the region; 
these include the α1 and α2A adrenoceptor subtypes.  The α2A subtype mediates 
noradrenaline’s inhibitory effect on LC neuronal firing and membrane potential [47, 73, 74]. 
The neuropeptide galanin, co-expressed by the LC also negatively regulates LC activity. 
Application of galanin to LC neurons produces a long-lasting reversible hyperpolarisation by 
increasing K
+
 conductance and reduces the rate of spontaneous firing [66, 75-77];  
intracerebroventricular (ICV) infusion of galanin attenuates noradrenaline transmission in 
vivo in the rat [78]. In addition to control of the LC nucleus proper, there is extensive 
regulation of the LC via extranuclear dendrites by inputs from the dorsomedial 
hypothalamus, dorsal raphe, amygdala, frontal, insular and perirhinal neocortices [47, 72, 79, 
80].  
The LC is most active during wake and may regulate switching between wake and sleep 
One of the most striking observations about the LC is that it is mainly active during 
wakefulness, and not during REM sleep, and indeed starts to fire just before wakefulness 
emerges [27]. The LC has varying tonic discharge rates over the sleep-wake cycle, but also 
has periodic phasic discharges that might optimize target neuron responses to salient sensory 
stimuli [81]. These two types of discharge have different frequencies: the tonic 0.1-5 Hz 
stochastic discharge rate roughly correlates with the sleep-wake continuum [70], whereas the 
phasic discharge is a brief burst of two or three action potentials at 10-20 Hz, frequently 
followed by a 200-500 ms suppression of spontaneous activity [81-84]. Tonic noradrenaline 
release from the LC regulates the excitability of target neurons; there is a dose-dependent 
inverted-U relationship between noradrenaline release and facilitation of target neuron 
sensitivity to sensory input [85, 86]. It is thought that tonic activity facilitates targets of 
varying neuromodalities, whereas phasic activity preferentially facilitates the responsiveness 
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of certain neuronal populations to certain sensory modalities above others. During phasic 
discharge, differential effects on neuron populations may be achieved by co-release of co-
transmitters, such as neuropeptide Y and galanin, with noradrenaline, or even by preferential 
release of galanin over noradrenaline [81, 87]. When neuron depolarisation is slow and 
regular, little or no galanin is released. On the other hand, when depolarisation is rapid, such 
as that in phasic burst firing, release of galanin increases [88]. 
During wake, LC activity is closely related to shifts in behaviour that follow salient stimuli 
and is thus implicated in attention, vigilance and behavioral flexibility [89-93]. Over the 
sleep-wake cycle the LC appears to be predominantly wake-active; tonic discharge rates are 
highest during wake, lowest during NREM and absent in rapid eye-movement sleep (REM) 
[94-101]. In addition, LC activity varies with time of day; rat LC neurons recorded during the 
dark period (the active period) fire faster than those taken in the light period (experiments 
conducted in the presence of halothane anaesthesia). This time-of-day-dependent LC activity 
is abolished if the dorsomedial hypothalamus (the region relaying suprachiasmatic nucleus 
input to the LC) is lesioned [72], so this may be a circadian variation. The changes in LC 
firing between wake and NREM sleep slightly precede the changes in electroencephalogram 
(EEG) activity [94, 96, 97]. Inhibition of the LC by local micro-infusion of 2 adrenoceptor 
agonist clonidine shifts the cortical EEG from low-amplitude, high-frequency activity typical 
of wake to large-amplitude, slow-wave activity typical of NREM sleep and light anaesthesia 
[102].  In contrast, optogenetic activation of tyrosine-hydroxylase-positive cells in the LC 
during sleep promotes immediate transitions to wake [103, 104].  
This relationship between LC activity and cortical EEG, as well as its physiological 
anticipation of sleep/wake suggests that the LC could be involved in wake pressure 
accumulation or switching of arousal states. It also suggests that inhibition of this area would 
prolong sleep or induce sedation. This region has been studied by chronic LC destruction, 
using electrolytic lesioning, or poisoning, using catecholamine-selective toxins 6-
hydroxydopamine (6-OHDA) and N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4). 
The LC has also been stimulated or inhibited acutely by micro-infusion of drugs, cooling, 
electrical stimulation or hijacking of cell firing via exogenously expressed channel rhodopsin 
or designer drug receptors. A wide selection of these studies is summarized in Table 1-1.   
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Manipulation of the LC leads to conflicting effects on sleep-wake 
Chronic lesioning studies have been informative but suffer from two key drawbacks – 
damage to nearby pontine structures and compensatory effects post-lesion. It is likely that 
when targeting the LC by lesion or toxin that surrounding neuronal populations will suffer. 
LC lesion studies have been largely conducted in the cat and the rat. Cat LC is less 
anatomically compact compared to rodents which make it less suitable for electrolytic 
lesions. Early cat LC lesion studies [105] report complete loss of spontaneous urination in 
their animals, likely due to additional damage to the adjacent pontine urination centre – 
Barrington’s nucleus [106]. Also adjacent to the LC are the parabrachial nucleus and the peri-
locus coeruleus – both regions are recognized as important in REM sleep regulation [107-
109]. Excessive lesioning or local inflammation as a result of catecholaminergic toxin 
treatment (this is repeatedly reported for non-catecholamine cells surrounding those treated 
with 6-OHDA [110-113]) could damage these two areas and produce a complex phenotype. 
Converse to a sleep phenotype resulting from excessive damage, incomplete damage appears 
to result in compensatory mechanisms that obscure the role of the LC. Chiodo et al.,  showed 
that after 6-OHDA treatment, surviving LC neurons significantly increased their expression 
of tyrosine hydroxylase, more than 4-fold increased their basal firing rate and appeared less 
sensitive to feedback inhibition by noradrenaline [114]. This parallels post-mortem studies of 
patients who experience significant LC loss in AD – their remaining LC neurons also showed 
significantly increased tyrosine hydroxylase expression post-mortem [115]. Such 
compensatory mechanisms may explain why several of the studies listed in Table 1-1 report a 
transitory phenotype that disappears after several days [116-118]. 
Studies of complete noradrenergic deficiency suggest that noradrenaline is important in REM 
but not necessary NREM sleep control. Complete absence of noradrenaline due to congenital 
deficiency results in elevated slow-wave sleep and reduced REM in both mice and humans 
[119, 120]. But treating congenitally noradrenaline-deficient patients with L-threo-
dihydroxyphenylserine (L-DOPS) to restore noradrenaline levels increased REM sleep 
without significantly affecting slow-wave (NREM) sleep [121]. An overview of the LC-
lesion literature reveals an equally weak relationship between noradrenergic tone and NREM. 
Several, but not all, studies report increased sleepiness in lesioned animals and two studies in 
the rat report that NREM sleep rebound is blunted after sleep deprivation in LC lesioned 
animals [122, 123]. The congenital noradrenaline deficiency studies however do not directly 
link the LC and REM. There are at least three noradrenergic regions implicated in REM 
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generation (subcoerulean region, ventrolateral pontine A5 and LC are all silent during REM 
[109]) . However, LC lesion studies provide evidence for a causal link between LC and REM  
 Lesions of the LC produce increased, decreased or no effect on REM (summarized in Table 
1-1 and more completely in a review by Claude Gottesman [124]). This may be due to 
differing effects on nearby regions (discussed above) or due to differences in the severity of 
the lesion, thus leading to a different balance of impairment/compensation. Several groups 
have proposed that low noradrenaline and LC silence are crucial for REM generation [125] 
and that LC firing actively inhibits REM from intruding into both NREM sleep and into wake 
[126]. Noradrenaline levels over sleep-wake increase with LC firing rates and are lowest, but 
still detectable, during REM (see bottom panel of Figure 1.3) [127-130]. If the results of 
previous studies are ordered by how likely they are to totally abolish LC activity, mildly 
suppress it, mildly increase it or strongly stimulate it, an inverted-U relationship emerges (a 
cartoon is shown in Figure 1.3). In this model, total ablation of the LC will decrease REM 
because a minimal amount of noradrenaline is still necessary for REM generation but 
suppression (from acute manipulation or incomplete lesion) will instead increase REM by 
lowering noradrenaline to a REM-permitting level. Strong stimulation will increase ambient 
noradrenaline and in turn inhibit REM circuitry. The inverted-U model of noradrenergic tone 
may not predict the effect of LC lesions on REM sleep because other LC signalling is not 
accounted for, such as galanin.  Galanin given alone increases REM sleep duration in healthy 
male volunteers (attributed by the authors to inhibition of the LC [131]) or increases REM 
latency in depressed patients as well as having an anti-depressant effect [132]. Galanin has to 
be applied in a pulsatile manner to produce its effects [133], perhaps to mimic its endogenous 
release during periodic phasic LC discharge [134]. 
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Figure 1.3. Model of LC activity and associated REM sleep probability 
Top panel: Model of LC activity that predicts probability of REM, based on effects of lesion, 
LC inhibition and LC stimulation studies. LC activity during NREM, quiet wake and alert 
wake inhibits REM sleep. Increasing LC activity by electrical stimulation and 
photostimulation will inhibit REM sleep. Lowering LC activity will increase REM sleep, 
providing there are residual levels of noradrenaline. Complete inhibition of LC activity 
abolishes the minimal amount of noradrenaline required for REM and so paradoxically 
inhibits REM. Bottom panel: Microdialysis data of cat LC noradrenaline levels  plotted from 
table in Shouse et al., 2000[128]  that supports inverted-U model. Noradrenaline levels 
during REM sleep are substantially lower than in NREM and wake but are still detectable. 
Errors shown are standard deviation. 
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Acute manipulation of the LC paints a more consistent picture of its role in arousal. Inhibition 
of the LC by cooling or photoinhibition significantly shortens sleep latency whereas electrical 
or light stimulation promotes transition to wake from REM or NREM sleep [103, 104]. Long-
term bilateral stimulation of the LC in freely-moving rats decreases REM whilst decreasing 
active wake [135, 136]. This observation may explain two seemingly opposed reports. 
Gonzalez and colleagues reported that 30 minutes after DSP-4 injection (which preferentially 
targets LC neurons [137]), animals adopted a ‘frozen attitude’ that lasted for several hours 
[116]. Meanwhile, recently, Carter et al.,  discovered that intense photostimulation of the LC 
also produces ‘behavioural arrest’ during which the animals appear to freeze [103]. Either the 
early stages of DSP-4 poisoning cause frantic activity in LC neurons or persistent LC 
stimulation effectively inhibits the region, the result is the same – the animals are frozen but 
not sedated. This freezing behaviour suggests that moderate LC activity is necessary for 
normal behaviour during wake.  
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Manipulation of the LC Effect on sleep/wake Ref 
Global noradrenaline deficiency 
Dopamine beta hydroxylase knockout 
mouse 
Shortened sleep latency, no effect on REM [138] 
Dopamine beta hydroxylase knockout 
mouse 
Shortened sleep latency, +2 hours sleep time, decreased REM, 
increased transitions between wake and NREM (authors suggest 
small amount of noradrenaline necessary for REM generation) 
[119] 
Human congenital dopamine beta 
hydroxylase deficiency 
High levels of slow wave sleep, low to normal REM. REM 
episode length and overall REM increased after noradrenaline 
levels were restored with L-DOPS 
[120, 
121] 
Drug infusions into LC 
Unilateral infusion of clonidine into the 
cat LC (inhibits LC firing) 
Decreased waking and increased NREM but no effect on REM [108] 
Bilateral infusion of clonidine into cat 
dorsal pontine tegmentum (containing 
the LC)  
No effect on waking or NREM but reduces REM sleep (authors 
mention effect may be on non-noradrenergic cells) 
[139] 
Bilateral infusion of GABAA antagonist 
picrotoxin into LC of freely moving rat 
Decreased REM sleep [140] 
Bilateral infusion of hypocretin 1 
(increases LC firing) into rat LC 
Significantly decreased REM, SWS2 and increased wake [141] 
LC lesions 
DSP-4 lesions in adult rat REM decreased but only during light period. After 10 hour sleep 
deprivation, NREM and REM rebound were attenuated (attribute 
this partly to “reduced stress impact”) 
[122] 
DSP-4 lesions in adult rat REM and wake suppressed while NREM increased in first 24 
hours. NREM remained elevated at expense of wake at 48 hours 
after which all sleep states returned to normal 
[116] 
DSP-4 lesions in adult rat No effect on any sleep state (measured >1 week after DSP-4) [142] 
DSP-4 lesions in adult rat. Injected 
bilaterally into amygdala 
NREM increased at the expense of wake, no effect on REM. 
NREM and REM rebound attenuated after 10 hour sleep 
deprivation. Implicate LC in sleep rebound processes. 
[123] 
6-OHDA lesions in the rat Increased REM sleep (2-3 weeks after treatment) [143] 
6-OHDA lesions in the cat Initial acute REM suppression and then lower than normal REM 
for 18 days 
[118] 
Diathermocoagulation unilateral lesion in 
the cat 
Increased REM for one month post-lesion [144] 
6-OHDA bilateral injection into rat LC 
(small volume injection) 
Increased wake, decreased REM and NREM. Loss of REM 
atonia 
[106] 
Anti-DBH-saporin bilateral LC lesion in 
rat 
First week, significantly decreased NREM and REM during 
light period and increased NREM during dark. Second week, no 
major differences. Third week, NREM was reduced during 
beginning of light period and elevated in the subsequent dark 
period. 
[117] 
  
34 
 
Stimulation or inhibition of LC 
Bilateral electrical stimulation of LC in 
freely moving rat 
Decreased REM sleep with reduced active wake. Post-
stimulation there was REM rebound. 
[135, 
136] 
Bilateral cooling of LC in cat Rapid transition to NREM and in roughly half the trials also by 
REM. REM duration increased by 120% and NREM by 32%. 
[104] 
Bilateral electrical stimulation of LC in 
cat 
Caused NREM to wake or REM to wake transition [104] 
Photostimulation of mouse LC Caused NREM to wake or REM to wake transition.  Long-term 
stimulation increased wake and reduced NREM. No significant 
effect on REM. 
[103] 
Photoinhibition of mouse  LC Reduced wake and increased NREM. Trend towards increased 
REM. 
[103] 
Table 1-1. LC manipulation and sleep-wake 
Compiled using independent literature search and several reviews [124, 145, 146] 
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Inhibition of the LC is necessary for the mechanism of action of certain anaesthetics 
This expression profile of molecular targets of anaesthetics in the LC suggests that region 
could be a common anaesthetic target. All three key molecular targets of anaesthetics 
outlined by Franks in his 2008 review [1] can be found in the LC: GABAA receptors [147-
149], K2P channels [29] and NMDA receptors [150]. Additionally, there is strong expression 
of α2A adrenergic receptors [151-153] that are the anaesthetic target of the hypnotic 
dexmedetomidine [4, 154, 155] and glycine receptors [156], which may mediate the effects of 
some volatile anaesthetics [157] and the sedative effects of ethanol [158]. Interestingly, not 
all anaesthetics appear to suppress LC output. The LC is the key source of frontal neocortex 
noradrenaline yet differing classes of anaesthetics (based on their mechanism of action) have 
opposing effects on cortical noradrenaline. GABAergic drugs, such as propofol, and the α2A 
adrenergic receptor agonist dexmedetomidine substantially lower cortical noradrenaline [159, 
160], while NMDA antagonists, such as nitrous oxide, xenon and ketamine, appear to 
increase cortical noradrenaline [161, 162]. Other drugs such as the volatile anaesthetics 
isoflurane and sevoflurane, which target GABAA receptors, K2P channels and unknown 
additional targets, also appear to enhance cortical noradrenaline levels during the first twenty 
minutes post-induction [163]. This suggests that, while LC is normally a wake-active 
nucleus, LC silence/noradrenergic depletion is not necessary for falling unconscious. This is 
illustrated in a study by Kushikata et al., where DSP-4-mediated lesion of the LC resulted in 
decreased sensitivity to ketamine anaesthesia and analgesia, but increased sensitivity to 
thiopental anaesthesia [164]. 
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Drug Manipulation of LC Effects on anaesthetic 
sensitivity 
Ref 
Dexmedetomidine Dopamine beta hydroxylase 
knockout mouse  
 
Selective knockdown of the α2A 
adrenergic receptor in mouse LC 
 
Selective expression of the α2A 
adrenergic receptor noradrenergic 
cells (including the LC) 
 
Antisense oligodeoxynucleotide 
against α2A adrenergic receptor 
infused into rat LC for 8 days via 
cannula 
 
Atipamezole (α2 antagonist) 
infusion directly into LC of 
cannulated rats 
Increased anaesthetic sensitivity 
 
 
Reduced anaesthetic sensitivity (LORR) 
but no effect at sedative doses 
 
Could not rescue abolished response to 
dexmedetomidine.  
 
 
Decreased anaesthetic sensitivity 
(increased latency and reduced duration 
of LORR) 
 
 
Dose-dependent decrease in anaesthetic 
sensitivity 
[165] 
 
 
[166] 
 
 
[4] 
 
 
 
[3] 
 
 
 
 
[167] 
Thiopentone 6-OHDA lesion of neonate rat LC 
 
DSP4-mediated lesion of the LC 
 
6-OHDA lesion of LC 
Increased sleeping time  
 
Increased anaesthetic sensitivity 
 
Increased sleeping time 
[168] 
 
[164] 
 
[169] 
Pentobarbitone Atipamezole (α2 antagonist) 
infusion directly into LC of 
cannulated rats 
 
6-OHDA lesion of neonate rat LC 
No effect 
 
 
 
Increased sleeping time 
[167] 
 
 
 
[168] 
Phenobarbital Neonatal DSP-4 lesion in rat No change to sleeping time, longer 
latency to LORR 
[170] 
Alfaxalone LC stimulated optogenetically in 
anaesthetized rats via ChR2 
Increased analgesia or decreased 
analgesia depending on which portion of 
LC was stimulated (deeper positioning of 
electrode increased analgesia) 
[171] 
Cyclopropane Electrolytic lesion of rat LC Increased anaesthetic sensitivity (lower 
MAC) 
[172] 
Halothane Dopamine beta hydroxylase 
knockout (no noradrenaline) 
 
DSP4-treated rats 
 
Electrolytic lesion of rat LC 
No effect 
 
 
Increased anaesthetic sensitivity (lower 
MAC) 
Increased anaesthetic sensitivity (lower 
[165] 
 
 
[173] 
 
[172] 
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LC inhibited by clonidine during 
halothane anaesthesia 
MAC) 
Shifts cortical EEG from low voltage fast 
activity to large irregular slow activity  
 
[102] 
Isoflurane Rat LC selectively activated by 
CNO via hM3Dq receptors 
 
Dopamine beta hydroxylase 
knockout mouse 
Reduced anaesthetic sensitivity – 
induction takes longer while emergence is 
sooner 
Increased anaesthetic sensitivity 
[174] 
 
 
[165] 
Sevoflurane Dopamine beta hydroxylase 
knockout mouse 
Increased anaesthetic sensitivity [165] 
Urethane 6-OHDA lesion of neonate rat LC  
 
 
Electrical stimulation 
No effect on sleeping time 
 
 
Shifts cortical EEG from large irregular 
slow activity to low voltage fast activity 
(atropine-sensitive) 
[168] 
 
 
[175] 
Nitrous Oxide LC (plus A5 and A7) lesioned No effect on sedation but reduced 
analgesic effect 
[176] 
Ketamine 6-OHDA lesion of neonate rat LC  
 
DSP4-mediated lesion of the LC 
No effect on sleeping time 
 
Decreased anaesthesia and analgesia 
[168] 
 
[164] 
Table 1-2. Literature overview of LC manipulation and anaesthesia 
  
  
38 
 
Nevertheless, except for NMDA antagonist drugs, most manipulations resulting in a loss of 
brain noradrenaline, whether genetic, pharmacological or through inhibition of the LC, 
appear to result in heightened anaesthetic sensitivity (an array of studies are summarized in 
Table 1-2). Mice incapable of synthesizing noradrenaline due to loss of dopamine beta 
hydroxylase exhibit elevated sensitivity to dexmedetomidine, isoflurane and sevoflurane 
(they have normal sensitivity to halothane sedation) [165]. Drugs that lower noradrenaline 
signaling result in a similar ‘anaesthetic-sparing’ effect. Human patients treated with α-
methyl DOPA (thought to displace noradrenaline from binding sites) require substantially 
less anaesthetic for adequate surgical anaesthesia (using halothane and nitrous oxide). 
Meanwhile, pre-treatment of rats with α-methyl DOPA or reserpine (which depletes 
noradrenaline by interfering with the vesicular monoamine transporter) produces dose-
dependent decreases in minimum alveolar concentration (MAC) of cyclopropane required for 
surgical anaesthesia [177]. Reserpine also reduces the halothane dose required for anaesthesia 
in rats [173] and reduces the doses of cyclopropane or halothane required to anaesthetise dogs 
[178]. The sparing effect of noradrenaline reduction on anaesthesia is not restricted to 
anaesthetic induction. A recent paper showed that propranolol and prazosin (noradrenergic 
antagonists) given during isoflurane anaesthesia prolong emergence time [174]. Conversely, 
stimulation of the rat LC during isoflurane and urethane anaesthesia promotes changes in 
cortical EEG from those typical of the unconscious state (low frequency, high amplitude) to 
that typical of wake (higher frequency, low amplitude) [174, 175]. In the isoflurane study, 
this activation coincided with a shorter latency to emerge from anaesthesia, although there is 
no report of the stimulation alone producing emergence from anaesthesia [174]. 
It is widely reported that the LC is the primary target of the unusual hypnotic 
dexmedetomidine. The neuronal networks recruited in dexmedetomidine anaesthesia are 
interesting to both the sleep and anaesthesia fields because the sedated state it induces has a 
sleep-like EEG signature [2] and is partially reversible if humans and animals are given 
sufficient external stimulation [152, 179-181]. As mentioned previously, dexmedetomidine is 
selective for α2 adrenergic receptors and requires the α2A subtype to produce loss of righting 
reflex (LORR); deletion or knockdown of these receptors in the mouse brain abolishes the 
ability of dexmedetomidine to induce unconsciousness [4, 154, 155, 179, 182]. Noradrenergic 
deficit makes it easier for dexmedetomidine to induce LORR [165] and our own work has 
shown that knockdown of α2A receptors in the LC significantly impairs the ability of 
dexmedetomidine to induce righting reflex. However, mice lacking dexmedetomidine 
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receptors in the LC were just as sedated by low doses of the drug as controls [166]. Many of 
the studies listed in Table 1-2 used relatively high doses of anaesthetic and demonstrated that 
inhibition of the LC facilitates onset of loss of consciousness and loss of surgical reflexes 
induced by volatile halogenated anaesthetics, such as isoflurane, sevoflurane and halothane. 
However, what is less clear is whether the LC is necessary for the behavioural inhibition and 
muscle relaxation induced by low doses of certain anaesthetics. 
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Chapter 2  
Selective targeting of the locus coeruleus confirms role in REM 
sleep and reveals role in behavioural arrest 
Abstract 
The locus coeruleus (LC) is a widely projecting pontine noradrenergic region that displays 
heightened activity during arousal and vigilance, slows to tonic firing during NREM sleep 
and falls silent during REM sleep [96, 97]. I investigated the effect of chronic LC suppression 
and acute LC activation on sleep and behavior in mice. Selective targeting of the LC has been 
previously difficult due the LC’s small size and close proximity to other brain structures 
involved in arousal. I overcame this by genetically targeting galanergic/noradrenergic LC 
neurons in adult Gal-Cre mice [62], and inhibiting noradrenaline transmission by expressing 
a Cre-inducible tetanus toxin light-chain transgene (TeLC) using stereotaxically-injected 
adeno-associated viral vectors (AAV) [183]. To complement our chronic suppression study, I 
also exogenously expressed designer receptors exclusively activated by designer drugs 
(DREADDs) in Gal-Cre mice.  These excitatory receptors, hM3Dq-mCherry, could be 
activated by systemic administration of their ligand CNO. TeLC expression did not abolish 
diurnal sleep-wake alternations or affect sensitivity to two anaesthetics (dexmedetomidine 
and isoflurane); but (1) elevated REM sleep and (2) delayed sleep latency after sleep 
deprivation. Activation of hM3Dq-mCherry receptors increased LC firing rate in vitro and 
paradoxically inhibited locomotion. The in vivo effects of LC activation were abolished if 
hM3Dq-mCherry receptors were co-expressed with TeLC. My findings highlight the 
involvement of the LC in REM sleep gating and arousal processes.  
 
  
41 
 
Introduction 
The locus coeruleus (LC) is a small pontine region whose widely divergent axons supply a 
large portion of brain noradrenaline and exclusively supply the neocortex [52]. In humans, 
catecholaminergic neurons of the brainstem, such as those found in the LC are particularly 
vulnerable to neurogeneration in disorders such as synucleinopathies and taupathies 
[184].This degeneration contributes to sleep disturbances that accompany the primary 
symptoms of these conditions. Degeneration of the LC occurs in Pick’s Disease, Down 
syndrome and major depressive disorder and in Parkinson’s disorder (PD) and Alzheimer’s 
disease (AD), LC degeneration precedes full clinical symptom onset [58, 59, 184-187]. REM 
behavioural sleep disorders and excessive sleepiness sometimes seen in PD have been 
attributed to a noradrenergic deficit resulting from a damaged LC [184, 188-190].  During 
this degenerative process, surviving LC neurons compensate noradrenergic loss by increasing 
tyrosine hydroxylase expression [115]. The same is seen in neurons surviving LC lesion, 
which additionally increase their firing rate and appear less sensitive to negative feedback 
[114]. 
The LC exhibits two distinct modes of firing. Tonic (0.1-5 Hz) firing is highest during wake, 
decreases during slow-wave sleep (NREM) and is absent during rapid eye-movement sleep 
(REM) [96, 97]. Several groups have proposed that LC silence is necessary for REM 
initiation, while LC signaling actively inhibits REM intrusion into wake and NREM [126, 
191]. On the other hand, phasic (10-20 Hz) discharge from the LC is thought to optimize 
attention to salient stimuli during wake [81, 192].  Despite a strong pattern of sleep-wake 
activity, experimental manipulation of the LC has produced mixed effects on the sleep-wake 
cycle (for review see Chapter 1 and [124]). A key issue in these studies has been sparing 
nearby regions that are also involved in sleep [107, 108]. We sought to overcome this issue 
by genetically targeting the LC in adult mice.  
We selectively targeted the LC by using adult mice expressing Cre recombinase under the 
control of the galanin regulatory elements [62]. Galanin is expressed by 80-100% of LC 
neurons and is co-released with noradrenaline, particularly during phasic discharge [63, 65, 
88]. Using recombinant adeno-associated viruses [183, 193], we selectively expressed tetanus 
toxin light chain (TeLC) to chronically interfere with synaptic release from the LC [194] or 
the designer drug receptor human muscarinic receptor 3 coupled to Gq (hM3Dq) [195] to 
activate the LC following systemic injection of its ligand clozapine-N-oxide (CNO). TeLC is 
one of the two cleavage products of the clostridium neurotoxin tetanus, the other product 
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referred to as the ‘heavy chain’. The light chain is a zinc-dependent endopeptidase, which 
cleaves the synaptic vesicle docking protein synaptobrevin, while the heavy chain  is 
involved in uptake of the toxin [194]. By incorporating only the cleaving enzyme portion of 
tetanus toxin, toxin spread was limited to the transduced neuron [183].  
LC neurons regulate their own activity and the activity of their neighbours via autoreceptors 
and heteroreceptors; noradrenaline exerts an inhibitory, hyperpolarizing effect on LC neurons 
via α2A-receptors [47, 73, 74]. TeLC treatment was expected to change this inhibitory tone by 
removing noradrenaline from the extracellular environment and thus interfere with 
autoregulation. To investigate this, Dr. Houston applied two drugs that were expected to 
affect these autoregulatory processes to LC neurons in a whole-cell current clamp; 
tetrodotoxin (TTX) and methylphenidate (MPH). TTX, a potent voltage-gated sodium 
channel blocker, was expected to inhibit synaptic release of noradrenaline and, by removing 
its inhibiting effect on LC cells, cause depolarisation. Conversely, MPH, referred to clinically 
as Ritalin, is an amphetamine that inhibits noradrenaline reuptake [196]; by increasing 
extracellular noradrenaline levels, MPH would cause LC cells to hyperpolarise. Previous 
studies support this model: LC neurons hyperpolarise after MPH application and depolarise 
after TTX [197, 198].  MPH application to LC-GFP cells produced modest to no 
hyperpolarisation (mean and SD (mV), -1.9±2.2, n=8) and had no effect on LC-TeLC cells 
(mean and SD (mV), 0.7±1.8, n=7) (Fig. 2.1 A). This modest effect on LC-GFP cells may be 
due to high background levels of noradrenaline caused by LC damage during slicing. 
Following TTX application, all LC-GFP cells displayed a significant (p<0.05) 5-10 mV 
depolarisation. However, in LC-TeLC cells the effects were mixed; while four out of seven 
cells showed comparable depolarisation, the remaining three cells hyperpolarised. Overall, 
TTX induced a 5-10 mV depolarisation in MPH-treated LC-GFP cells but this effect was 
significantly attenuated to 0-5 mV in MPH-treated LC-TeLC cells (p<0.05) (Fig. 2.1 B). We 
noticed TTX-resistant firing in the LC slices, which supports previous observations of 
residual calcium-dependent action potentials in TTX-treated LC neurons [198, 199]. Overall, 
we observed that TTX and MPH treatment consistently affected membrane potential in 
control LC-GFP neurons. In LC-TeLC neurons these changes were harder to effect as 
noradrenaline levels in the extracellular space could not be influenced by TTX or MPH.   
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Figure 2.1 Electrophysiology of LC neurons expressing TeLC-GFP or GFP alone 
A. Whole cell current clamp of LC neurons in acute slices. Representative traces of LC-GFP 
and LC-TeLC neurons before treatment (control) and after methylphenidate (MPH) and 
tetrodotoxin (TTX) treatment. B. Effect of drugs on resting membrane potential (RMP), (LC-
GFP n=8, LC-TeLC n=7). Student’s t-test showed LC-TeLC neurons were significantly less 
affected by drug treatment compared to LC-GFP cells (p<0.05). Electrophysiology 
experimental data collected and plotted by Dr. Catriona Houston (see Contributors to 
presented data).  
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Designer receptors exclusively activated by designer drugs (DREADDs) are G-protein 
coupled muscarinic receptors (GPCRs) modified to favour the synthetic exogenous ligand 
CNO (a pharmacologically inactive metabolite of the antipsychotic clozapine) over their 
natural ligands [195]. Human muscarinic receptor 3 DREADD coupled to Gq (hM3Dq) is 
human muscarinic receptor 3 mutated at two conserved residues (Y149C and A239G), which 
results in loss of sensitivity to acetylcholine, while gaining sensitivity to CNO [195] (Fig. 
2.2). When expressing this designer muscarinic receptor class in the LC, we expected the 
increase in firing and accompanying increase in noradrenaline release previously seen after 
cholinergic agonist application to the LC [200-202]. Thus, TeLC expression in the LC and 
the resulting blockade of synaptic release of noradrenaline would mimic chronic LC 
inhibition (this mouse group was referred to as LC-TeLC and their control cohort as LC-
GFP), while hM3Dq expression in the LC would have no effect until acute application of the 
designer ligand CNO resulted in LC firing (this mouse group was referred to as LC-hM3Dq). 
Dr. Houston applied 5 μM CNO to acute LC slices from LC-hM3Dq mice which resulted in a 
modest but reliable increase in firing frequency from approximately 1-2 Hz to 3-4 Hz (Fig. 
2.3 B). This closely resembles previous reports of 150% increased firing activity in the 
hM3Dq-expressing LC after CNO application [174]. As a result, we expected that CNO 
would excite LC neurons in vivo. 
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Figure 2.2. hM3Dq receptors no longer respond to acetylcholine and gain sensitivity to 
CNO 
A. Schematic of signal cascade initiated by hM3Dq activation. Original image compiled 
using published reports of hM3Dq effects. Glowing edges represent published effects of 
hM3Dq activation, i.e. extracellular-signal-regulated kinase (ERK) phosphorylation and 
intracellular inositol triphosphate (IP3) dependent calcium release [195, 203] B. Data from 
Armbruster et al., 2007 [195]; Wildtype human muscarinic M3 receptors (Wildtype) and 
mutated ‘hM3D’ receptors were expressed in immortalised human pulmonary artery smooth 
muscle cells. Application of acetylcholine to wildtype receptors increased ERK-1/2 
phosphorylation threefold while the designer ligand clozapine-N-oxide (CNO) had no effect. 
Meanwhile, hM3D receptors no longer responded to acetylcholine but CNO application 
produced a fivefold increase in ERK-1/2 phosphorylation.  
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Figure 2.3. Application of CNO to hM3Dq-expressing LC neurons significantly 
increases action potential firing rate 
A. Schematic of AAV-FLEX-hM3Dq-mCherry injection into the LC of Gal-Cre mice. 
Representative AAV-hM3Dq-mCherry transgene expression in LC section co-stained for 
biocytin (marker of cells used for electrophysiology). Arrow shows mCherry-positive cell 
filled with biocytin. B. Representative traces before and after CNO application. Application 
of 5 μM CNO to acute LC slices significantly increased action potential frequency (paired 
Student’s t-test, p<0.01, n=8). Electrophysiology experimental data collected and plotted by 
Dr. Catriona Houston (see Contributors to presented data). 
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One month after viral injection, we measured baseline sleep-wake behaviour in LC-TeLC 
mice and found a significant (p<0.05) elevation in REM sleep compared to LC-GFP controls 
that was restricted to the light period. These animals also showed a delay in NREM and REM 
sleep rebound after three hours’ sleep deprivation. Previous work studying the relationship 
between the LC and dexmedetomidine anaesthesia had demonstrated that knockdown of α2A 
receptors in the mouse LC drastically attenuated the ability of dexmedetomidine to induce 
loss of righting reflex when administered in high doses (Fig. 2.4 A). However, when given at 
lower doses, insufficient for inducing loss of righting reflex, dexmedetomidine induced 
sedation, i.e. inhibition of voluntary movement and delta dominated EEG activity, regardless 
of α2A receptor knockdown (Fig. 2.4 B). These findings suggested that dexmedetomidine 
sedation and loss of righting reflex were induced by separate mechanisms and the LC was 
only involved in the effects of high dose dexmedetomidine. In order to support this theory, 
we also subjected LC-TeLC mice and LC-GFP controls to the same protocol, assessing 
voluntary locomotion at lower doses and loss of righting reflex at higher doses of 
dexmedetomidine. No difference was found at either dose in dexmedetomidine sensitivity. 
Meanwhile, LC-hM3Dq animals were given a range of CNO doses and their locomotion and 
EEG monitored. To our surprise, CNO administration resulted in a significant reduction in 
locomotion, punctuated with minute-long periods of complete immobility. This behavioural 
arrest is reminiscent of that described by Carter and colleagues upon strong photostimulation 
of the LC [103]. Co-expression of hM3Dq with TeLC in the LC abolished the effects of CNO 
on locomotion.  
 
  
  
48 
 
 
Figure 2.4. Adrenergic α2A receptor knockdown in the LC impairs dexmedetomidine-
induced loss of righting reflex (LORR) but not sedative effects at lower doses 
A. Low doses of dexmedetomidine (12.5 μg/ kg, 25 μg/ kg, 50 μg/ kg and 100 μg/ kg IP) 
reduce locomotion and produced a shift to delta range (1-4 Hz) frequencies in the EEG of 
mice with and without adrenergic α2A receptor knockdown (LC-adra-KD vs. LC-scramble). 
B. High doses of dexmedetomidine (400 μg/ kg IP) induce LORR in all control LC-scramble 
mice but only two of eight LC-adra-KD mice. There is a shift to delta range frequencies in 
both cohorts but in LC-adra-KD mice, this shift is both attenuated in amplitude and peaks at 
higher frequency (n=4). Modified from our data published in Zhang et al., 2015 [166] 
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Results 
Effects of LC inhibition on electrophysiology and cortical noradrenaline 
 
Figure 2.5. Cortical noradrenaline after TeLC expression in the LC 
A. Schematic of AAV-FLEX-TeLC-GFP sequence and its injection into the LC of Gal-Cre 
mice. Representative AAV-TeLC-GFP transgene expression in LC section immuno-stained 
for GFP marker, visualised with AlexaFluor®488 secondary antibody. B. Noradrenaline 
measurements from prelimbic cortex (PrL, projection site of LC) by ELISA (Naïve n=4, LC-
TeLC n=3, Naïve + dexmedetomidine n=3). Mice injected with 400 μg/ kg dexmedetomidine 
were used as a positive control.  
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Injection of AAV-FLEX-TeLC-GFP into the LC region resulted in widespread transduction 
of the LC region (Fig. 2.5 A).  Noradrenaline levels of LC-TeLC mice and naïve mice were 
assessed in cortical tissue punches using a commercially available enzyme-linked 
immunosorbent assay (ELISA). As a positive control we used animals injected with an 
anaesthetic dose of dexmedetomidine (400 μg/ kg) which reduces levels of cortical 
noradrenaline [160]. We found that our assay could not detect any reduction in prelimbic 
cortical noradrenaline in LC-TeLC mice compared to naïve controls but could detect a 
substantial reduction in noradrenaline in the dexmedetomidine-injected animals (One-way 
ANOVA comparing to Naïve group (n=4), 400 μg/ kg significantly p<0.01 (n=3) reduced 
noradrenaline while LC-TeLC treatment did not produce a significant difference (n=3)) (Fig. 
2.5 B). This may be due to compensatory mechanisms post-inhibition. While acute inhibition 
of the LC produces a measurable reduction in prefrontal cortex noradrenaline levels [103], 
chronic lesions of the LC/noradrenergic brainstem have previously had only modest effects 
on extracellular noradrenaline levels [71]. In addition, when LC degeneration is seen in AD 
patients, this coincides with significantly elevated tyrosine hydroxylase mRNA expression in 
the surviving cells, which suggests compensatory mechanisms buffer cell loss [115]. Given 
that our inhibition of the LC did not affect 100% of cells, it is likely that the LC 
noradrenergic network was able to buffer this loss by increasing noradrenaline release or by 
reducing uptake and degradation of noradrenaline in the prefrontal cortex. 
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Effects of TeLC treatment on mouse sleep-wake activity 
 
Figure 2.6. LC-TeLC mice display elevated REM sleep in the light period 
Occurrence of wake, NREM and REM in two hour epochs over 24 hour light dark cycle 
(GPF-LC n=11, LC-TeLC n=10). EEG and EMG activity was recorded from “lights-on” via 
wireless headstage and scored into sleep states, plotted as percentage time spent in state in 
previous two hours. LC-TeLC appeared to have elevated REM during the light period at the 
expense of both wake and NREM. Two-way ANOVA with Sidak's post-test to correct for 
multiple comparisons (* p<0.05). 
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Animals expressing TeLC and GFP (LC-TeLC) and control animals expressing only GFP 
(LC-GFP) were monitored for 24 hours using a wireless headstage and the resultant EEG and 
EMG signatures scored in wake, NREM and REM in five second epochs. During scoring, 
EEG signatures appeared normal for both cohorts (Fig. 2.7). There was no apparent 
difference in power spectra of wake, NREM and REM between control and LC-TeLC animals 
in home cage sleep-wake recordings. The characteristic spectral profile for wake, NREM and 
REM can vary with inbred strain background [204, 205]. Our mice, which have a mixed 
strain background, appeared most similar to C57bl6 mice; there was a broad distribution of 
wake frequencies without a distinctive peak frequency in the 0.5-15 Hz range and the peaks 
of the REM and NREM spectra were of comparable amplitude [204].The proportion of time 
spent in wake, NREM and REM for LC-GFP control mice was comparable to that reported 
for C57bl6 mice (published: wake 59.4 +/- 1.8, NREM 35.6 +/-1.5, REM 4.8 +/- 0.3 [204]) 
(Fig. 2.6). Sleep architecture did not differ majorly in the LC-TeLC mice except for a marked 
elevation of REM sleep during the light period at the expense of both NREM and wake 
(p<0.05). The increase in REM sleep was due to an increase in episode number as opposed to 
increased episode length (plotted and discussed subsequently in Fig. 2.8). Our result is 
unusual in the context of previous studies; most studies of LC suppression that found a 
difference in REM did not see it restricted to half the sleep-wake cycle. One study showed 
decreased REM in the light period after DSP-4 lesion in rats [122].  
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Figure 2.7. Power spectra of LC-GFP and LC-TeLC mice appear similar across arousal 
states 
Mean spectral profiles, calculated by Fast Fourier Transform, of LC-GFP and LC-TeLC 
mice in wake, NREM and REM (LC-GFP n= 8, LC-TeLC n=6). Power spectra from Power 
was normalised to mean AUC during LC-GFP wake. No significant difference was observed 
so all three states of all animals were plotted to show distinct power spectra of arousal states 
(n=14). 
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To understand the role of the LC during increased homeostatic sleep drive, we exposed mice 
to three hours of controlled sleep deprivation at the beginning of the light period. After three 
hours’ sleep deprivation, both LC-TeLC and control LC-GFP mice remained awake for a 
further hour. In LC-GFP mice this was followed by strong increase in NREM sleep and a 
later increase in REM sleep, which is typical of sleep rebound following deprivation. In LC-
TeLC this sharp transition into NREM was significantly blunted in the first hour after full 
sleep deprivation. Sleep deprivation also abolished the propensity for higher REM during the 
light period in LC-TeLC animals (REM during the light period was no longer significantly 
different). In both treatments, sleep deprivation increased REM episode length in subsequent 
recovery sleep (Fig. 2.8. means and SD (seconds): LC-GFP 44.9 ± 8.8, n=4, LC-TeLC 47.6 ± 
6.7, n=5, p<0.05 significant for LC-TeLC treatment) (Figure 2.8, panel B) and modestly 
increased delta power (0-4 Hz) (Area under curve for 0-15 Hz significantly increased for LC-
TeLC treatment). Previous reports of DSP-4 lesioned rats undergoing a ten hour sleep 
deprivation also report attenuated NREM and REM rebound in lesioned animals [122, 123]. 
This is, to the best of our knowledge, the first report of a similar effect in mice.  
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Figure 2.8. LC-TeLC mice have a delayed homeostatic sleep response to sleep 
deprivation 
A. Sleep deprivation started at the beginning of the light period and lasted three hours 
followed by rebound sleep. LC-TeLC animals had significantly blunted NREM rebound one 
hour after sleep deprivation (LC-GFP n=4, LC-TeLC n=5). Two-way ANOVA with Sidak's 
post-test to correct for multiple comparisons (*p<0.05) B. REM episode bout length 
increased in the six hours post sleep deprivation compared to bout length in the same time 
period during baseline (Baseline: LC-GFP n=9, LC-TeLC n=7, Sleep Deprivation:  LC-GFP 
n=4, LC-TeLC n=5. Two-way ANOVA with Sidak's post-test to correct for multiple 
comparisons (*p<0.05). C. Power spectra of REM and NREM sleep in six hours post-SD 
normalised to mean area under the curve during LC-GFP wake. LC-TeLC animals 
experienced a significant elevation in 0-15 Hz EEG power during NREM after sleep 
deprivation. There was no significant change in REM power in either cohort. Unpaired t-
tests (LC-GFP: REM (p=0.8554), NREM (p=0.2473), LC-TeLC: REM (p=0.0995), NREM 
(p=0.0152 *)). 
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LC inhibition in Gal-Cre strain does not affect anaesthetic sensitivity 
 
Figure 2.9. LC-TeLC mice display normal sensitivity to anaesthetic doses of isoflurane 
and dexmedetomidine. 
A. 100 μg/ kg dexmedetomidine reduced locomotion within five minutes of injection. Plotted 
values represent distance travelled in previous 30 seconds. Both control and LC-TeLC mice 
showed a substantial reduction in movement and a shift to delta (0-4 Hz) frequencies in the 
EEG (LC-GFP n=4, LC-TeLC n=5)  B. 400 μg/ kg dexmedetomidine induced loss of righting 
reflex (LORR) in approximately 70% of both cohorts within 20 minutes of injection. 
Meanwhile 1.2% isoflurane induced LORR in all tested animals. 400 μg/ kg produced a 
characteristic shift to delta frequencies in EEG of both cohorts (LC-GFP n=6, LC-TeLC 
n=4). Relative EEG power during dexmedetomidine sedation normalised to area under curve 
in preceding wake period for each individual animal. 
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We tested the sedative effects of dexmedetomidine by dosing the animals and immediately 
placing them in an activity box, where their spontaneous activity was monitored by infra-red 
beam crossings. A 100 μg/ kg dose was expected to have a strong sedative effect but not 
cause LORR (based on previous studies of mice with a C57/bl6 background [152]). Both 
cohorts displayed typical responses to dexmedetomidine – a three- to four-minute delay in 
action and then a drastic reduction in voluntary movement that persisted for the duration of 
the recording (Fig. 2.9 A). This supports our published finding that α2A adrenergic receptors 
in the mouse LC are dispensable for its sedative effects [166]. Based on our finding that α2A 
adrenergic receptor knockdown in the LC severely impairs the ability of dexmedetomidine to 
cause LORR [166], we expected that inhibition of the LC would also interfere with 
dexmedetomidine’s mechanism of action. However, eight out of the twelve LC-TeLC animals 
tested were able to lose righting reflex in response to a 400 μg/ kg dose of dexmedetomidine 
(a comparable proportion of LC-GFP mice also lost righting reflex) (Fig, 2.9. B). Moreover, 
both 100 and 400 μg/ kg doses of dexmedetomidine produced a comparable shift in EEG 
frequency to delta (0-4 Hz) activity typical of sedation. The peak shift after drug injection 
was similar to previous reports [152, 166]. Those unable to lose righting reflex to 
dexmedetomidine were able to lose righting reflex when exposed to 1.2% isoflurane which 
shows that unresponsive animals had not lost the ability to fall unconscious per se.  
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 LC inhibition has no detectable effect on behaviour 
 
Figure 2.10. LC-TeLC mice appear normal on behavioural tests 
A. Locomotion of LC-GFP and LC-TeLC animals in the open field did not differ (LC-GFP 
n=6, LC-TeLC n=8). Plotted values represent distance travelled in previous five minutes. B. 
Long term memory novel object recognition test demonstrated that both cohorts were able to 
discriminate a novel object and a familiar one (LC-GFP n=6, LC-TeLC n=9. C. LC-GFP 
and LC-TeLC animals showed the same degree of preference for the dark portion of an arena 
(LC-GFP n=4, LC-TeLC n=6 which suggests comparable exposure anxiety). 
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In our study of LC inhibition, we did not observe any measurable difference in the LC-TeLC 
mice compared to LC-GFP controls on three behavioural parameters: exploration of a novel 
object compared to a familiar one after 24 hours’ delay (long term memory), spontaneous 
locomotion in the open field and preference for light or dark portion of the chamber (a 
paradigm of rodent anxiety). Both LC-TeLC and LC-GFP animals explored the novel object 
for a larger proportion of the time and for longer than the familiar object, demonstrating that 
they retained a memory of the familiar object (Fig. 2.10 B). The spontaneous locomotion of 
the two cohorts was not significantly different although a small trend towards reduced 
locomotion was seen in the LC-TeLC mice (Fig. 2.10 A). Our finding is contrary to previous 
reports of reduced exploratory behaviour in DSP-4-treated animals [142]. This may be a 
result of different transduction of projection sites; the Gal-Cre projections from LC (shown in 
Fig. 1.2) may not extend to the cerebellum while DSP-4 lesioning was likely to affect all LC 
projections. Both cohorts preferred to stay in the dark (less exposed) portion of the light/dark 
testing chamber, venturing into the light zone for only a third of the ten minute trial period 
(Fig. 2.10 C). Thus anxiety levels were not significantly altered in LC-TeLC mice.   
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LC activation via hM3Dq receptor inhibits locomotion 
Mice co-expressing TeLC and the DREADD receptor hM3Dq were compared with mice 
expressing hM3Dq alone. To determine the basic effects of CNO application in vivo, we 
administered CNO intraperitoneally to mice and allowed 30 minutes for the drug to take 
effect before recording locomotion. Mice were placed in an activity monitor and spontaneous 
locomotion activity was assessed by infra-red beam crossings over the course of an hour. To 
our surprise, we found that animals dosed with a twentyfold range of CNO doses 
significantly reduced their voluntary locomotor activity (Fig. 2.11 A, one-way ANOVA 
compared to Saline, found 5 mg/kg significantly reduced locomotion (p<0.05)). This 
responsiveness to a 0.01-10 mg/kg range of CNO doses is similar to that reported previously 
[203]. The markedly reduced locomotor activity in mice was punctuated with prolonged 
periods of complete inactivity where animals appeared frozen with some remaining postural 
tone (if transferred to a rotating rod, these animals could still walk albeit with shorter latency 
to fall). Their EEG activity showed complete abolition of theta range (6-10 Hz) activity, most 
likely due to absence of movement (Fig. 2.11 C). Both saline and CNO injected animal EEG 
contained delta activity (1-4 Hz) and because this delta component did not increase or change 
between saline and CNO injection, the remaining delta activity in CNO-injected animals 
could not be confidently assumed to be evidence of a shift into a sedated or sleep-like state. 
The animals responded to painful pinch with paw withdrawal (n=4 out of 4) but did not 
escape as expected. Together, this supports two previous reports of LC manipulation resulting 
in behavioural arrest [103, 116]. Animals co-expressing TeLC were not significantly affected 
by CNO treatment, suggesting that synaptic release of noradrenaline was necessary for 
behavioural arrest (Fig. 2.11 B and D). The trend towards generally reduced locomotion in 
LC-TeLC mice was not significant but consistent with our observations of these mice in the 
open field without injection (Fig. 2.10, means and SD (cm travelled in 30 minutes): LC-GFP 
3424 ± 1070, n=6, LC-TeLC 2707 ± 1192, n=8)). 
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Figure 2.11. LC-hM3Dq mice have diminished locomotion and a shift in EEG power 
following CNO administration. 
A. Locomotion of LC-hM3Dq mice after CNO administration (CNO given 30 minutes prior to 
locomotion test). Plotted values represent total distance travelled in previous five minutes B. 
Locomotion of mice co-expressing tetanus toxin light chain with hM3Dq receptors (LC-
TeLC-hM3Dq). Plotted values represent total distance travelled in previous five minutes C. 
EEG Power spectra in LC-hM3Dq mice after CNO and saline. Traces were normalised to 
area under the curve in power spectra of EEG during uninjected wake period. D. Effect of 
increasing doses of CNO on total locomotion in the open field in LC-hM3Dq mice and LC-
TeLC-hM3Dq mice (shown on graph as +TELC). 5 mg/ kg produced a significant reduction 
in locomotion of LC-hM3Dq mice (p<0.05, Two-way ANOVA with Sidak’s post-test to 
correct for multiple comparisons to Saline) but not LC-TeLC-hM3Dq mice. 
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Discussion 
The LC is a key arousal nucleus that produces a significant proportion of brain noradrenaline 
and fires during wakefulness and less so during NREM sleep. Noradrenergic signalling has 
been implicated in mood, pain, arousal and attention [71, 192] while LC degeneration has 
been associated with early stages of AD and PD [58, 115, 185, 186, 206]. However, despite 
years of study, it is still unknown whether the LC plays a role in switching between sleep and 
wake and whether its inhibition is necessary for anaesthesia.  
LC output was chronically suppressed by selectively expressing GFP-tagged tetanus toxin 
light chain (TeLC) under the control of LC galanin regulatory elements in adult Gal-Cre mice 
[62]. I compared LC-TeLC mouse sleep and wake, behaviour and anaesthetic sensitivity to 
mice selectively expressing GFP alone (LC-GFP). LC-TeLC mice had normal working 
memory, exploration and anaesthetic sensitivity (to dexmedetomidine and isoflurane) but 
significantly elevated REM during the sleep phase and a delayed latency to sleep after sleep 
deprivation. These data reveal a crucial role for the LC in REM sleep gating and possibly 
sleep homeostasis. Meanwhile, when the LC is partially suppressed, its role in anaesthesia, 
memory and exploration can be functionally compensated by unknown network mechanisms. 
Overall, this predicts that when the LC degenerates early on in AD and PD patients, its loss 
will affect sleep-wake (and possibly mood, which I didn’t study in my LC-TeLC animals) 
rather than memory or anaesthetic sensitivity.   
To contrast with the effects of chronic suppression, I also acutely activated the LC using the 
same experimental protocol as for LC-TeLC mice. Instead of being injected with AAV-
FLEX-TeLC-GFP [183], Gal-Cre adult mice were injected with AAV-FLEX-hM3Dq-
mCherry [193], which resulted in expression of functional muscarinic hM3Dq designer 
receptors that have no baseline activity, but are activated by their designed ligand CNO. 
Systemic administration of CNO to waking LC-hM3Dq mice resulted in behavioural arrest; a 
paradoxical result given the LC’s positive role in arousal. Transducing LC neurons with a 
mix of AAV-FLEX-TeLC-GFP and AAV-FLEX-hM3Dq-mCherry abolished the 
locomotion-inhibiting effects of CNO, which suggests that LC synaptic output is necessary 
for the effects of CNO on locomotion. This behavioural inhibition after LC activation 
supports a previous study by Carter et al., 2010 [103] who expressed light-gated 
channelrhodopsin receptors under the control of tyrosine hydroxylase regulatory elements in 
the LC. Photostimulation of these receptors also caused behavioural arrest.   
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TeLC expression in the LC interferes with autoregulation but is insufficient to reduce 
cortical noradrenaline 
Acute whole-cell clamp study of pontine brain slices from LC-TeLC mice demonstrated that 
expression of TeLC significantly interferes with autoregulation in the LC. Dr Catriona 
Houston’s electrophysiology data showed that while LC neurons from LC-GFP mice were 
hyperpolarised by MPH and depolarised by TTX, the same drugs had little effect on the 
membrane potential of LC-TeLC neurons (Fig. 2.1). I next tested whether transduction of LC 
neurons with AAV-FLEX-TeLC-GFP to produce TeLC was sufficient to reduce 
noradrenaline output in the prelimbic cortex, a region solely supplied with noradrenaline by 
the LC. As a positive control, I administered the hypnotic drug dexmedetomidine to a group 
of naïve mice and was able to detect the acute drop in noradrenaline that has been reported 
previously [160]. In naïve mice uninjected mice, I found noradrenaline levels of 0.4-0.6 ng/ 
mg tissue, very similar to what has been reported previously [207]. LC-TeLC mice showed a 
trend towards lower noradrenaline levels but this was not significant. With a larger cohort 
(n=8 compared to my n=3), Francis et al., 2012 found a similar magnitude drop in 
noradrenaline, from approximately 0.55 ng/ mg to 0.4 ng/ mg (p<0.001), occurred 
spontaneously in a mouse model of AD [207]. Perhaps with a larger cohort, a significant 
reduction in cortical noradrenaline in LC-TeLC mice would be revealed. The magnitude of 
noradrenergic deficit induced by chronic LC suppression parallels the AD mouse model but 
is much more modest than the acute deficit induced by dexmedetomidine.  
When the LC is partially damaged, tyrosine hydroxylase expression and firing rate in the 
remaining LC neurons increase [114, 115], which may explain why AD patient studies have 
controversially reported above-normal levels of CSF noradrenaline [208, 209], despite 
concurrent reports of LC degeneration[185]. This compensatory process could have occurred 
in LC-TeLC mice over the weeks between viral injection and noradrenaline measurement. As 
a result, our noradrenergic data may not reflect the direct effect of LC silence on 
noradrenaline levels. It is unknown whether LC suppression affects the firing patterns of 
remaining LC neurons over sleep-wake, so at this stage we don’t know whether the sleep and 
behavioural phenotypes of LC-TeLC mice reflect a reduction in normal LC activity or 
unknown changes in residual activity.  
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LC-TeLC mice are equally sensitive to anaesthetics dexmedetomidine and isoflurane 
Recent work in our group [166] revealed that knockdown of α2A adrenoceptors in the LC 
reduced mouse sensitivity to anaesthetic doses of dexmedetomidine. This was measured by 
LORR, an anaesthetic end-point in animals; the dose needed to induce LORR in rodents 
closely correlates with the dose of anaesthetic needed to induce loss of consciousness in 
humans [1]. In the same study, we found that lower doses of dexmedetomidine reduce 
locomotion – for this reduction in locomotion α2A adrenoceptors in the LC were dispensible 
[166] (Fig. 2.4). I performed the same experiments on LC-TeLC and LC-GFP animals to test 
whether suppression of the LC interferes with dexmedetomidine-induced LORR. The Gal-
Cre mouse strain used for these studies initially did not lose righting reflex to 
dexmedetomidine, similar to the 129X1 inbred mouse strain [152]. Much like the 129X1 
mice, dexmedetomidine still produced deep sedation and a characteristic shift to delta 
frequencies (unpublished observations by Dr. Valentina Ferretti) but rousability was either 
increased or ataxia reduced such that they were able to right themselves in a rotating rod.   
We back-crossed Gal-Cre mice with C57bl6 animals (known to lose righting reflex to 
dexmedetomidine [152, 166]) and partially restored LORR (Fig. 2.9 B). In this strain, 70% of 
LC-GFP and 66% of LC-TeLC mice lost righting reflex after 400 µg/ kg dexmedetomidine 
which, contrary to our previous data, suggests that the LC is dispensible for 
dexmedetomidine-induced LORR. It is possible that the residual LC neuron population could 
still be targeted by dexmedetomidine which obscured the role of the LC in dexmedetomidine 
sedation. The background insensitivity of Gal-Cre mice to dexmedetomidine complicates 
interpretation of these data as the mechanism of action of dexmedetomidine in these animals 
may be subtly different. As predicted by our previous data, sedative doses of 100 µg/ kg 
dexmedetomidine did not act via the LC; LC-TeLC and LC-GFP mice both dramatically 
reduced voluntary movement five minutes after injection (Fig. 2.9 A). Finally, I tested 
whether LC suppression affected isoflurane sensitivity. Previous studies had shown that 
global noradrenaline knockout mice were more sensitive to isoflurane while LC stimulation 
via hM3Dq receptors reduced anaesthetic sensitivity in the rat [165, 174]. I did not find any 
difference in anaesthetic sensitivity to isoflurane in LC-TeLC mice. This additionally 
confirmed that the Gal-Cre had not generally lost the ability to lose righting reflex – all tested 
animals lost righting reflex to isoflurane. The LORR induced by isoflurane appears to employ 
a different mechanism of action to the LORR induced by dexmedetomidine.   
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LC-TeLC mice have normal long term memory, locomotion and preference for light: 
dark 
In addition to tuning brain activity to respond to salient stimuli, i.e. a role in vigilance, the LC 
is also implicated in memory formation in both rodents and humans [92, 210]. For example, 
the LC transiently fires more during NREM after a rat has learned a new task than if no 
learning experience occurred [211]. Noradrenaline has been shown to increase in the rat 
prefrontal cortex after an appetitively-reinforced learning task, while infusion of beta-
adrenoceptor antagonists into the same region post-learning results in amnesia [212]. Finally, 
activation of the LC hM3Dq receptors in a mouse model of Down’s syndrome, rescued a 
learning deficit on an object recognition task [213]. I tested whether LC-TeLC mice had a 
deficit in encoding/retrieving new memories by exposing them to two objects and then, 24 
hours later, re-exposing them to one original and one novel object. This ‘novel object 
recognition’ task is a classic rodent test of memory; recognition is measured by time spent 
exploring each object [214]. Both LC-TeLC and LC-GFP mice spent more time with the 
novel object, thus demonstrating their ability to a) remember the two objects they saw on the 
first day and b) recognise that one of them had changed.  
My data suggest that the LC is not essential in encoding or perhaps retrieving object 
memories. It is possible that other types of memory not tested here may be impaired. LC 
function has been particularly implicated in fear/emotional memories in both rodents and 
humans [210], which weren’t tested directly, e.g. by rat exposure test. Given this potential for 
a role in anxiety and fear memory, I looked at how both LC-TeLC and LC-GFP mice behave 
in a light: dark box, i.e. an arena half of which is brightly lit and half of which is covered, 
providing a shelter for the animal. Anxious mice exhibit a strong preference for the dark 
portion of the arena, venturing rarely, if at all, into the exposed light section (unpublished 
observations with Dr. Xiao Yu of anxious mouse strain using the same protocol). Both 
cohorts of mice tested here preferred the dark portion of the box but spent a significant 
amount of time exploring the light arena, which suggests that neither cohort was excessively 
anxious.  
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TeLC expression in the LC increases REM activity during the light period 
Despite normal behaviour, anaesthesia and noradrenaline release, LC-TeLC treatment 
nonetheless produced a sleep phenotype that persisted for months after viral injection (Fig. 
2.6), unlike many previous reports of LC lesion studies, where effects were transitory [116-
118].  LC expression of TeLC appeared to lower the threshold for REM initiation during the 
sleep period (light phase), which is consistent with the inverted-U pattern reported by 
previous studies. Figure 2.12 shows the model of LC activity in REM sleep (originally shown 
in Fig. 1.3) with our findings now included (Fig. 2.12, middle panel, TeLC-AAV, shown in 
green). Both REM initiation and maintenance appear to be regulated by a network in the 
caudal midbrain and pons, which contains the LC [215]. Our findings associate REM 
initiation, but not maintenance, with LC activity because REM episode length remained the 
same between LC-GFP control mice and LC-TeLC mice and was comparably increased 
during sleep deprivation (Fig. 2.8). Equally, the gross distribution of REM over the sleep 
wake cycle (more during the sleep phase, less during the active phase) was not affected by 
LC manipulation (Fig 2.6, right panel). 
The question remains as to why the REM effects were restricted to the light phase. One 
explanation is that by expressing TeLC in the LC, we somehow exaggerated the REM cycle, 
which was previously kept in check by an intact LC. Another explanation is that REM 
initiation during consolidated sleep in the light phase is different to REM initiation in the 
periodic shorter sleep episodes during the active phase, although this seems unlikely. A third 
explanation is that ambient levels of noradrenaline, which differ over the sleep-wake cycle, 
affect whether LC activity is crucial for REM generation. The microdialysis studies of 
noradrenaline levels over sleep-wake [128, 130] reveal that despite LC silence throughout 
REM [15, 16, 40-45], noradrenaline levels are not immediately diminished by enzyme 
degradation or reuptake such that they are undetectable. As a result, higher levels of ambient 
noradrenaline from the remainder of the LC, from neighbouring catecholaminergic regions 
and of other wake-associated catecholamines, such as dopamine, may be sufficient to 
normally regulate REM during the dark phase. Conversely, during a period of relative 
quiescence from most catecholaminergic regions during the sleep phase, loss of LC activity 
has a stronger permissive effect on REM. 
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Figure 2.12. Increased REM sleep during light period in LC-TeLC mice demonstrates 
role of LC in REM sleep gating 
LC-TeLC have significantly increased REM during the light period (Two-way ANOVA, 
p<0.05). LC activity was impaired but noradrenaline in the prefrontal cortex was not 
significantly diminished which suggests that LC activity was diminished but not absent. In the 
inverted U model of LC activity, this predicts that REM sleep will increase as the threshold 
for REM initiation will be diminished. Our findings support this prediction and the findings 
of previous studies of incomplete LC inhibition.  
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LC-TeLC mice exhibit longer wakefulness before rebound sleep in a three-hour sleep 
deprivation paradigm 
LC-TeLC and LC-GFP animals were sleep deprived in order to challenge sleep homeostasis 
mechanisms. The results of our sleep deprivation study seem unexpected: LC-TeLC mice had 
a longer latency to fall asleep after sleep deprivation (Fig 2.7). One might expect that these 
mice would fall asleep sooner without the arousing effects of the LC. Indeed, dopamine beta 
hydroxylase KO mice, which are unable to synthesise noradrenaline, have a shorter latency to 
fall asleep after mild and strong laboratory stressors (cage change and saline injection 
respectively) [138]. Nonetheless, our data supports two previous reports of extended wake 
after sleep deprivation in LC-inhibited animals [122, 123]. The longer wake period in LC-
TeLC mice seems to be truly longer sleep deprivation as compensatory changes such as 
elevated NREM delta EEG power and longer REM episode length was significantly different 
to baseline in these animals but not in the less sleep-deprived LC-GFP controls (Fig. 2.8).  
Such compensatory mechanisms would suggest that the altered response to sleep deprivation 
does not reflect reduced sleep need in LC-TeLC animals. In a damaged LC, remaining 
neurons have an elevated firing rate and are less sensitive to inhibition [114]. During sleep 
deprivation, we exposed the mice to several novel experiences, including new objects and a 
cage change. The prolonged wake after this exposure in LC-TeLC animals may reflect an 
inability to ‘switch-off’ after novelty related to compensatory effects in the LC. It is unlikely 
that prolonged wake was caused by significantly different anxiety levels because in all tests 
of behaviour featuring novelty, touch-escape and preference for dark areas in a lit arena, LC-
TeLC mice scored normally. Further study is needed to elucidate why latency to sleep is 
prolonged in sleep-deprived LC-TeLC mice. The ‘switch-off’ idea requires 
electrophysiological study of uninfected neurons in the vicinity of LC-TeLC neurons that 
proves or disproves compensatory changes in ‘surviving’ neurons. This idea also suggests 
that a protocol involving less salient stimuli may affect LC-TeLC mice less.  
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Activation of the LC via hM3Dq DREADD receptors produces behavioural arrest 
The final part of this project investigated the effect of selective LC activation using hM3Dq 
designer drug receptors. Expression of hM3Dq was successful in the LC and 
electrophysiology of infected cells demonstrated the stimulatory effect of hM3Dq’s designer 
ligand CNO. Application of CNO to acute LC slices expressing hM3Dq receptors resulted in 
a 2-3 fold increase in firing (Fig. 2.3) which is similar to 150% increase in firing reported in 
similar experiments in the rat [174]. This comparison to rat data is salient because two recent 
studies of selective hM3Dq expression in the rat LC found that CNO given to rats either did 
not affect locomotion [174] or increased it [216]. Notably, no effect was seen for a slightly 
higher dose of 1 mg/ kg CNO while 0.3 mg/ kg resulted in increased wakefulness and 
locomotion. In a study of a Down’s syndrome mouse model, Fortress et al., 2015 [213] 
expressed hM3Dq receptors in the LC under the control of the dopamine beta hydroxylase 
promoter in both Ts65Dn mice and normosomic controls. Administration of 0.3 mg/ kg CNO 
to normosomic animals had no effect on locomotion [213]. In contrast to all these studies 
using hM3Dq in the LC, I found that hM3Dq activation in the LC of adult mice produced 
periodic behavioural arrest over a 0.25-5 mg/ kg range of CNO doses (Fig. 2.11). At lower 
doses this effect did not significantly reduce total locomotion (Two-way ANOVA with 
Sidak’s post-test for multiple comparisons to saline), which may reconcile our findings with 
those of Fortress et al., 2015. This ‘low’ dose of CNO reduced locomotion in Ts65Dn Down 
syndrome mice but because they are considered hyperactive, it is difficult to directly compare 
with our animals.  
Meanwhile, in our study, 5 mg/ kg CNO produced marked lethargy/immobility in LC-hM3Dq 
mice; they completely ‘froze’ for minutes at a time. Postural tone appeared reduced but mice 
were capable of walking on a rotating rod if forced to move which suggests that the effect 
was not fully attributable to ataxia. This arrest looks strikingly similar to that shown in videos 
in Carter et al., 2010 [103] after strong photostimulation of channel rhodopsin receptors in 
the LC. The authors attributed this behavioural arrest to rapid depletion of noradrenergic 
stores following unnaturally high activity of the LC. In our study, mice that co-expressed 
TeLC with hM3Dq (LC-TeLC-hM3Dq), therefore incapable of synaptic release of 
noradrenaline, did not experience any behavioural arrest or indeed significantly reduced 
locomotion, which supports the hypothesis that noradrenergic signalling and possibly its 
sudden depletion results in behavioural arrest. 
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Having seen such modest effects after chronic LC silencing (LC-TeLC animals behave 
normally, appear healthy, sleep, wake and are sedated relatively normally), the effect of 
strongly stimulating the LC reveals a crucial role in waking behaviour. No known anaesthetic 
exclusively exerts sedation via the LC and, while LC silencing shortens latency, LC 
inhibition does not immediately produce sleep. Stimulating the LC appears to reliably 
produce wake [103]. Our strong stimulation of the LC did not produce a state that could be 
confidently described as sleep but certainly did not resemble normal waking behaviour. 
These mice were able to move and did so periodically but, through an unknown combination 
of ataxia and loss of motivation, spent the majority of their time frozen in their locomotion 
arena. This freezing was not confined to corners or walls of the arena, which might indicate 
anxious behaviour. We cannot exclude the possibility that the heightened noradrenergic 
(galaninergic, glutamatergic or any other LC co-transmitter) tone or converse depletion of LC 
output produced a state of extreme anxiety but none of our data suggest LC-hM3Dq mice 
were anxious. Mice are known to freeze when experiencing extreme threat but this is 
normally associated with theta range activity in the EEG [217], something we did not observe 
in the EEG of CNO-injected animals.  
It is difficult to posit why high levels of LC stimulation result in freezing in mice but had no 
such effect in rats. One tentative explanation is that dosing of CNO may affect the two 
species differently; there are no reports of doses higher than 1 mg/ kg CNO in relation to rat 
locomotion while our results were significant at 5 mg/ kg (Fig. 2.11). Perhaps, at doses 
around and exceeding 5 mg/ kg, the freezing effect can be reproduced in rats because freezing 
in the very early stages of DSP-4 LC lesioning has been observed in these animals [116]. A 
reasonable conclusion at this early stage is that acute manipulation of the LC in rodents (via 
designer drug receptors or light receptor stimulation) has an effect on wake behaviour and 
voluntary locomotion in another inverted-U relationship, while chronic suppression of the LC 
does not affect locomotion to any significant degree.  
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Conclusions and Future Directions 
Our study used recent advances in genetically targeting selected neuronal populations to 
study an old problem: what the role of the LC is in the neuronal mechanisms of sleep and 
arousal. Much of what we found adds to a body of existing LC research, not least that chronic 
manipulation of the LC produces only modest effects on sleep-wake while acute 
manipulation strongly influences behaviour. Despite the likely effects of compensation and 
non-significant effects on noradrenaline in the cortex, LC inhibition resulted in a lasting 
elevation of REM sleep during the light phase, highlighting its importance in orchestrating 
this sleep stage. This supports the recent clinical association of early LC degeneration in AD 
and PD and the equally early, prodromal sleep disturbances seen in these disorders [58, 190].  
There are several aspects of this project that could be extended into further study. Our LC-
TeLC model resulted in undetectable effects on locomotion, anaesthesia and behaviour but a 
measurable effect on sleep architecture. There may have been effects of LC-TeLC on these 
parameters that were not detected by our choice of methods; a number of different memory 
tests could have been used instead of novel object recognition, a detailed battery of anxiety 
tests may have revealed a difference and a large proportion of available anaesthetics were not 
systematically tested on these animals. For example, LC dysregulation (related to glutamate 
signalling and astroglia) has been reported in major depressive disorder [187] but we did not 
conduct rodent tests of depression such as ‘despair behaviour’ tests on our LC-TeLC animals. 
Further study of LC-TeLC mice in longer sleep deprivation paradigms is needed to confirm 
that LC inhibition blunts immediate sleep rebound or alternatively reveal an underlying 
difference in sleep need as a result of altered LC activity. The sleep deprivation results are 
promising but modest given the short duration of the deprivation. A number of interesting 
sleep and anaesthetic experiments could be conducted on LC-hM3Dq animals but the 
‘freezing’ effect poses a great caveat. For example, a preliminary study of co-administration 
of dexmedetomidine and CNO in LC-hM3Dq mice showed no change in sedation. However, 
given that our sedative end-point is lack of voluntary movement, the result is difficult to 
interpret. It would be hugely informative to understand the mechanism behind this freezing 
behaviour and essential to see if it can be reproduced with higher CNO doses in rats.  
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Materials and Methods 
AAV vector production 
All AAV vectors used in this project relied on the coding sequence being inserted in the 3’-5’ 
(reverse) orientation relative to the promoter between heterologous loxP and lox2272 sites. 
The plasmids were developed by two groups; pAM-FLEX-TeLC and pAM-FLEX-GFP 
plasmids were developed by the Wisden group [183] while pAAV-hSyn-DIO-hM3D(Gq)-
mCherry was developed by Krashes et al., 2011 [193] and purchased by our group from 
AddGene (Cambridge, USA, plasmid number 44361). AAV plasmids were packaged into 
virions in HEK-293 cells. The AAV cis plasmid, the adenovirus helper plasmid (pFΔ6), an 
AAV serotype 1 capsid plasmid (pH21) and AAV serotype 2 plasmid (pRV1) were 
transfected into HEK-293 cells. Packaged virions were purified from HEK-293 cells in 
HiTrap heparin columns (based on method by Klugmann et al., 2005 [218]). 
Tetanus toxin light chain-GFP fusion AAV (AAV-FLEX-TeLC-GFP) 
The backbone plasmid pAM-FLEX was developed by Murray et al., 2011[183] and then 
modified by the same group to contain either GFP or GFP-TeLC in the reverse orientation. 
The backbone pAM-FLEX contains a modified CMV enhancer/ chicken β-actin promoter 
(CBA), a FLEX cassette including a multiple cloning site (MCS) between two sets of 
heterotypic antiparallel loxP sites, a woodchuck posttranslational regulatory sequence 
(WRPE) and a bovine growth hormone polyadenylation signal (BGHpA). To generate pAM-
FLEX-TeLC, the reading frame of a codon-optimized variant of the tetanus toxin light chain 
was tagged at the N-terminus with EGFP and inserted in reverse orientation between EcoR1 
and Not1 restriction sites of the MCS. The pAM-FLEX-GFP plasmid contained the reading 
frame for EGFP inserted in reverse orientation between Xho1 and Not1 sites of the MCS. See 
Supplemental Methods for details of plasmid amplification, virion production and 
purification.  
hM3Dq-mCherry fusion AAV (AAV-FLEX-hM3Dq-mCherry) 
The hM3Dq coding sequence was cloned upstream of mCherry (using a mCherry vector) to 
generate a C-terminal mCherry fusion protein. This fusion protein was ligated in the reverse 
orientation into a Cre-inducible AAV vector under a human synapsin 1 promoter [193].  
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Animals 
All procedures were carried out in accordance with the UK Animals Scientific Procedures 
Act (1986) and Imperial College London ethical review. Tg(Gal-cre)KI87Gsat/Mmucd mice 
(FVB/N-Crl:CD1(ICR) hybrid strain) referred to as “Gal-Cre” mice  were developed as part 
of the Gene Expression Nervous System Atlas (GENSAT) project, obtained from Mutant 
Mouse Regional Research Centre [62] and bred on site. Cre recombinase mouse lines rely on 
precise transgene expression that has been possible since the development of phage 
recombination techniques in genetic engineering (so-called “recombineering”) [219]. 
However, the bacterial artificial chromosome (BAC) Cre recombinase cassette that inserts 
randomly into the mouse genome is fairly large. Expression of this large fragment on both 
chromosomes in a homozygotic animal could result in a phenotype due to interruption of 
surrounding gene function or simply due to high gene dosage. Therefore we maintained our 
BAC transgenic mouse line as hemizygotes by crossing heterozygous Gal-Cre females with 
C57bl6 males. Non-transgenic offspring were used for naïve animal experiments. All animals 
in this strain were initially found to not lose righting reflex in response to dexmedetomidine 
(observation by Dr. V. Ferretti). Strain is known to affect sensitivity to dexmedetomidine 
[152]. We back-crossed the Gal-Cre mice with C57bl6 mice in excess of six times which 
partially restored the ability to lose righting reflex to high doses of dexmedetomidine. 
Animals were group-housed prior to surgery in solid-bottomed cages with sawdust bedding 
and environment enrichment. Food and water were available ad libitum with temperature and 
humidity maintained at 21 ± 2°C and 55 ± 10% respectively and lights on in a 12:12 hour 
reversed light-dark cycle. 
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Genotyping 
 
Figure 2.13. Example of Cre Genotyping Gel. 
Presence of luminous bands at approximately 240 bp indicates Cre-positive animals 
Genotype was confirmed using ear punches taken from the animals during tagging and 
processed immediately or kept at -20°C until DNA extraction. DNA was extracted using a 
variation of the HotSHOT method [220]. Briefly, the tissue was submerged in Alkaline Lysis 
Reagent (25 mM NaOH, 0.2 mM EDTA, pH 12) and heated to 95°C for 30 minutes. The 
solutions were allowed to cool before an equal volume of Neutralization Reagent (40 mM 
Tris-HCl, pH 5) was added to the samples and mixed thoroughly. A small volume of the 
DNA extraction was processed by PCR using primers recommended by the Mutant Mouse 
Regional Research Centres (Primer Gal F1: 5’- CCA GAC GTG TGC GTG TTG AGG T -
3’, Primer CreGS R1: 5’- CGG CAA ACG GAC AGA AGC ATT-3’). In a PCR total 
volume of 25 µl; 10 µM of each primer, 1 µl DMSO, 12.5 µl 2x GoTaq Green Master mix 
(Promega, UK) was added. DNA was amplified in standard PCR conditions with 5 minutes at 
95°C followed by 25 cycles of 1 minute at 95°C, 1 minute at 60°C and 1 minute at 72°C and 
a final extension of 5 minutes at 72°C. PCR samples were stored at 4°C until resolution on a 
1.8% agarose gel containing 1:10000 SYBR® Safe (Invitrogen, USA) as DNA gel stain. The 
agarose gel was prepared in Tris-acetate EDTA running buffer (TAE):  40 mM Tris-acetate, 1 
mM EDTA, pH ~8.3 (we routinely prepared this as 50 x stock using 242 g L
-1
 Tris Base, 10 
% v/v 0.5 M EDTA and  57.2 ml L
-1
 glacial acetic acid). Gels were run for 1 hour at 90 V and 
bands visualised using a Kodak DC290 camera under UV light and 535 nm WB50 emission 
filter. The Cre fragment band was expected at 240 bp and no band was considered negative. 
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In vivo recordings and sleep scoring 
 
Figure 2.14. Schematic of electrode placement 
Schematic of electrode positions on the skull and the underlying brain structures which 
influenced cortical EEG signal. Screws were inserted into the frontal (green), parietal 
(yellow) and occipital bones (red). The frontal screw was proximal to the motor, prefrontal, 
cingulate and somatosensory cortices, the parietal screw recorded directly above the 
hippocampus and central medial thalamus via the somatosensory and parietal cortices and 
the occipital screw lay above the cerebellum. The differential between the frontal and 
parietal screw was used for sleep-scoring in the majority of the studies as this EEG signal is 
known to have clear differences in frequency composition between sleep states [13].The 
parietal-occipital differential was used if good quality frontal-parietal signal was 
unavailable. Teflon-coated wires with the proximal ends exposed were inserted into the 
nuchal muscles. Differentials from either pair of nuchal recordings were used to determine 
muscle tone. 
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For sleep-wake recordings, 2-3 month old mice received a set of three 0.5 μl rAAV injections 
per LC region and were instrumented with a cranial implant connected to three stainless steel 
cranial screws (for EEG recording) and three Teflon-coated stainless steel wires under the 
nuchal trapezial muscles (for EMG recording) (see Supplementary Methods for full details 
of the surgery). Following surgery, animals were housed individually. Animals were allowed 
>21 days to recover from surgery and for viral expression to develop before being used for 
any subsequent procedures and monitored daily for signs of ill health for the remainder of 
their life. Once recovered, animals were handled and habituated to wearing a headstage for a 
minimum of 48 hours before the experiment. Sleep-wake parameters were recorded using a 
“neurologger” headstage, updated from that developed for use in pigeons [221]. Sleep-wake 
recordings were scored into five-second vigilance scores in Spike 7 software (Cambridge 
Electronic Design, UK) using a script based on the automated sleep-scoring algorithm of 
Costa-Miserachs et al., 2003 [10]. There was a 10% allowance for missing data or data that 
was difficult to score (‘doubt’) – animals exceeding the 10% allowance (for example if 
recording ended before 24 hours) were not included in 24 hour analysis (Fig. 2.15). 
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Figure 2.15. Example of how EEG and EMG signal are scored into vigilance states 
An example thirty minute segment of EEG and EMG data from a LC-GFP mouse scored in 
Spike 7software (Cambridge Electronic Design, UK) using standard scoring criteria [10] . A 
simplified version of the scoring criteria is detailed. The script used the root mean square 
(RMS) of the EMG calculated over 2.5 seconds of data, power in the delta band (0-4 Hz) and 
power in the theta band (6-10 Hz) of the EEG. High EMG periods were considered wake if 
accompanied by mixed frequency, low amplitude activity, high delta power periods were 
considered NREM if accompanied by low EMG tone. Within sleep, periods of exclusively 
theta-range activity (low delta, high theta determined by theta/delta calculation) 
accompanied by very low EMG were scored as REM. Fast Fourier Transforms (FFT) of the 
wake, NREM and REM epochs show distinct frequency composition characteristic of each 
vigilance state. 
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Sleep deprivation 
Animals were sleep deprived for three hours starting at ‘lights-on’, i.e. the beginning of their 
inactive period when sleep pressure would be elevated. At lights-on, mice were transferred 
from the holding area to the experimental room, their cage lids were removed and for the 
subsequent three hours, whenever the mice appeared drowsy or inactive the side of the cage 
was tapped, novel objects were placed in the cage, the introduced objects were moved or 
swapped between cages. Care was taken to interfere as little as possible whilst suppressing 
resting behaviour and to minimally handle the animals. After three hours, mice were moved 
into a fresh cage with new sawdust, food and bedding and cages returned to the holding area. 
Although all mice remained awake for the subsequent hour hence we refer to this as a three 
hour sleep deprivation. This paradigm is closely modelled on that described by Irene Tobler 
and colleagues [222]. 
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Electrophysiology 
Tetrodotoxin; TTX (T8024, Sigma) and methylphenidate hydrochloride; MPH (M2892, 
Sigma) were formulated as 1000x stock in sterile water (Sigma) and then diluted to 1x (2 μM 
for TTX and 30 μM for MPH) into ACSF (detailed below). Animals were killed >21 days 
after viral transduction by cervical dislocation followed by decapitation. For acute whole-cell 
current clamp recordings of LC neurons, transverse cerebellar 250 μm-sections were cut with 
a Vibratome (Campden Instruments) in ice-cold slicing solution containing (in mM): 85 
NaCl, 2.5 KCl, 1 CaCl2, 4 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, 75 sucrose, 25 glucose, 1 
kynurenic acid, pH 7.4 when bubbled with 95% O2 and 5% CO2. After incubating in slicing 
solution for 15–30 min at 22 ± 2 °C, slices were then transferred to oxygenated ACSF 
containing (in mM): NaCl 125, KCl 2.5, CaCl2 2, MgCl2 1, NaH2PO4 1.25, NaHCO3 26, 
glucose 11. Patch pipettes (4–6 MΩ) were backfilled with internal solution containing (in 
mM): 145 K-gluconate, 4 NaCl, 5 KCl, 0.5 CaCl2, 5 EGTA, 10 HEPES, 4 Mg-ATP, 0.3 Na-
GTP, and 10 sucrose, pH 7.3. This whole-cell current clamp recording method has been 
previously detailed in Zhang et al., 2015 [166]. Baseline was established for approximately 
three minutes before washing on drug, in most recordings the same neuron was treated with 
MPH followed by TTX. Full drug effect took approximately 10 minutes for MPH and 
occurred slightly sooner for TTX. Resting membrane potential calculations were taken over 
one minute of recording during baseline and at full drug effect for MPH and TTX. A 
Gaussian curve was fitted to the voltage membrane distribution over the minute’s recording 
and the peak of the Gaussian considered representative of resting membrane potential.  
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Noradrenaline measurement by ELISA 
 
Figure 2.16. Dose-dependent increase in noradrenaline content with increased sample 
volume in naïve mice 
Frozen brains were sliced into 1 mm sections on a stainless steel adult mouse brain slicer 
matrix (Zivic Instruments, USA).  Tissue punches (1 mm diameter) were taken from the 
prelimbic cortex and cingulate cortex and snap frozen in liquid nitrogen. Brain tissue was 
homogenised in cold 0.01 N hydrochloric acid and the supernatant assessed for 
noradrenaline content using a commercially available ELISA (DRG Diagnostics, UK) 
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Animals were culled by cervical dislocation, the brain dissected out and frozen on a slicing 
matrix (Zivic Instruments, USA) in dry ice. A 1 mm thick slice was taken containing the 
prelimbic cortex and bilateral 1 mm diameter punches taken from the prelimbic region. The 
punches were immediately flash-frozen by immersion in liquid nitrogen and stored at -80°C 
until analysis (usually not more than 3 months). Punches were homogenized using a pestle in 
100 μl cold 0.01 N HCl, 1 mM EDTA, 4 mM sodium metabisulfite and centrifuged at 4°C, 
10000 G for 10 minutes. 10 μl of the supernatant was used for noradrenaline content analysis 
using the Norandrenaline Research ELISA (DRG Diagnostics, EIA-4706, UK) along with 
standards and controls. Each analysis plate contained both TeLC-treated and control brain 
samples to mitigate the effects of plate-to-plate variation. 
Histology 
Correct injection placement in the LC was confirmed by histology. Mice were given a 
terminal overdose of pentobarbital sodium anaesthetic (Euthatal
TM
) by IP injection and 
monitored for loss of surgical reflexes. Once paw withdrawal, corneal and righting reflexes 
were lost, the animal underwent transcardial perfusion. Briefly, a thoracotomy was performed 
to expose the heart and a sterile needle (connected to a pump) inserted into the left ventricle. 
Immediately after the insertion, the top of the right atrium was lanced with sharp tweezers 
and 10-15 ml ice-cold PBS was perfused through the body via the heart at a flow rate of 1 ml/ 
min. Once perfusate was running clear from the heart and the liver had cleared (turning 
yellow-grey as a result of ex-sanguination), 20 mls 4% paraformaldehyde (in PBS) was 
passed through to fix the tissues. The brain was dissected out and post-fixed in 4% 
paraformaldehyde overnight at 4°C. Subsequently the brain was transferred into 30% w/v 
sucrose and allowed approximately 48 hours to saturate to aid cryoprotection. Brains were 
then frozen and sliced 40 μm thick on a microtome and kept as free-floating sections in 1x 
PBS at 4°C until immunohistochemistry.  
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Immunohistochemistry 
All solutions were made up in 1x PBS (Sigma, P4417) and all washes performed on a slowly 
revolving belly-shaker at room temperature unless otherwise specified. Free-floating sections 
were washed three times in 1x PBS. Slices were then permeabilised in 0.2% Triton
TM
 
detergent (Sigma, X100) for 1 hour, washed three times in 1x PBS and blocked for 2 hours in 
‘High Blocking Solution’ (10% w/v  normal goat serum (Vector, S-1000), 1% w/v bovine 
serum albumin (Sigma, A4503), 0.1% Triton X-100). Primary monoclonal antibodies against 
tyrosine hydroxylase (Sigma, T2928) and GFP (Molecular Probes, A6455) were diluted 
1:1000 into ‘Low Blocking Solution’ (4% w/v normal goat serum, 1% w/v bovine serum 
albumin, 0.1% Triton X-100). Slices were washed in this solution for approx. 16 hours at 
4°C. The primary antibody solution was washed off with increasing concentrations of 
blocking solution for ten minutes per wash; 1x PBS followed with Low Blocking Solution 
and then High Blocking Solution. Secondary fluorescent antibodies against rabbit and mouse 
were diluted 1:600 in Low Blocking Solution, avoiding exposure to light. The secondary 
antibodies were AlexaFluor®488 conjugated anti-rabbit antibody (green) and 
AlexaFluor®594 conjugated anti-mouse antibody (red). Slices were shielded from light and 
washed in secondary antibody solution for two hours. Secondary antibody solution was 
washed off with decreasing concentration of blocking agent; ten minutes of Low Blocking 
Solution followed with ten minutes of 1x PBS. Finally, slices were washed in 0.1x PBS to 
reduce saline concentration and mounted on glass slides using VECTASHIELD
®
 (Vector) 
mounting media to prevent photobleaching. Slides were stored shielded from light in a dry, 
cool environment until imaging. Animals with incorrect placement were excluded from 
analysis.  
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Behavioural Assessment 
Isolation is known to affect mouse behavior so wherever possible, animals used for 
behavioural assessments were group housed with littermates however for the purpose of 
animal reuse, individually-housed animals were also included. A mixture of isolated and 
group housed animals contributed to data in this thesis. We did not observe any behavioural 
differences between the two cohorts. 
SHIRPA phenotype assessment 
Genetic manipulation of the galaninergic mouse LC, although similar to lesioning studies, 
was a novel perturbation and so warranted a basic phenotype assessment. A modified version 
of the ‘SHIRPA’ phenotype assessment test [223] was used to assess the following 
parameters 
Stage 1 Stage 2 Stage 3 
Body position, evidence of 
tremor, defecation, urination, 
palpebral closure, 
lacrimation, coat score, 
whiskers 
Transfer arousal, gait 
(using walking rod), 
pelvic elevation, tail 
elevation, touch escape 
Positional passivity, trunk curl, 
limb grasping, pinna reflex, corneal 
reflex, contact righting reflex, 
evidence of biting,  evidence of 
vocalisation 
 
LC-TeLC mice and LC-GFP mice both appeared to score normally on the SHIRPA test with 
healthy coat scores, normal gait and reflexes and absence of biting and vocalisation (even 
when approached with a cotton bud to test corneal reflexes!).  
Baseline locomotion 
Mice were transferred in their home cages from the holding room into the behavioral room 
and allowed >30 minutes to habituate. Locomotion was assessed for 30 minutes in an activity 
box that used infra-red beam crossings to track movement (Med Associates Activity Monitor 
Version 5 for mice). All experiments were conducted during the dark ‘active’ part of the 
sleep-wake cycle.  
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Novel object recognition – Long term memory 
We used a modified version of the protocol described by Bevins 2006 in Nature Protocols 
[214] to assess the capacity of our animals to recognize novelty in an environment. Mice 
were handled for at least a week prior to the procedure to allow them to acclimatize. They 
were exposed to the room, to manual handling by the experimenter and to random objects, 
excluding those used for the experiment. The experiment was conducted over two days 
during the dark period and mice were filmed for analysis. Apparatus and objects were 
cleaned with 10% v/v ethanol between experiments. On Day 1 mice were placed in an empty 
activity monitor and allowed to explore the environment for 10 minutes before being placed 
in a temporary holding chamber for three minutes. Two identical objects were placed in the 
centre of the activity monitor, spaced apart to ease discrimination, the mouse reintroduced 
and allowed 10 minutes to explore before being returned to the home cage for 24 hours. On 
Day 2, one of the original (familiar) objects and one novel object were placed in the same 
positions in the centre of the activity monitor, the mouse allowed to explore the objects for 10 
minutes and then returned to their home cage. For analysis, the experimenter was blind to the 
identity of the mouse. Duration of directed contact with each object was scored for the 
familiar and novel sessions from video using key-press software (Mouser, Gilestro Lab). 
Light/dark preference test 
We used a modified version of the protocol described by Bourin and Hascoet [224] to assess 
mouse preference for light or dark portions of an arena as a measure of anxiety. Half of the 
arena used for baseline locomotion was boxed in with only a small 5 cm
2
 opening located in 
the partition at floor level to allow the animal access – this was the dark portion. As before, 
mice were transferred to the behavioural room and allowed to acclimatize for in excess of 30 
minutes. A white light was switched on and the mouse placed in the ‘light’ portion of the 
activity monitor. Infra-red beam crossings (see ‘Baseline locomotion’) were used to measure 
time spent in the light and dark portions of the arena. The arena was cleaned with 10% v/v 
ethanol between animals. 
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Assay for sedation and LORR 
Dexmedetomidine (Tocris, Bioscience) was dissolved in 0.9% w/v sterile saline and 
administered intraperitoneally (IP) for all procedures. This hypnotic agent is known to cause 
hypothermia so post-assay mice were kept in a warm environment (recovery box used for 
post-operative recovery) with food and drink until they showed voluntary locomotion. For 
some cases where high dose dexmedetomidine was given, a 5 mg/ kg subcutaneous dose of 
the α2 adrenergic antagonist atipamezole was given after the assay to speed recovery. Mice 
were monitored for signs of ill health on subsequent days and a minimum of one week was 
allowed between repeated doses of dexmedetomidine. All assays were performed during the 
“dark period” in the mouse circadian cycle when wake would be highest. For sedation assays, 
100 μg/ kg (10 ml/ kg formulation) dexmedetomidine was given IP, animals were placed in 
an activity monitor for 30 minutes (Med Associates Activity Monitor Version 5 for mice) and 
then allowed to recover. For dexmedetomidine LORR assays, mice were injected IP with 400 
μg/ kg dexmedetomidine and immediately placed in a continuously rotating cylinder (3 
revolutions/ minute) and monitored for 10 minutes. If the animal fell on its back, rotation was 
paused; absence of righting response for >60 seconds was reported as LORR. For isoflurane 
LORR assays, mice were placed in a sealed cylindrical chamber through with isoflurane in 
medical oxygen was circulated at a rate of 1 L/minute. The isoflurane dose in the chamber 
was increased in a step-wise manner every five minutes (0%, 0.5%, 0.75%, 1.0%, 1.2%, and 
1.5%) and LORR was assessed by slowly rotating the chamber by hand after every dose 
increase. There was no difference in isoflurane sensitivity between LC-TeLC and LC-GFP 
mice and all lost righting reflex at 1.2% so only this dose is shown.  
CNO locomotion experiments 
Clozapine-N-oxide (Tocris, Bioscience) was dissolved in 0.9% w/v sterile saline and 
administered intraperitoneally for all procedures. Mice were transferred in their home cages 
from the holding room into the behavioral room and allowed >30 minutes to habituate. CNO 
or saline were injected and the mice placed in an empty home cage for 30 minutes to allow 
the drug to take effect. Locomotion was assessed for 60 minutes in an activity box (as above). 
When EEG recordings were performed, the headstage was attached 20 minutes before 
injection to record baseline wake. CNO was administered no more than once per week to 
allow recovery.  
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Chapter 3  
TASK-3 K
2P
 channels in the central nervous system: role in 
health and disease 
K2P Channel Family 
TWIK - tandem of P-domains weak inward rectifying K+ channel 
TWIK-1 (KCNK1), TWIK-2 (KCNK6), TWIK-3 (KCNK7) 
TREK - TWIK-related K+ channel 
 TREK-1 (KCNK2), TREK-2 (KCNK10) 
TASK -TWIK-related acid-sensitive K+ channel 
 TASK-1 (KCNK3), TASK-3 (KCNK9), TASK-5 (KCNK15) 
TRAAK - TWIK-related arachidonic acid-activated K+ channel (KCNK4) 
TALK - TWIK-related alkaline-sensitive K+ channel 
  TALK-1(KCNK16), TALK-2 (KCNK17) 
THIK - TWIK-related halothane-inhibited K+ channel 
 THIK-1 (KCNK13), THIK-2 (KCNK12) 
TRESK - TWIK-related spinal cord K+ channel (KCNK18) 
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TWIK-related acid-sensitive K+ (TASK) channels 
Tandem two-pore potassium (K2P) channels are membrane proteins found in model species of 
plants, yeast, D.melongaster, C.elegans, pond snail and mammals [225-227]. TWIK-related 
acid-sensitive K+ (TASK) channels are a subfamily of the K2P family in mammals with 
widespread CNS and peripheral expression where they regulate membrane conductances 
[228, 229].  The structure of TASK channels has not yet been solved but the crystal structures 
of three other K2P channels TRAAK, TREK-2 and TWIK-1 provide insight into TASK’s 
likely structure [230-232]. The primary subunit, a cartoon of the dimer and putative 
regulation by compounds used in this study are shown in Figure 3.1.  
All potassium channels, K2Ps included, contain a potassium-selective pore composed of four 
‘P’ domains, each of which contain outer and inner transmembrane helices, a selectivity 
filter, a signature sequence and a pore helix [230]. Conventionally, potassium channel 
subunits are expressed with one ‘P’ domain and the functional channel assembles as a 
tetramer. Uniquely for known potassium channels, K2P channels are expressed as subunits 
with two ‘P’ domains between four transmembrane domains. The N- and C-termini of the 
channel are intracellular and, also uniquely, an extended ~55 amino acid extracellular loop is 
predicted between transmembrane domains 1 and 2. This loop contributes to an ‘A-frame’ 
cap over the potassium pore. The distance between the cap and the pore is thought to be large 
enough to permit the passage of K+ ions but may block certain toxins from binding; 
explaining perhaps why TASK channels are insensitive to the ganglionic blocker 
tetraethylammonium [230, 233] (see Fig 4.1).  
TASK subunits already contain two of the four ‘P’ domains, and so assemble into dimers, 
which can be homomers, TASK-1/TASK-3 heteromers [234-239] or TWIK-TASK 
heteromers (seen in cerebellar neurons [240]). There may be further heterodimerisation with 
other K2P family members such as THIK-TASK heteromers predicted by expression profiles 
[241]. These dimers, based on the two crystal structures of TREK, may flip between down 
states, which do not conduct K+ ions and up states which permit K+ efflux [232]. How many 
of these dimers are trafficked to the membrane surface, and the subsequent amplitude of the 
TASK-3 current, appears to be regulated at the transcriptional and post-translational level and 
independently requires the last five amino acids of the C-terminus [242, 243] (a region not 
necessary for single channel operation or dimer assembly [229, 243]) and the short N-
terminus [243]. Neurons expressing TASK-3 may be able to control membrane excitability 
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by regulating the proportion of channels trafficked to the surface vs. those retained in the 
intracellular compartment [244]. Once at the membrane surface and in normal extracellular 
pH, TASK-3 does not behave as a “K+ selective hole” as previously thought [245], but 
displays both voltage and time dependent activity instead [246]. TASK-3 does not have a 
voltage-sensing domain but it does have a weak voltage-dependence; in vitro the Popen, which 
is low at negative voltages, increases with depolarisation [6].  
Regulation of TASK-3 channels by Gq/11 and pH via two distinct mechanisms 
There are two main regulators of TASK-3: extracellular pH and Gq/11-coupled receptors 
which act via independent gating mechanisms. TASK-1 and -3 channels are highly sensitive 
to extracellular pH in a narrow physiological range; currents are maximal at neutral pH 
(approx. 7.5) and are rapidly inhibited by acidification (currents fall to 10% of the maximum 
by pH 6.7) [245]. Within this physiological range, TASK channels -1 and -3 are inhibited by 
hormones and transmitters via the Gq/11-coupled receptors. Gq/11-mediated inhibition acts via 
the C-terminus sequence proximal to the transmembrane region. This same gating mechanism 
is thought to be involved in TASK-3’s sensitivity to voltage and anaesthetics, such as 
halothane [6]. Inhibition by acidification meanwhile acts via a distinct mechanism to 
halothane, Gq/11 or voltage [6, 247]. Gq/11 second messenger cascades are classically thought 
to act on K2P channels via depletion of phosphatidylinositol 4, 5-bisphosphate (PIP2) by 
phospholipase Cβ (cleavage of PIP2 results in inositol triphosphate (IP3) and diacylglycerol 
(DAG)) (Fig. 3.1) [248, 249]. Surprisingly, PIP2 depletion does not regulate TASK-3 
channels; instead they appear to be directly inhibited by DAG. This is the first report of DAG 
directly affecting cell excitability [249-251]. Bista et al., 2014 suggest that differing 
mechanisms of action for different K2P channels, controlled by the same GPCR, permits fine-
tuned modulation in different sub-cellular compartments [250].  
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Figure 3.1. TASK-3 channel regulation by Gq/11 pathway 
Schematic of TASK-3 subunit and assembled dimer. The subunit has four membrane 
spanning domains (TM), intracellular N- and C- termini and two pore-forming ‘P’ domains. 
The assembled dimer contains a potassium-selective pore over which an A-frame cap is 
predicted. This A-frame cap permits the passage of potassium ions but may prevent classic 
potassium channel blockers from affecting TASK-3 channels. Based on studies of TREK-1, 
the TASK-3 dimer is predicted to flip between two states, one which permits potassium efflux. 
Activity of this channel is directly regulated by halothane and the TASK-3 antagonist C23 
and indirectly regulated by Gq/11-coupled receptors. Gq/11-coupled receptors negatively 
regulate the activity of TASK-3 channels. The mechanism was recently discovered to require 
diacylglycerol (DAG). DAG is released downstream of Gq/11-coupled receptors when 
phospholipase C (PLC) cleaves phosphatidylinositol 4,5-bisphosphate into inositol 
triphosphate (IP3) and DAG. Original figure assembled using TREK-1 crystal structure 
cartoon, K2P channel review and subunit schematic from Franks review [1, 232, 252]. 
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TASK-3 involved in mouse sleep, wake, anaesthetic sensitivity and behaviour 
TASK-3 and TASK-1 homodimers and heterodimers with distinct electrophysiology can be 
found in the CNS, sometimes within the same neuronal population [234-239]. TASK-3 
expression is prominent in the cerebellum, neocortex, hippocampus and sleep-wake related 
nuclei such as the dorsal raphe, locus coeruleus and paraventricular nuclei of the thalamus 
[29, 241, 253]. Despite a significant overlap in CNS expression between TASK-1 and TASK-
3 [241], TASK-3 KO mice have an altered sleep phenotype while TASK-1 KO mice appear 
normal [5, 7, 254-259]. TASK-3 KO mice have exaggerated sleep-wake architecture [5, 257, 
258], a fragmentation of REM sleep and an absence of atropine-sensitive halothane-induced 
theta oscillation [258]. A number of general anaesthetics have been tested on both TASK-1 
KO and TASK-3 KO mice. TASK-3 KO mice display a reduced sensitivity to anaesthetic 
doses of halothane while retaining normal sensitivity to other classes of anaesthetic such as 
propofol, cyclopropane and etomidate [7, 256, 258]. TASK-1 KO mice are also less sensitive 
to halothane and are additionally less sensitive to the α2 agonist dexmedetomidine and more 
sensitive to GABAA receptor ligands and modulators [254, 256, 258]. These distinct 
anaesthetic sensitivities, and selective effects on sleep, suggest that TASK-3 homodimers 
play an important role in sleep and wakefulness. The distinct effects of losing one of two 
closely-related K2P channels on anaesthetic sensitivity also highlights how the anaesthetic 
mechanisms of action vary [34]. 
In addition to sleep-wake alterations, TASK-3 KO mice have demonstrated roles for this 
channel class in behaviour. These mice are more motivated to run in behavioural tasks such 
as mazes and novel arenas ([7, 257] and unpublished results in Chapter 5). There is mixed 
evidence for cognitive impairment in these animals; two studies report a lack of spontaneous 
alternation in T- or Y-maze tasks in these animals [7, 257] which suggests a deficit in 
working memory. However, the same animals behave normally on a novel object recognition 
task and perform better than controls in tests of despair behaviour (tail suspension test and 
forced swim test) [257], which suggest that their memory and behavioural motivation is 
normal. Interestingly, male TASK-3 KO mice are on average 9.6% heavier than age-matched 
littermates, which may reflect an increased drive to eat [7] although double TASK-1/-3 KO 
mice test normally for food anticipatory behaviour [260]. Recent human genome-wide 
analysis also associated a single nucleotide polymorphism site near the TASK-3 (KCNK9) 
gene with adult obesity [261]. Despite widespread cerebellar expression [29, 241, 253] and a 
role in cerebellar granule cell excitability [236], TASK-3 KO mice exhibit a normal gait and 
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normal or even increased locomotion [7]. Overall, TASK-3 KO mice are more resistant to 
stress and more motivated to move but may suffer subtle cognitive impairments revealed in 
some tasks but not others. 
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Figure 3.2. TASK-3 expression in the adult rodent brain 
In situ studies have demonstrated the widespread expression of TASK-3 in both the rat and 
the mouse brain; staining images modified from published figures (A.[253], B. [241], C. 
[29]), sagittal cartoon (D) composed using data from Talley et al., 2001 and Aller and 
Wisden 2007 [29, 241] and sagittal outline from Allen Brain Atlas [48]. TASK-3 is highly 
expressed in cerebellar granule neurons (Cer), in the locus coeruleus (LC), dorsal raphe 
nuclei (DR), in the thalamus (TH), preoptic area (PO), superchiasmatic nucleus (SCN) and 
hippocampus (HPC), basal nucleus of Meynert (B) particularly the pyramidal cell layer 
CA1(in parvalbumin-positive interneurons[262]) and granule cell layer dentate gyrus (DG). 
In the cortex (Ctx) expression is particularly prominent in layer II/III, claustrum and piriform 
cortex [29]. Several of these regions are salient in the study of sleep – LC, DR, SCN, POA 
and TH, the hippocampal expression may be related to the learning deficit observed in these 
animals and the high expression in the cerebellum should be borne in mind for tests involving 
locomotion or motor reflexes.  
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Emerging roles for TASK-3 in neuroprotection, pain and thermosensation 
Current evidence suggests that certain K2P channels are involved in pain sensation. These are 
the TREK and TRESK channels, while TASK-3 channels have low expression in the 
nociceptor neurons of the dorsal root ganglia [29, 263, 264]. One study found that TASK-3 
KO mice are less sensitive to the antinociceptive effects of the cannabinoid agonist 
WIN55212 but the same study found that at baseline TASK-3 KO mice have normal pain 
reflexes in hot-plate and tail-flick tests [7]. However, TASK-3 down-regulation has now been 
implicated in cold sensation and cold hypersensitivity that accompanies inflammation or 
neuropathic pain [265]. TASK-3 channels are highly enriched in a subset of TRPM8-positive 
cold receptor neurons, where they regulate neuron sensitivity to temperature; TASK-3 
antagonist ‘C23’[5] (used in this study) shifts the mean temperature activation threshold of 
TRPM8-positive cold receptor neurons from approximately 28.7 to 30.6°C [265]. In TASK-3 
KO mice, these high-threshold TRPM8-positive neurons are more excitable and the animals 
appear hypersensitive to cold stimuli [265]. TASK-3 channels are down-regulated during 
inflammation at a time corresponding to onset of spontaneous pain in rats [264], which could 
impact cold sensation via TRPM8-positive neurons and result in hypersensitivity. Overall, 
while TASK-3 channels are only subtly involved in pain sensation, their role in cold 
sensitivity and neuroprotection (detailed below) may contribute to neuropathic pain 
mechanisms or help counter the effects of neuronal damage. 
There is an emergent role for TASK channels in immune function and neuroprotection [266]. 
TASK-3 channels are expressed in CNS T-lymphocytes [267-269] and TASK-3 KO animals 
show an ameliorated disease course in several model disorders.  Following experimental 
autoimmune encephalitis (a model for multiple sclerosis) TASK-3 KO mice had less severe 
symptoms [270]. TASK-3 KO mice also displayed a modest reduction in infarct volume 
following cerebral ischemia [271, 272]. Double TASK-1/TASK-3 KO mice are less sensitive 
to the seizure induction produced by toxic levels of local anaesthetics (local anaesthetics such 
as lidocaine directly inhibit TASK channels) [273]. Meanwhile, in human temporal lobe 
epilepsy patients, TASK expression is significantly altered post-mortem; TASK-3 channels 
are significantly reduced in pyramidal and dentate gyrus neurons of the hippocampus and 
simultaneously increased in nearby astrocytes and microglia [274]. Changes in TASK-3 
expression may contribute to the development of epilepsy or may occur as protective 
response to epileptic activity. In humans, the KCNK9 gene for TASK-3 is located in 8q24; a 
site associated with human idiopathic generalised epilepsy and benign neonatal febrile 
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convulsions [275] and in rats the first mutation in a genetic model of absence epilepsy was 
found in TASK-3 [276]. However, the rat mutation did not appear to convey any functional 
changes [276] and a study directly investigating the role of TASK-3 in childhood and 
juvenile idiopathic absence epilepsy found no TASK-3 variants that affected the amino acid 
sequence [277]. At this stage it is unknown whether TASK-3 changes in epileptic studies 
reflect changes in brain excitability or brain responses to epileptiform activity. 
TASK-3 mutation results in Birk-Barel syndrome 
TASK-3 channels are the only K2P channels to be genetically imprinted; they are expressed 
exclusively from the maternal allele [278]. This means that mutation on the maternal allele, if 
important for function, is guaranteed to affect phenotype: genetically imprinted defects are 
responsible for the relatively rare Angelman and Prader-Willi syndromes. Another maternally 
imprinted syndrome – Birk-Barel mental retardation dysmorphism syndrome is now known 
to be caused by a mutation in TASK-3 [279]. The G236R mutation in TASK-3 does not 
abolish the function of the channel but alters its electrophysiology to lower outward current 
[280] and this altered activity during development may be the cause of the clinical symptoms 
of Birk-Barel syndrome. Birk-Barel patients have severe to moderate mental retardation, 
hypotonia, hyperactivity and distinct dysmorphic changes, including elongation of the face 
[279]. TASK-3 channels and TREK channels are highly expressed in mouse CNS during 
development including all layers of the cortex excluding layer I [29, 241, 281]. 
Overexpression of the G236R mutant TASK-3 in developing mice disrupted neuronal 
migration to the cortex, although the misdirected neurons were somehow able to mature by 
post-natal day 35 [281]. A similar misdirection of neuronal populations may occur in Birk-
Barel patients during prenatal development resulting in altered neuronal circuitry. Because 
the G236R mutant retains some functional activity, it is difficult to draw parallels between 
this human syndrome and TASK-3 KO animals in which the channel was totally absent during 
development. In addition, CNS expression of TASK-3 is not identical between species; in 
humans TASK-3 expression is much higher in the cerebellum compared to rodents [282, 
283]. What is clear, however, is that TASK-3 plays an important role in human CNS 
development [279, 280] and affects neuronal migration and excitability in rodents [236, 281]. 
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Conclusions and Future Directions 
Much of what we understand about the role of TASK-3 channels in behaviour, sleep, wake 
and sensation comes from the study of two TASK-3 KO mouse lines [236, 284]. Their 
phenotype is complex; their increased wakefulness and resistance to despair behaviour 
suggests that TASK-3 inhibition may be an attractive pharmacological strategy [257]. 
However, the mental retardation of Birk-Barel syndrome patients and the subtler cognitive 
impairment of TASK-3 KO mice in addition to changes in cold sensation and possibly CNS 
immune function mean that blunt inhibition of TASK-3 channels may not be desirable. It is 
unknown whether genetic variation in this channel class (including Birk-Barel patients) is 
associated with differences in sleep architecture or anaesthetic sensitivity. It is also currently 
unknown whether TASK-3 antagonism can reverse anaesthesia which would support its 
necessary role in wakefulness. So far it is clear that widespread TASK-3 expression in the 
CNS is important for wakefulness, memory, sensation and halothane anaesthesia. 
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Chapter 4  
TASK-3 K
2P
 channels in temperature regulation and stress-
induced hyperthermia 
Abstract  
TASK-3 potassium channels regulate the membrane conductance of many neuronal 
populations. Recently, it was reported that TASK-3 KO mice have an elevated sensitivity to 
external cold [265]. This new role for TASK-3 channels has not been fully characterized. 
Adult male TASK-3 KO mice and their wild-type littermates were implanted with abdominal 
telemeters to measure temperature and locomotion. Following cage changing and handling, 
littermate animals showed a stress-induced hyperthermia (p<0.0001) but this effect was 
absent in TASK-3 KO mice. Wild-type littermate animals also responded to a range of 
injection methods (intraperitoneal, oral and subcutaneous) with a modest but significant 
hyperthermia (increase of approx. 0.5º C above expected temperature, p<0.01). To our 
surprise, TASK-3 KO mice responded to subcutaneous injection with a 2-4 ºC hypothermia, 
the opposite effect to control littermates. Moreover, administration of the TASK-3 antagonist 
C23 also produced a marked 2-4 ºC hypothermia in wild type animals (p<0.05). Our findings 
reveal an important role for TASK-3 potassium channels in mammalian thermoregulation.   
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Introduction  
TWIK-related acid-sensitive K+ (TASK) channels, a subfamily of the K2P family in 
mammals with widespread CNS and peripheral expression, contribute to membrane leak 
conductances [228, 229].  Collectively, the channels are opened or closed by a broad range of 
stimuli. Changing the magnitude of TASK-leak conductances can strongly affect cell 
excitability [236]. Studies of TASK channel knockout mice have revealed that TASK-1 and 
TASK-3 channels contribute to arousal, sensation, oxygen sensing [285] and behaviour [5, 7, 
34, 254, 255, 257, 265]. TASK-3 KO animals, in particular, appear to be resistant to the 
negative effects of stress on test performance and have reduced REM sleep that cannot be 
further diminished by the antidepressant fluoxetine [257]. These phenotypes suggest that 
TASK-3 may be a novel antidepressant target [257]. 
Recent findings have implicated TASK-3 in temperature regulation and sensation. TASK-3 
KO mice [284] have an exaggerated temperature cycle over 24 hours [257], and an increased 
sensitivity in a cold-avoidance task [265]. The expression of TASK-3 channels also supports 
a putative role in thermoregulation. In the periphery, TASK-3 channel transcripts are 140-
fold enriched in peripheral TRPM8-positive cold-sensitive neurons, which significantly 
contribute to cold sensation [265]. In the CNS, TASK-3 is expressed in regions conveying 
cold-sensation [286]. There is high expression in the hypothalamic preoptic area, a 
sensorimotor integration site for thermoregulation [29, 286],  additionally TASK-3 mRNAs 
occur in the external subdivision of the lateral parabrachial nucleus (lateral to the locus 
coeruleus), a site activated by cold stress and a proposed integration site for visceral and 
cutaneous thermal signals that directly transmits to the preoptic area [29, 265, 286-288]. 
We studied TASK-3 KO adult mice and their wild-type littermates that were originally 
generated by Brickley et al., 2007 (a parallel TASK-3 KO mouse line was developed by 
Mulkey et al., 2007 and used for the temperature studies of Gotter et al., 2011 and Morenilla-
Palao et al., 2014). Mice were chronically implanted with abdominal telemeters that 
wirelessly recorded temperature and locomotion, and then housed individually. We examined 
their daily temperature rhythm, their temperature response to basic handling, cage changing, 
restraint and vehicle injections, and their temperature response to the TASK-3 antagonist C23 
[5]. While their body temperature rhythm appeared normal, TASK-3 KO mice showed no 
significant temperature response to handling and cage change and a briefer response to 
vehicle injection compared to littermates, which had elevated temperature in response to all 
three stressors. Subcutaneous injection resulted in an unusual hypothermia in TASK-3 KO, 
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while littermates showed a typically modest elevation in temperature associated with stress. 
This hypothermic response after subcutaneous injection was reproduced in littermates by 
administration of the TASK-3 antagonist C23. Taken together, our findings uncover a novel 
role for TASK-3 K2P channels in thermogenic responses to subcutaneous injection and 
confirm and expand on the stress-resistant phenotype of the TASK-3 KO mouse strain. 
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Results 
Adult male TASK-3 KO mice and their littermates were individually housed with a normal 
12:12 hour light: dark cycle and normal ambient temperature (21 ± 2°C). The locomotor 
activity and abdominal temperatures of these animals were recorded over 62 hours using 
chronically-implanted wireless telemeters (Fig. 4.1). While locomotor activity was elevated 
during the dark period, when this was normalised to time awake, both cohorts appeared 
similar (mean ± SD locomotor counts/minute of wakefulness TASK-3 KO = 23.29 ± 4.70, 
littermates = 20.90 ± 4.00), contrary to previous reports of hyperactivity in TASK-3 KO 
animals [7]. Equally, in both cohorts, body temperature oscillated by approximately ± 0.5°C 
from mean body temperature (mean body temperature ± SD TASK-3 KO = 36.42 ± 0.57, 
littermates = 36.47 ± 0.37), remaining elevated throughout the ‘active’ dark period and falling 
by up to 1°C during the light phase. This is also contrary to previous reports of an 
exaggerated temperature cycle in TASK-3 KO mice [257]. Littermate mice showed 
anticipatory increases in body temperature before the beginning of the dark period (Fig. 4.1, 
top panel).  
Five hours after the beginning of the second light period (ZT 5), mice were exposed to 
‘Handling’ – several experimenters entered the holding room, animals were weighed and 
their bedding and food changed for new ones. In littermates, this manipulation produced a 
reliable rise in body temperature of approximately 0.5°C, which lasted for approximately one 
hour compared to the temperature during the previous undisturbed ‘Baseline’ light period 
(Fig. 4.1, bottom panel, left, p<0.0001, Two-way ANOVA with Sidak post-test) . This 
temperature rise is a recognised physiological stress response to restraint and cage change. 
The change in temperature and duration of the response is comparable to previous reports 
[289, 290]. In TASK-3 KO animals, this temperature response was absent when compared to 
‘Baseline’ (Figure 4.1, bottom panel, right). Notably, TASK-3 KO and littermate controls still 
responded equally to handling with increased wake and locomotion (Fig. 4.2A & B, see 
Figure legend for respective p values). The trend towards slightly lower locomotion in the 
first hour after handling in TASK-3 KO mice was not significant when change in locomotor 
from baseline was considered for each animal (mean ± SD Δ locomotor counts from baseline 
TASK-3 KO = 423 ± 278, littermates = 761 ± 515). 
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Figure 4.1. TASK-3 KO animals display normal body temperature rhythm but respond 
differently to gentle manual handling compared to littermates 
Mouse EEG, EMG, abdominal temperature and locomotion were monitored over the course 
of 62 hours (where plotted periods of environmental darkness are shaded in grey).Top panel: 
Temperature was recorded by abdominal telemetry. Absolute and change (deviation from 
baseline mean) in temperature were measured over time in average temperature/ hour bins 
(red circles TASK-3 KO n=13, black circles Littermates n=14). Plotted points represent the 
average temperate in the previous hour. Animals were disturbed five hours into the second 
light period (‘Handling’ represented by dashed blue line) after which a significant elevation 
in temperature was seen in littermates compared to TASK-3 KO mice. Bottom panel: 
Temperature in the ‘Handling’ period was compared to the previous undisturbed light period 
in each genotype (0-12 hours vs. 24-36 hours). Two-way ANOVA (animals matched to own 
baseline) with Sidak test to correct for multiple comparisons (*-p<0.05, **=p<0.01, 
****=p<0.0001). 
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Figure 4.2. Locomotor and wake responses to handling were normal in TASK-3 KO 
animals. 
Wake was scored in each cohort using EEG and EMG recordings and plotted as percentage 
of wake/hour (red circles TASK-3 KO n=10, black circles Littermates n=11). A. Plotted 
points represent the average wake in the previous hour. Percentage of wake in the 
‘Handling’ period was compared with the previous undisturbed light period in each 
genotype. B. Locomotion was recorded by abdominal telemeter (red circles TASK-3 KO 
n=12, black circles Littermates n=14). Plotted points represent the average locomotor 
activity in the previous hour. Number of locomotion counts in the ‘Handling’ period was 
compared to the previous undisturbed light period in each genotype. All comparisons made 
using two-way ANOVA with Sidak's post-test to correct for multiple comparisons (* p<0.05, 
** p<0.01, *** p<0.001, **** p<0.0001). 
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We compared stress-induced temperature responses following intraperitoneal, subcutaneous 
and oral dosing methods of pharmacologically inactive solutions (see Methods). Each 
injection was also accompanied by a cage change. In littermates, for all three routes of drug 
administration, initial temperature responses were the same amplitude as that after handling 
(approx. 0.5ºC) and took roughly the same time to recover to baseline temperature (Fig. 4.3A, 
B & C left panels). TASK-3 KO animals also responded to intraperitoneal and oral dosing 
with a 0.5ºC initial temperature increase (intraperitoneal p<0.0001, oral p<0.01, Two-way 
ANOVA, Sidak post-test), but they recovered to baseline faster than littermates, suggesting a 
blunted stress-induced response. Surprisingly, subcutaneous administration of a vehicle 
solution (20% modified cyclodextrin) in TASK-3 KO mice produced a four-hour hypothermia 
with either masked or no stress-induced hyperthermia in the initial hour post-administration 
(Fig. 4.3C, bottom right panel, significant three and four hours post-injection, p<0.05 Two-
way ANOVA, Sidak post-test). 
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Figure 4.3. Temperature responses to different modes of drug dosing in TASK-3 KO 
mice and wild type littermates. 
Temperature was recorded by abdominal telemetry over the course of 62 hours starting at the 
beginning of a 12-hour light period. Animals were disturbed five hours into the second light 
period and given a dose of vehicle by one of three routes – intraperitoneal, oral or 
subcutaneous injection (time of dosing represented by dashed blue line).  Temperature in the 
dosing period was compared to the previous undisturbed light period in each genotype (0-12 
hours vs. 24-36 hours). A) Intraperitoneal injection of 0.25% methylcellulose was followed 
by a significant elevation in temperature lasting approximately an hour in littermates and 
TASK-3 KO animals (red circles TASK-3 KO n=12, black circles Littermates n=14). B) Oral 
dosing of 1% carboxymethylcellulose was followed by a significant elevation in temperature 
lasting two hours in littermates and one hour in TASK-3 KO animals (red circles TASK-3 KO 
n=13, black circles Littermates n=14). C) Subcutaneous injection of 20% modified 
cyclodextrin was followed by a significant elevation in temperature lasting an hour in 
littermates and a delayed two hour reduction in temperature in TASK-3 KO animals (red 
circles TASK-3 KO n=12, black circles Littermates n=12). All comparisons made using Two-
way ANOVA with Sidak's post-test to correct for multiple comparisons (* p<0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001). 
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It was reported that TASK-3 KO mice perform better than controls after restraint, which 
identified TASK-3 as ‘a novel target for anti-depressant treatment’ [257], but whether TASK-
3 antagonism can attenuate stress-responses in mice is not known. We administered 
increasing doses of the TASK-3 antagonist C23 [5] to both littermates and TASK-3 KO mice 
at ZT 5 and observed the effects on temperature. At the lowest dose of 30 mg/ kg, C23 
produced significant hypothermia (p<0.05 after one hour and p<0.0001 after two hours) in 
littermates (Fig. 4.4, green trace and circles, left panel) similar to that seen in TASK-3 KO 
mice dosed with vehicle (Figure 4.3). In TASK-3 KO animals, 30 mg/ kg C23 produced no 
further hypothermia beyond that induced by vehicle (Fig. 4.4, green traces and circles, right 
panel). A higher dose of 100 mg/ kg C23 produced a significantly greater hypothermic 
response in all littermate animals (p<0.0001 for two hours post-injection), however in the 
TASK-3 KO mice there was no further change in hypothermia over vehicle. (Fig. 4.4, green 
traces and circles – 30 mg/ kg, red traces and circles – 100 mg/ kg). Finally, a dose of 300 
mg/ kg C23 produced severe hypothermia in both TASK-3 KO mice and littermates (p<0.05 
after one hour and p<0.0001 after two hours in TASK-3 KO mice, insufficient animals for 
statistical testing in littermates); this high-dose  effect may recruit TASK-1, for which C23 
has a ten-fold lower affinity or additional targets [5]. Recovery from hypothermia was 
observed in the littermates (Fig. 4.4, blue trace and circles), however in the TASK-3 KO mice 
the hypothermia at this dose was so severe that the mice were humanely killed after showing 
several hours of non-recovery. Overall, TASK-3 KO mice responded to a subcutaneous 
injection with hypothermia, and administration of the TASK-3 antagonist C23 to wild-type 
mice produced a similar and dose-dependent hypothermic response. C23 administration to 
TASK-3 KO mice did not elicit a drug-mediated response, however at the highest dose it 
produced a severe hypothermic effect with no apparent recovery from hypothermia. 
  
  
105 
 
 
 
Figure 4.4. Dose-dependent effects of TASK-3 antagonist C23 on temperature. 
Temperature was recorded by abdominal telemeter over the course of 62 hours starting at the 
beginning of a 12-hour light period. Animals were disturbed five hours into the second light 
period and given a subcutaneous injection of vehicle (20% modified cyclodextrin), 30 mg/ kg, 
100 mg/ kg or 300 mg/ kg C23. Animal numbers were as follows: vehicle  (shown in black 
traces or circles, TASK-3 KO n=12, Littermates n=11), 30 mg/ kg (shown in green traces or 
circles, TASK-3 KO n=10, Littermates n=13), 100 mg/ kg  (shown in red traces or circles, 
TASK-3 KO n=8, Littermates n=13) and 300 mg/ kg  (shown in blue traces or circles, TASK-
3 KO n=3, Littermates n=2). All three TASK-3 KO mice failed to recover from C23-induced 
hypothermia and were humanely killed. All comparisons made using Two-way ANOVA with 
Sidak's post-test to correct for multiple comparisons (* p<0.05, ** p<0.01, *** p<0.001, 
**** p<0.0001). 300 mg/ kg littermate numbers were insufficient to be used for statistical 
testing. 
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Discussion 
Stress-induced hyperthermia is an autonomic increase in body temperature in response to 
stress. This study and others have demonstrated that the temperature increase is actively 
initiated post-stress and is independent from other stress behaviours such as increased 
locomotion. Whether this increase is regulated in the same way as other types of heat 
generation is unknown. TASK-3 KO mice had no temperature response to cage changing and 
manual handling and a blunted temperature response to intraperitoneal injection or oral 
gavage. Meanwhile, littermates responded to all three stressors with significant elevations in 
body temperature. After subcutaneous injection, TASK-3 KO mice displayed an unusual drop 
in body temperature; this effect could be fully recapitulated in littermates by administration 
of the TASK-3 antagonist C23. In this study we have uncovered a contribution from K2P 
TASK-3 channels to both heat responses to subcutaneous cold and to the initiation of stress-
induced hypothermia.  
The body temperature of mice in our study was continuously monitored with an abdominal 
telemeter. Contrary to previous reports [257], we did not find that body temperature was 
significantly elevated in TASK-3 KO mice during the active phase (lights off) compared with 
littermates. In fact, their temperature rhythms aligned closely with those of littermates 
throughout the cycle. The circadian oscillation in body temperature was approximately ± 
0.5°C, although the anticipatory increase in body temperature before lights-off appeared 
slightly blunted in the TASK-3 KO animals. The presence of this oscillation suggests the 
mechanisms orchestrating daily increases and decreases in temperature remain intact or are 
capable of compensating loss of TASK-3 during development. 
Stress-induced hyperthermia is attenuated in TASK-3 KO mice 
While studying the sleep-wake temperature cycle of TASK-3 KO mice compared with wild-
type littermates, we unexpectedly found that TASK-3 KO mice did not show the typical hour-
long elevation in temperature that we saw in littermates after handling and cage changing. 
Both wake and locomotion increased after handling for both cohorts, demonstrating that the 
increase in body temperature after handling was not a secondary effect of increased 
movement. The temperature increase we saw in littermates is most likely stress-induced 
hyperthermia (“emotional fever”), a robust autonomic response to stress reported in both 
laboratory animals and humans [291]. The approximately 0.5°C increase in body temperature 
was not increased further by more stressful procedures and yet was intact after months of 
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weekly procedures in the littermate mice. This robust response with a ‘ceiling effect’ supports 
previous reports of stress-induced hyperthermia in mice [291]. More stressful procedures 
such as restraint and drug injection extended the duration of stress-induced hyperthermia in 
littermates and succeeded in producing stress-induced hyperthermia in TASK-3 KO animals 
albeit of shorter duration. It is possible that this blunting of the stress-induced temperature 
response in TASK-3 KO animals reflects a disturbance of autonomic functioning. However, 
given that another TASK-3 KO mouse line [284] has shown resistance to other effects of 
restraint, we suggest this blunted stress-induced hyperthermia response reflects the stress-
resilient phenotype of TASK-3 KO mice.  
TASK-3 inhibition produces hypothermia 
We sought to understand the contribution of TASK-3 channels to thermoregulation by 
administration of the TASK-3 antagonist C23 [5] to mutant and littermate control animals 
and found it produced marked and long-lasting hypothermia in wild-type mice. But TASK-3 
KO animals showed a hypothermic response to subcutaneous vehicle injection alone that 
could not be further exaggerated by C23 administration. High doses of C23 produced 
profound hypothermia in both cohorts, most likely due to off-target effects. Based on our 
limited observation of animals at this high dose, TASK-3 KO animals appeared incapable of 
compensating for the effects of C23-induced hypothermia; within hours their body 
temperature fell to that of the surrounding environment.  
Conclusions and Future Directions 
Collectively, these findings together suggest that TASK-3 channels are involved in 
thermogenesis in response to subcutaneous cold, but not in generating heat during stress-
induced hyperthermia or the daily temperature rhythm. TASK-3 KO animals responded to 
handling with increased wake and locomotion showing sensitivity to certain aspects of the 
procedure, possibly novelty. Despite the changes in wake and locomotion, the accompanying 
temperature rise we saw in littermates was completely abolished in TASK-3 KO animals after 
handling. However, following the intuitively more stressful procedure of drug dosing, TASK-
3 KO mice responded with temperature increase of the same magnitude as littermates, 
demonstrating that they were capable of stress-induced hyperthermia if the stimulus was 
sufficiently stressful. Previous reports showed that TASK-3 KO mice have modest hyper-
responsivity to external cold; TASK-3 KO mice responded by paw withdrawal to temperatures 
of 21.6 ± 0.4°C compared to 20.1 ± 0.4°C in wild-type animals [265]. Based on this, it seems 
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unlikely that TASK-3 KO animals are incapable of sensing subcutaneous cold or indeed 
visceral cold when experiencing the strong hypothermia induced by C23. Nevertheless, it is 
possible that a distinct TASK-3 channel population exists in subcutaneous tissues, the 
absence of which abolishes sensation of cold and therefore a thermogenic response. We 
suggest, however, that CNS TASK-3 channels may be important in the initiation or 
maintenance of cold-defence responses (such as vasoconstriction, muscle shivering and non-
shivering thermogenesis in brown adipose tissue) to a bolus injection of room temperature 
fluid under the skin and to the C23-induced off-target hypothermia. This may also explain 
why a lower dose of C23 produces a comparable hypothermia in littermate animals. This 
‘abolished cold defence’ explanation rests on the assumption that a bolus of room 
temperature fluid is a sufficiently strong cold stimulus to require cold-defence in littermate 
animals. 
In conclusion, our work reveals a blunted temperature stress response and a putative absence 
of thermogenic cold defence response in TASK-3 KO animals while their temperature rhythm 
remains intact. Of interest is whether the hypothermia induced by subcutaneous vehicle 
injection in TASK-3 KO mice truly is the absence of heat compensation or if it results from 
some other process. The hypothermia induced in both TASK-3 KO mice and littermates by 
higher doses of the TASK-3 antagonist C23 abolishes normal temperature maintenance and it 
would be informative to understand which receptor populations mediate this.   
  
109 
 
Materials and Methods 
Animal surgery for temperature recordings 
All animal procedures were performed in accordance with Imperial College London and Lilly 
UK animal care committees’ regulations. The development of TASK-3 knockout (KO) mice 
(in which the first exon was disrupted) and their littermates (129sv/C57BL6 genetic 
background) has been described previously [236]. Male mice were genotyped by PCR using 
genomic DNA with the following primers (Primer 1: 5’-
TCTGTCCCGCTACCGATCCTGC-3’, Primer 2: 5’-
TTCCGTGGGCGCAGCGGGTTCCGC-3’) – TASK-3 KO animals were identified by a 
400-bp product; littermates showed a 350-bp product. Both before and after surgery, animals 
were housed in solid-bottomed cages with sawdust bedding and environment enrichment. 
Food and water were available ad libitum with temperature and humidity maintained at 21 ± 
2°C and 55 ± 10% respectively and lighting on a 12:12 hour light-dark cycle. 
2-3 month-old male mice were instrumented with a cranial implant connected to five stainless 
steel cranial screws (for EEG recording) and two Teflon-coated stainless steel wires under the 
nuchal trapezial muscles (for EMG recording). A miniature telemeter (Minimitter, USA) to 
monitor body temperature and locomotor activity was implanted in the abdominal cavity. 
Following surgery, animals were given a rehydration pack in addition to their dry diet and 
housed individually. Animals were allowed at least 21 days to recover from surgery before 
being used for any subsequent procedures and monitored daily for signs of ill health for the 
remainder of their lives (see Supplementary Methods for details of surgery).  
Drug Dosing 
The TASK-3 antagonist 1-[1-[6-[[1,1'-Biphenyl]-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-
d]pyrimidin-4-yl]-4-piperidinyl]-1-butanone (C23) was developed by Coburn et al., 2011 and 
synthesized at Eli Lilly. Mice were handled and/or dosed between zeitgeber (ZT) 5 and 5.2 
hours post light onset. C23 or vehicle solutions were dosed in a volume of 10 ml/ kg. A fresh 
dose of 30 mg/ kg, 100 mg/ kg or 300 mg/ kg C23 was formulated in 20% modified 
cyclodextrin (Captisol, USA), pH 6.0 on the day of each experiment. C23 or vehicle (20% 
modified cyclodextrin, pH 6.0 (Captisol, USA)) were dosed subcutaneously. Animals 
received a dose of drug or vehicle on alternate weeks in a random crossover. Other vehicle 
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solutions used were 0.25% methylcellulose (M7140, Sigma, UK) for intraperitoneal dosing 
and 1% carboxymethylcellulose (C5678, Sigma, UK) for oral dosing. 
Data Analysis 
Once recovered, mice were housed individually in recording chambers and data collected for 
62 hours every week. Disturbance of the animals was restricted as much as possible to ZT 5 
once a week – animals were weighed and their bedding, food and water refreshed in addition 
to receiving drug, vehicle or no treatment (no drug or vehicle treatment referred to as 
‘Handling’). Sleep-wake parameters, locomotion and temperature were monitored using 
SCORE-2004, an updated version of a real-time sleep-wake monitoring system [292]. 
Temperatures for each individual animal were calculated as deviations from their mean 
temperature over first 24 hours. Data were reported as mean ± S.E.M. Two-way ANOVA 
with Sidak's post-test to correct for multiple comparisons was performed using GraphPad 
Prism version 6.04 for Windows (GraphPad Software, La Jolla California USA, 
www.graphpad.com).  
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Chapter 5  
TASK-3 knockout mice retain sensitivity to wake-promoting 
compounds but have elevated nocturnal wake and diminished 
cortical power 
Abstract 
TWIK-related acid-sensitive K+ (TASK) channels are opened by anaesthetics such as 
halothane [293] and inhibited by the signalling cascades of Gq/11- coupled receptors [252]. 
TASK-3 KO mice have diminished sensitivity to the anaesthetic halothane and increased 
wakefulness compared to wild-types [258]. Administration of TASK-3 antagonist C23 to 
wildtype animals also increases wakefulness [5, 257]. Together these findings suggest that 
inhibition of TASK-3 channels may be necessary for wake-promotion or maintenance while 
their opening promotes sedation. To investigate whether wake-promoting compounds act via 
TASK-3, we gave TASK-3 KO and wild-type mice [236] three wake-promoting compounds 
(GSK-5, LSN2814617 and taltirelin) that act through Gq/11-coupled receptors. In support of 
previous reports, we found that TASK-3 KO mice showed a baseline elevation in wake that 
was highest during the dark period (p<0.01). All three wake-promoting compounds 
significantly increased wake in both TASK-3 KO mice and wild-types, suggesting that TASK-
3 is dispensible for their wake-promoting mechanism of action. However, the gamma-range 
(50-80 Hz) EEG activity induced by two of these compounds (GSK-5 and LSN2814617) was 
significantly diminished in TASK-3 KO mice (p<0.01 and p<0.0001). In addition, we found 
TASK-3 KO mice showed a wide-band (0-15 Hz) reduction in cortical EEG power (p<0.05) 
during wake and NREM sleep. 
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Introduction 
TWIK-related acid-sensitive K+ (TASK) channels are a subfamily of tandem two-pore 
potassium channels (K2P) that contribute to membrane leak conductances throughout the CNS 
[228, 229]. There are two functional members of this subgroup – TASK-1 and TASK-3 and 
both homodimers and heterodimers of these channels can be found in overlapping neuronal 
populations [234-239]. Changing the magnitude of TASK leak conductances can strongly 
affect cell excitability [236] so, when these channels were first characterised in the early 
1990s, there were hopes that this class may effect wide-spread changes in neuronal 
excitability as the brain transitions in and out of sleep or unconsciousness. Studies of mouse 
knockout lines lacking TASK channels have revealed that TASK-3 [5, 7, 257, 258] but not 
TASK-1 channels [259] play a role in sleep architecture and that halogenated anaesthetics 
require TASK and TREK channels (another subgroup of K2P channels) to induce loss of 
consciousness and subsequent loss of pain reflex [34]. TASK-3 channels are opened by 
isoflurane and halothane in vitro [293] and TASK-3 KO mice are less sensitive to a wide 
range of halothane doses, while retaining normal sensitivity to other anaesthetics such as 
propofol, etomidate and cyclopropane [7, 256, 258]. The same mice also exhibit exaggerated 
wake and suppressed REM, as well as deficits in working memory and a resistance to despair 
behaviour [5, 7, 257, 258]. These phenotypes suggest that TASK-3 channels are important in 
the function of neural circuits that regulate wake behaviour.  
Direct inhibition of TASK-3 using a recently developed TASK-3 antagonist reproduces the 
wake-promoting and REM-suppressing phenotype of TASK-3 KO mice in wildtype animals 
[5]. There is no known endogenous TASK-3 inhibitor; instead TASK-3 channels are 
inhibited downstream of Gq/11-coupled receptors [252] via the release of diacylglycerol [249-
251] (see Chapter 3, Fig. 3.1). A number of wake-promoting compounds activate Gq/11 [294-
297], but it is unknown whether their wake-promoting effects depend on the subsequent 
inhibition of TASK-3. We sought to determine whether three such wake-promoting 
compounds require TASK-3 for their mechanism of action by administering them to TASK-3 
KO [236] and wild-type littermate animals. We compared the wake-promoting effects of 1-
(N-substituted piperidin-4-yl)benzimidazolone, a selective allosteric muscarinic receptor M1 
agonist [297], referred to as ‘GSK-5’, (7S)-3-tert-butyl-7-[3-(4-fluorophenyl)-1,2,4-
oxadiazol-5-yl]-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine, a positive allosteric 
modulator of mGlu5, referred to as ‘LSN2814617’ [294] and the TRH analog taltirelin [298], 
using the TASK-3 antagonist ‘C23’ [5] as a positive control.  
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All three distinct wake-promoting compounds produced prolonged wakefulness in both 
TASK-3 KO mice and their wild-type littermates, suggesting that TASK-3 is dispensable in 
the Gq/11-mediated wake-promoting cascade. However, we found substantial reduction in the 
EEG amplitude of TASK-3 KO mice, both during baseline activity and under the influence of 
wake-promoting compounds. In addition, our study of the baseline sleep-wake of these mice 
compared to same-strain littermates (previous EEG studies have used C57bl6 mice as 
comparators [5, 257, 258]) confirmed an increased wakefulness in the TASK-3 KO mice, 
most prominent during the active period. Finally, similar to previous reports, the TASK-3 KO 
strain ran more trials than littermates [7, 257] but contrary to previous study showed no 
cognitive impairment. TASK-3 KO mice performed better than littermates on a delayed 
alternation working memory task (p<0.05).  
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Results 
Elevated wake activity in TASK-3 KO animals is most prominent during the dark period 
We studied TASK-3 KO mice using two recording protocols; short-term 24 hour untethered 
recording following the protocol of Pang et al., 2009 [258] and long-term 62 hour 
undisturbed tethered recording. Mice in the short-term ‘Pilot’ experiment closely reproduced 
the phenotype reported in Pang et al., 2009 (Fig 5.1. A and B); wake was elevated in TASK-3 
KO mice at the beginning of the light inactive phase and comparable to controls in the dark 
period. The Pang et al., study used C57bl6 mice as a comparator strain and strain effects on 
sleep phenotype [205] may have obscured the TASK-3 KO phenotype. By using same-strain 
littermates, we confirmed that the TASK-3 KO have a reproducible elevation in wake at the 
beginning of a 24 hour recording.  
During sleep-scoring, we discovered that EEG power was consistently diminished in TASK-3 
KO mice in all sleep stages (p<0.05 for wake and p<0.01 for NREM and REM, Fig. 5.1. C). 
This was also seen in the Pang et al., 2009 study but normalised out because strain difference 
is known to affect EEG power [205, 299]. Despite the diminished EEG power in TASK-3 KO 
sleep and wake, the frequency composition remained consistent, e.g. NREM periods had a 
characteristic power spectra dominated by delta range (0-4 Hz) activity. A larger scale study 
was then conducted to determine baseline sleep-wake activity in TASK-3 KO mice and 
littermates over 62 hours in an undisturbed environment. Adult male TASK-3 KO mice and 
their littermates were individually housed with a normal 12:12 hour light: dark cycle for the 
duration of the study which lasted for several months. They were undisturbed for six out of 
seven days of the week, on the ‘Handling’ day mice were disturbed between ZT 5 and ZT 
5.2, i.e. five hours into the light period, cage bedding and food was changed and the mice 
weighed. In subsequent weeks, mice were also dosed with vehicle or wake-promoting 
compound during this time-window. EEG was collected via a tethered cable which allowed 
the mouse to freely explore the home cage.  
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Figure 5.1. Pilot study using headstage protocol supports sleep phenotype reported by 
Pang et al., 2009 and reveals diminished EEG amplitude 
A. Vigilance states of TASK-3 KO mice and littermates over 24 hours expressed as 
percentage time spent in vigilance state over two hours. Animal EEG and EMG were 
recorded via wireless headstage, using similar protocol to that published by Pang et al., 2009 
[258] (TASK-3 KO (red), n=4), Littermates (black) n=4). B. Graph modified from Pang et 
al., 2009. C57bl6 mice rather than littermates were used as control strain for TASK-3 KO 
mice. C. Average power spectra for littermates and TASK-3 KO mice in wake, NREM and 
REM. Area under the curve was significantly reduced for WAKE (p<0.05 unpaired t-test), 
NREM (p<0.01 unpaired t-test) and REM (p<0.01 unpaired t-test). All power spectra traces 
normalised to mean area under the curve for littermates during wake.  
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During the first 24 hours of the long-term sleep recording, the phenotype of TASK-3 KO mice 
resembled that seen in our Pilot study; wake was elevated at the beginning of the light period 
and then returned to normal for the subsequent dark period (Fig. 5.2.). Five hours into the 
next 24 hour period, mice were handled (represented by dashed line) and the difference in 
minutes of wake, NREM, REM between littermates and TASK-3 KO mice calculated for the 
remainder of the light period (L1) and the following dark and light periods (D and L2). 
Handling did not affect sleep-wake in the first seven hours but during the following 24 hours, 
wake was significantly (p<0.01) elevated at the expense of NREM. This wake increase was 
particularly prominent during the dark phase, which supports previous long-running tethered 
studies of these animals [5, 257] and the original study of the locomotion patterns of these 
mice [7, 254].  
The difference between our Pilot data and the data from the long-term study is probably 
caused by the effects of physical restraint [300] and environmental novelty [301] on the 
sleep-wake behaviour of the both TASK-3 KO and littermate animals. TASK-3 KO mice are 
less sensitive to the effects of restraint [257] inherent in the tethered study, more stimulated 
by novelty [7, 257] (the environment of the Pilot study was not undisturbed and the mice 
handled just before recording, while the long-term study had no external stimulation until ZT 
5). In Chapter 4, I demonstrated that this difference in stress can be observed in the absence 
of stress-induced hypothermia in TASK-3 KO animals after handling (represented by the 
dashed line in Fig. 5.2). Notably, in contrast to previous reports [7], TASK-3 KO mice did not 
exhibit hyperactivity during the dark period; their locomotor counts were similar to controls 
when normalised to amount of time spent awake (mean ± SD locomotor counts/minute of 
wakefulness TASK-3 KO = 23.29 ± 4.70, littermates = 20.90 ± 4.00). The reduction in power 
observed during the Pilot study, was reproduced in the long-term study (Fig. 5.3), although 
the effect size was diminished (p<0.05 for wake and NREM and n.s. for REM). 
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Figure 5.2. TASK-3 KO animals display elevated wake during the dark period with a 
concurrent decrease in NREM sleep 
Vigilance states of TASK-3 KO mice and littermates expressed as percentage time spent in 
state over two hours. Animal EEG and EMG were recorded via a tether in the home cage in a 
long-running study. Left panel: Littermates (black), n=11, TASK-3 KO (red), n=10, animals 
handled five hours into the light period (dashed line). Plotted points represent percentage 
time spent in vigilance state in previous two hours. Right panel: difference in minutes 
between TASK-3 KO animals compared to littermates in the light period post-handling (L1), 
the subsequent 12 hour dark period (D) and following 12 hour light period (L2). Wake is 
significantly elevated and NREM significantly diminished in both light and dark, with both 
effects more evident in the dark period. Two-way ANOVA with Sidak post-test (*p<0.05, 
**p<0.01) 
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Figure 5.3. Larger scale study demonstrates reduced power in WAKE and NREM but 
not REM of TASK-3 KO animals. 
EEG data for TASK-3 KO mice and littermates were scored into vigilance states and the 
average frequency composition in each state calculated by Fast Fourier Transform. A. 
Average power spectra for littermates (grey) and TASK-3 KO (red) mice in wake, NREM and 
REM. Power spectra normalised to mean AUC littermates during wake. Area under the curve 
1-15 Hz is significantly reduced for WAKE (p<0.05 unpaired t-test), NREM (p<0.05 
unpaired t-test) but not significant for REM (p=0.0705 unpaired t-test). TASK-3 KO (n=10), 
Littermate (n=13). B. Delta power (0-4 Hz) during NREM sleep per hour over 62 hours. 
Plotted points represent delta power in previous hour. 
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Gq/11-coupled compounds do not require TASK-3 for wake-promoting mechanism of 
action 
Next, we administered four wake-promoting compounds to TASK-3 KO mice and littermates 
at ZT 5 and observed changes in sleep-wake. The three compounds acting via Gq/11-coupled 
receptors, GSK-5, LSN2814617 and taltirelin, produced prolonged wake in both TASK-3 KO 
and littermate mice when administered during the inactive period. These data suggest that 
TASK-3 is dispensible for the mechanism of action of these wake-promoting compounds. 
Meanwhile, doses of 30 mg/ kg and 100 mg/ kg TASK-3 antagonist C23 were unable to 
promote significantly more wake than vehicle injection in TASK-3 KO mice, supporting 
previous reports of C23 acting via TASK-3 [5] (Fig. 5.4 and 5.5). At the higher dose of 100 
mg/ kg C23, a trend towards increased wakefulness was seen in TASK-3 KO mice, which 
suggests C23 may recruit other wake-promoting targets at higher doses. This is most likely 
the other TASK channel TASK-1 for which C23 has 10-fold lower affinity relative to TASK-
3 [5]. In Chapter 4, I showed that a dose of 100 mg/ kg C23 also produces significant 
hypothermia of approximately -2°C in littermate animals (p<0.001, Fig. 4.4) while vehicle 
treatment did not substantially affect temperature. However, in TASK-3 KO mice both vehicle 
and C23 induced equivalent hypothermia. It is striking that the wake-promoting qualities of 
C23 are dissociated from the temperature effects. After vehicle dosing both TASK-3 KO mice 
and littermates experienced equivalent wake but TASK-3 KO mice were also hypothermic. 
Meanwhile, after C23 dosing both TASK-3 KO mice and littermates experienced hypothermia 
but only littermates had increased wakefulness relative to vehicle (Fig. 5.5).  
  
  
120 
 
 
Figure 5.4. The wake-promoting effects of all test compounds were not dependent on 
TASK-3. TASK-3 antagonist ‘C23’ was used a positive control. 
Percentage time spent in wake over 24 hours (drug injected at five hours) and amount of 
wake (minutes) occurring in seven hours post-treatment. 3 mg/ kg LSN2814617 (TASK-3 
vehicle (black) n=12, TASK-3 KO drug (red) n=12, Littermate vehicle (grey) n=11, 
Littermate drug (blue) n=14), 10 mg/ kg GSK-5 (TASK-3 vehicle n=10, TASK-3 KO drug 
n=9, Littermate vehicle n=11, Littermate drug n=13), 3 mg/kg Taltirelin (TASK-3 vehicle 
n=11, TASK-3 KO drug n=12, Littermate vehicle n=11, Littermate drug n=11), C23 (TASK-
3 vehicle n=12, TASK-3 KO drug n=12, Littermate vehicle n=10, Littermate drug n=11) 
Errors shown are standard errors of the mean. Two-way ANOVA (non-matched controls) 
with Sidak test to correct for multiple comparisons (***=p<0.001, ****=p<0.0001). 
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Figure 5.5. TASK-3 antagonist C23 promotes wake in littermates but its effects are 
significantly diminished in TASK-3 KO mice 
Percentage time spent in wake over 24 hours (drug injected at five hours) and amount of 
wake (minutes) occurring in seven hours post-treatment. Overlapping cohorts were used for 
the two studies. 30 mg/kg C23 (TASK-3 vehicle (black) n=12, TASK-3 KO drug (red) n=12, 
Littermate vehicle (grey) n=10, Littermate drug (blue) n=11), 100 mg/ kg C23 (TASK-3 
vehicle (black) n=7, TASK-3 KO drug (red) n=8, Littermate vehicle (grey) n=13, Littermate 
drug (blue) n=12). Errors shown are standard errors of the mean. Two-way ANOVA (non-
matched controls) with Sidak test to correct for multiple comparisons (***=p<0.001, 
****=p<0.0001). 
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GSK-5 and LSN2814617 have both reversed learning deficit in rodent models and been 
proposed as candidates to treat cognitive deficit in schizophrenia [294, 297]. The information 
processing disturbances seen in schizophrenia have been attributed in part to dysfunction in 
gamma range (30-90 Hz) activity [302, 303]. When we gave these drugs to wild-type 
littermate animals, we found a robust increase in gamma range (30-80 Hz) activity for seven 
hours post-treatment, particularly for LSN2814617 (mean ± SD increase in EEG density 
16.5% ± 2.3). However, in TASK-3 KO animals this increase from baseline EEG power 
density was substantially diminished for 30-50 and 50-80 Hz activity when given 
LSN2814617 (p<0.05 and p<0.0001 respectively) and for 50-80 Hz activity when given 
GSK-5 (p<0.01). I speculate that the cognitive-enhancing properties of these drugs may 
require TASK-3. I did not observe a learning deficit in TASK-3 KO mice (discussed later) so 
would need to experimentally induce learning deficit to test this hypothesis, e.g. by centrally 
administering the amnesic drug scopolamine [304]. 
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Figure 5.6. TASK-3 KO mice have diminished gamma range (50-80 Hz) EEG response to 
wake-promoting compounds 
Average change from baseline within frequency range (percentage power density) occurring 
in seven hours post-treatment. Overlapping cohorts were used for the various drug studies. 3 
mg/ kg LSN2814617 (TASK-3 KO drug n=7, Littermate drug n=8), 10 mg/ kg GSK-5 (TASK-
3 KO drug n=5, Littermate drug n=14). Errors shown are standard errors of the mean. Two-
way ANOVA (non-matched controls) with Sidak test to correct for multiple comparisons 
(***=p<0.001, ****=p<0.0001). 
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TASK-3 KO animals have normal alternation behaviour and hippocampal theta activity 
Rodents such as rats and mice display an innate preference for alternating between goal arms 
on a T-maze task [305]. Previous reports showed that this behaviour is impaired in TASK-3 
KO animals [7, 257]. We tested our animals in an automated delayed alternation task with an 
inter-trial delay time of 10 seconds, using the same protocol as Shoji et al., 2012 [306]. This 
slightly differed from the spontaneous alternation tasks previously performed on these 
animals in that in this paradigm i) the experimenter did not handle the animal during the test, 
ii) the delay between trials introduced an additional challenge to working memory and iii) the 
trials were rewarded with sucrose pellets. The tests were conducted during the light (inactive) 
phase during which the TASK-3 KO animals were least different in wake activity to controls. 
We found a trend towards increased number of trial runs during training which has been 
previously reported for these animals [7, 257]. Unexpectedly, these animals performed better 
than littermate controls on the delayed alternation task (Fig. 5.7, p<0.05 in unpaired t-test) 
and both animal cohorts performed far above 50% chance level. An explanation for the 
difference between reported behaviour could be that in this study any pre-existing deficit in 
alternation was remedied by reinforcing alternation behaviour with sucrose pellet rewards 
during training. Nevertheless, to perform above chance level on the task, TASK-3 KO and 
littermates would require intact working spatial memory and this appeared unimpaired. 
While performing trials on the delayed alternation task, hippocampal local field potentials 
(LFP) were recorded from mice via a wireless headstage. The frequency composition and 
amplitude of neuronal activity was computed by Fast Fourier Transform and the resulting 
power spectra plotted normalised to area under the curve of average power spectra for 
littermates during baseline. We compared TASK-3 KO and littermate animal average power 
spectra (frequency composition and amplitude) over the whole time on the maze and 
compared to LFP signals during a baseline task (mice were placed in an empty cage for 10 
minutes). Whole time analysis showed very similar, theta (7-12 Hz) dominated activity in 
both TASK-3 KO and littermate animals (Fig. 5.7.). There was a slight rightward shift in peak 
theta power in TASK-3 KO mice on the maze (mean ± SD peak frequency (Hz) TASK-3 KO 
8.8 ± 0.4, Littermate 8.4 ± 0.5, n=4 and 4). This is most likely due to increased running speed 
on the maze which is known to linearly increase peak theta [307, 308]. I didn’t measure 
running speed directly but infer this from shorter latency to complete the task (mean ± SD 
seconds to complete task TASK-3 KO 2728 ± 526 Littermates 3186 ± 576).  
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We then looked at hippocampal LFP signals with a finer time resolution; power spectra were 
calculated over two-second LFP data segments. Segments of data were pooled by whether 
they corresponded to time at the start, choice point, reward point and return arm and 
subdivided into ‘forced’ and ‘choice’ runs on the maze. An average trace for every point on 
the maze was calculated over all trials for every individual animal. At all points on the maze, 
there was a slight but non-significant trend towards reduced hippocampal power in TASK-3 
KO animals (Fig 5.8, Two-way ANOVA with Sidak’s post-test for AUC in the power 
between 5 and 12 Hz found no significant difference between TASK-3 KO mice and 
littermates). When returning to the start point, TASK-3 KO mice showed a stronger trend 
towards lower hippocampal power which may have been significant with a larger 
experimental cohort (Fig. 5.8). Overall, hippocampal power did not appear substantially 
reduced on the maze task and certainly was sufficient for spatial memory. The slight 
reduction in hippocampal power on salient portions of the maze, particularly the choice point, 
requires further study as natural variation in LFP power may obscure a subtle difference.  
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Figure 5.7. TASK-3 KO mice better than controls on delayed alternation task  
A. Animals were trained to run on the delayed alternation maze for three days and number of 
trials completed in an hour was recorded. During the training, animals were not required to 
make a choice and were forced to alternate. Each alternation was rewarded with a sucrose 
pellet (TASK-3 KO n=7, Littermate n=8). B. All animals that ran in excess of 10 trials/ hour 
were tested on the delayed alternation task. In the delayed alternation task, the first trial 
forced the animal in one direction, rewarded this with a sucrose pellet and allowed it to 
return to the start point. The animal was then allowed to make a choice of arm in a second 
run and where only the alternate (“sugar reward”) arm was baited with a sucrose pellet. 
Both TASK-3 KO and littermate controls displayed a preference for alternation (TASK-3 KO 
n=7 Littermate n=4). TASK-3 KO mice performed significantly better on the task than 
controls (Student’s t-test p<0.05). C & D. The frequency composition and amplitude 
composition of hippocampal LFP was calculated by Fast Fourier Transform (TASK-3 KO 
n=4, Littermate n=4) both before the task (in an empty cage) and during time on the delayed 
alternation task. 
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Figure 5.8. TASK-3 KO mice have diminished hippocampal theta during delayed 
alternation task 
The frequency composition of hippocampal LFP at four positions on the maze (start, choice 
point, pellet distribution point (whether or not they received reward) and return arm) was 
calculated by Fast Fourier Transform (TASK-3 KO n=4, Littermate n=4). Average power 
spectra were calculated over all trials for every position on the maze (time signatures for 
position on maze recorded by infra-red beam breaks) for every animal and the mean and 
standard errors of mean plotted for TASK-3 KO (pink) and littermates (grey). LFP power 
normalised to mean AUC littermate at the start of forced task, i.e. beginning of the trial.     
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Discussion 
TASK-3 channels have widespread expression in the CNS and TASK-3 KO mouse studies 
have revealed a role for these channels in wakefulness, memory, sensation and halothane 
anaesthesia (see Chapter 3). We tested the hypothesis that wake-promoting compounds that 
act via Gq/11-coupled receptors require TASK-3 inhibition to induce wake. EEG and EMG 
signals were recorded from TASK-3 KO mice and wild-type littermates in long-term 
undisturbed home cage studies. In addition, hippocampal LFP was recorded from a separate 
cohort of TASK-3 KO mice and littermates, while they ran on a delayed alternation task. 
During baseline sleep-wake, TASK-3 KO mice had significantly increased wake compared to 
wild-types, which was particularly prominent in the dark period.  
In contrast to this increase in wakefulness, EEG power was diminished across sleep-wake 
states. Also contrary to expectation [7, 257], TASK-3 KO mice demonstrated normal working 
memory on a delayed alternation task.  Three wake-promoting compounds that act via Gq/11-
coupled receptors (GSK-5, LSN2814617 and taltirelin) had equivalent wake-promoting 
effects on TASK-3 KO mice and wild-types, suggesting that TASK-3 is dispensible for their 
mechanism of action. In wild-type animals we found that GSK-5 and LSN2814617 increased 
gamma range (50-80 Hz) EEG activity, an effect associated with their cognitive enhancing 
properties [294, 297]. This increase in gamma range activity was significantly attenuated in 
TASK-3 KO animals. TASK-3 KO mice did not exhibit the anticipated memory deficit so we 
were unable to test whether GSK-5 and LSN2814617 were able to rescue learning deficit in 
animals lacking TASK-3.  
TASK-3 KO mice have elevated wake and diminished NREM 
A number of independent groups have found that TASK-3 KO mice have elevated wake [5, 7, 
257, 258] but our group controversially found  TASK-3 KO wake elevation in the light period 
[258], while others reported it was elevated in the dark period [5, 7, 257]. These studies used 
different protocols; our previous study recorded mice for 24 hours using a wireless headstage, 
an earlier study inferred waking and sleeping states from locomotor activity [7] and two 
further studies continuously recorded EEG and EMG from singly housed animals [5, 257]. In 
addition, three of four studies used C57bl6 mice as controls and the differing genetic 
background of these animals [204, 205] may have obscured the TASK-3 KO mouse 
phenotype. In this study, we used wild-type littermates, with the same genetic background as 
TASK-3 KO mice, as comparators and tested both genotypes in a 24-hour recording and a 
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long-term continuous recording paradigm. During 24 hour recording of sleep-wake, we found 
a wake elevation in TASK-3 KO mice at the beginning of the light period. This brief elevation 
was also seen at the beginning of the light period in long-term recordings, both findings 
confirming our group’s previous reports [258]. However, when continuously monitored, 
TASK-3 KO mice showed substantial elevation in wake throughout the dark ‘active’ period 
(wake was also significantly elevated in the light period). I speculate that the increased 
wakefulness at the beginning of the light period that we see when TASK-3 KO mice are 
recorded for 24 hours reflects their increased exploration activity after novelty [7, 257] and 
reduced stress after handling (discussed in Chapter 4) rather than a persistent sleep 
phenotype. Meanwhile, continuous study revealed that, if undisturbed, TASK-3 KO mice 
display significantly higher wake (at the expense of NREM) over the whole sleep-wake cycle 
compared to wild-types. This phenotype either reflects elevated baseline levels of arousal or a 
diminished sensitivity to long-term restraint. Brief restraint and tethering has increased 
subsequent sleep in some but not all rodent studies [309, 310] so it is possible that the stress-
resistant TASK-3 KO mice do not have elevated wake per se but instead the controls have 
diminished wake due to the stress of chronic tethering for EEG and EMG recording. This 
explanation requires study of stress hormone levels both before and after tethering in TASK-3 
KO mice and their littermates. Given that TASK-3 KO mice are repeatedly observed to have 
higher locomotion in behavioural tasks (including this study), it seems most plausible that 
these animals have an elevation in wake activity related to a change in excitability of arousal 
networks.  
Wake-promoting compounds that act via Gq/11-coupled receptors do not require TASK-
3 
We compared the wake-promoting effects of GSK-5 [297], LSN2814617 [294] taltirelin 
[298], and the TASK-3 antagonist ‘C23’ [5] by administering them to TASK-3 KO mice and 
wild-type animals five hours after lights on. GSK-5, LSN2814617 and taltirelin are all known 
to act through Gq/11-coupled receptors [294-297]. We posited that downstream inhibition of 
TASK-3 was necessary for these compounds to induce wake-based on the wake-promoting 
effects of TASK-3 antagonist C23 [5] and the elevated wake activity of TASK-3 KO mice. All 
four compounds produced significant elevations in wake in wild-type animals. TASK-3 KO 
animals were insensitive to the effects of C23, supporting previous reports [5] but were 
comparable to wild-types in their wake response to the remaining compounds. The wake 
experienced by TASK-3 KO mice post-drug was identical to controls but the accompanying 
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increase in gamma-range (50-80 Hz) EEG activity after GSK-5 and LSN2814617 was 
significantly diminished. These compounds have ‘cognitive-enhancing’ properties in that 
they rescue experimentally-induced learning deficits in mice [294, 297] and gamma-range 
EEG activity has been associated with enhanced cognitive processing [303]. The diminished 
EEG gamma response to GSK-5 and LSN2814617 predicts that these compounds may not 
rescue learning deficit if it were induced TASK-3 KO mice. Together, our findings show that 
while TASK-3 inhibition can produce wake, TASK-3 receptors are dispensible for the 
mechanism of action of GSK-5, LSN2814617 and taltirelin. 
TASK-3 KO mice have normal working memory but diminished EEG power 
 EEG power was reduced across a range of frequency bands in TASK-3 KO wake and NREM 
states. The reduction did not seem restricted to any particular frequency band, e.g. delta (0-4 
Hz), theta (6-10 Hz) which made it possible to sleep-score the animals. This general power 
reduction is in contrast to the specific disruption of halothane-induced atropine-sensitive theta 
activity and fragmented REM theta previously seen in these animals [258]. Such a phenotype 
is difficult to interpret. Brain oscillatory rhythms, such as delta and theta, appear to be 
generated by distinct microcircuits [303, 311] yet were impaired to the same degree by 
developmental removal of TASK-3. One alternative explanation is that change in skull 
morphology or subarachnoid space affects recording EEG from TASK-3 KO mice; the power 
changes seen in their cortical EEG would then reflect diminished electrode sensitivity. This 
seems unlikely. We instrumented TASK-3 KO mice with two different EEG screws for our 24 
hour and long-term study comparisons and histology often revealed small neocortical lesions 
at the electrode placement sites. Electrode placement could not account for the two-fold EEG 
power difference seen in the 24 hour study. Mouse EEG power is known to vary with genetic 
background [205] but to my knowledge, the genetic loci responsible for this difference have 
not been mapped. Our data suggest that K2P channel expression differences between mouse 
strains may result in differences in EEG power that can still support normal CNS function. 
Despite reduction in cortical power, TASK-3 KO mice performed normally on our test of 
working memory and had relatively normal hippocampal activity. Hippocampal theta 
activity, locomotion and spatial learning are considered to be closely related; the peak 
frequency of theta increases with running speed [307, 308] and increased theta power is 
associated with higher running speed and spatial decision-making [308, 312, 313]. TASK-3 
KO mice ran more trials than controls and performed consistently above chance-level on the 
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delayed alternation task yet their theta power was no higher than controls. Our study could 
not detect major differences in hippocampal theta power in TASK-3 KO mice running the 
maze, although a modest reduction was seen on the returning arms of the maze (Fig. 5.8). 
Conclusions and Future Directions 
TASK-3 channels and their roles in mouse physiology are an oddity. On one hand, TASK-3 
channels are clearly involved in arousal; their pharmacological inhibition promotes wake, 
they are downstream of wake-associated Gq/11-receptors and TASK-3 KO mice have markedly 
elevated arousal. However this increased wakefulness is not entirely normal. In Chapter 4, I 
discussed in detail that TASK-3 antagonism by C23 promotes wake but also promotes 
hypothermia, most likely via activity of central TASK-3 receptors in temperature regulatory 
regions. This suggests that TASK-3 activity in distinct brain regions is tightly controlled in 
vivo as hypothermia is not a desirable accompaniment for arousal. In TASK-3 KO animals, 
temperature oscillatory activity seems normal if not challenged by a hypothermic stimulus 
but the increased wakefulness is accompanied by a dampening of cortical EEG power. It is 
perhaps fortunate that none of the Gq/11-coupled wake-promoting compounds tested in this 
study require TASK-3 for their mechanism of action.  
However, in this study, no detrimental consequences of EEG power reduction were detected 
in TASK-3 KO mice. The delayed alternation task tests a number of mouse faculties including 
spatial memory, working memory, gait and motivation to run. These were all unaffected by 
TASK-3 absence, in fact, TASK-3 KO mice performed marginally better than wild-type 
littermates. This is contrary to previous studies which showed cognitive deficit in TASK-3 KO 
mice [7, 257]. It seems that TASK-3 KO mice are highly sensitive to protocol. We found this 
when directly comparing a 24 hour wireless recording in the home cage with a long-term 
undisturbed tethered sleep paradigm. TASK-3 KO mice only revealed their elevated nocturnal 
arousal if recorded over a long period. The same may be true of cognitive deficit. The lack of 
gamma EEG response to two cognitive-enhancing compounds suggests that TASK-3 KO 
mouse cognition may be altered but was not directly detected in this study.  
While this study has reconciled previously opposed reports of TASK-3 KO sleep phenotypes, 
the question of whether TASK-3 KO animals experience cognitive deficit remains open. In 
future study, the role of TASK-3 in learning could be investigated by inducing a learning 
deficit in TASK-3 KO mice, e.g. by scopolamine administration [304], and investigating 
whether LSN2814617 and GSK-5 are able to return learning ability.  In humans, expression 
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of a mutated form of TASK-3 in development produces Birk-Barel syndrome, which is 
characterized, in part, by learning difficulties [279]. But TASK-3 could have distinct roles in 
development and in adult cognition. Expression of this channel changes over development 
[241]. Its importance in normal brain development [281] does not mean that it is necessary 
for cognitive processes in the adult brain. What is clear is how important TASK-3 channels 
are in normal physiological arousal. Given the concurrent role of these channels in 
temperature regulation (see Chapter 4) it is likely that activity of these channels is tightly 
controlled and so we cannot yet speculate which neuronal populations are affected by TASK-
3 deletion such that arousal in heightened. Much remains to be studied in these corpulent, 
resilient and motivated little mammals.  
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Materials and Methods 
Animal surgery for sleep-wake recording and hippocampal local field potential 
recording 
All animal procedures were performed in accordance with Imperial College London and Lilly 
UK animal care committees’ regulations. The development of TASK-3 KO mice (in which the 
first exon was disrupted) and their littermates (129sv/C57BL6 genetic background) has been 
described previously [236]. Male mice were genotyped by PCR using genomic DNA with the 
following primers (Primer 1: 5’-TCTGTCCCGCTACCGATCCTGC-3’, Primer 2: 5’-
TTCCGTGGGCGCAGCGGGTTCCGC-3’) – KO animals were identified by a 400-bp 
product; littermates showed a 350-bp product. Both before and after surgery, animals were 
housed in solid-bottomed cages with sawdust bedding and environment enrichment. Food and 
water were available ad libitum with temperature and humidity maintained at 21 ± 2°C and 
55 ± 10% respectively and lighting on a 12:12 hour light-dark cycle. 
For sleep-wake recordings, 2-3 month-old male mice were instrumented with a cranial 
implant connected to five stainless steel cranial screws (for EEG recording) and two Teflon-
coated stainless steel wires under the nuchal trapezial muscles (for EMG recording). A 
miniature telemeter (Minimitter, USA) to monitor body temperature and locomotor activity 
was implanted in the abdominal cavity (surgery detailed in Supplementary Methods). For 
hippocampal tetrode recordings, the skull was exposed at -1.9 mm AP, - 1.2 mm ML from 
Bregma and a 2 mm long array of eight tetrode electrodes inserted into the region. Two 
cerebellar cranial screws served as reference and ground electrodes and the whole implant 
was tightly secured using dental cement and additional anchoring cranial screws (surgery 
detailed in Supplementary Methods). Following surgery, animals were given a rehydration 
pack in addition to their dry diet and housed individually. Animals were allowed at least 21 
days to recover from surgery before being used for any subsequent procedures and monitored 
daily for signs of ill health for the remainder of their lives. 
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Delayed Alternation T-Maze 
The tetrode-implanted mice were trained to perform a delayed alternation task on a modified 
T maze whilst wearing a wireless headstage (Plexon, USA). Signals were recorded at 2 kHz/ 
channel sampling rate via a Digital Lynx recording system (Neuralynx, Bozeman, MT). In 
this task, each trial involved the mouse being forced to turn either left or right (at random) on 
the maze, returning the start point, being retained at the start point for 10 seconds and then 
allowed to choose where they turn on the maze. The first run was always rewarded with a 
sugar pellet whereas the second “choice” run was only rewarded if the mouse alternated. 
Before testing, the mice were trained to run the maze for four days without any choice 
decisions. In order to motivate the animals to run the maze, their food intake was restricted. 
Mice were fed approximately 10% of their body weight in dry food once a day until the end 
of the maze experiments when they were returned to their ad libitum diet. Water was 
available freely throughout and slightly more food was given on days that animals were not 
receiving sugar pellet rewards. Their body weight was monitored daily; most animals lost 
approximately 7.5% of their weight during the food restriction period which was considered 
normal. None exceeded a weight loss of 10% of original body weight. The movements of the 
mice through the maze were monitored using infrared beam crossings within the maze and 
also recorded on video. A similar protocol is visually documented by Shoji et al., 2012 [306]. 
To establish baseline LFP hippocampal activity, mice were recorded exploring an empty cage 
for 10 minutes. 
Drug Dosing 
The TASK-3 antagonist 1-[1-[6-[[1,1'-Biphenyl]-4-ylcarbonyl)-5,6,7,8-tetrahydropyrido[4,3-
d]pyrimidin-4-yl]-4-piperidinyl]-1-butanone (C23) was developed by Coburn et al., 2011 and 
synthesized at Eli Lilly. All drug or vehicle solutions were was prepared on the day of each 
experiment and dosed in a volume of 10 ml/ kg. Animals received a dose of drug or vehicle 
on alternate weeks in a random crossover zeitgeber (ZT) 5 and 5.2 hours post light onset. The 
following were dissolved in their respective vehicle and the pH adjusted to between 6-7.5; 
LSN 2814617, 3 mg/kg in 1% carboxymethylcellulose dosed orally (PO), GSK-5, 10 mg/kg 
in 0.25% methylcellulose, dosed intraperitoneally (IP), C23, 100 and 30 mg/kg in 20% 
modified cyclodextrin (Captisol
TM
), dosed subcutaneously (SC) and Taltirelin, 3 mg/kg in 
0.9% saline, dosed IP.  
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Data analysis for sleep-wake recording 
Once recovered, mice were housed individually in recording chambers and data collected for 
62 hours every week. Disturbance of the animals was restricted as much as possible to ZT 5 
once a week – animals were weighed and their bedding, food and water refreshed in addition 
to receiving drug, vehicle or no treatment (no drug or vehicle treatment referred to as 
‘Handling’). Sleep-wake parameters, locomotion and temperature were monitored using 
SCORE-2004, an updated version of a real-time sleep-wake monitoring system [292]. Data 
were reported as mean ± S.E.M. Two-way ANOVA with Sidak's post-test to correct for 
multiple comparisons was performed using GraphPad Prism version 6.04 for Windows 
(GraphPad Software, La Jolla California USA, www.graphpad.com).  
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Data Analysis for hippocampal tetrode 
 
Figure 5.9. Choice of LFP channel by theta reversal 
Left: Raw signal of eight tetrode channels (channel 7 was inactive) which represent 
hippocampal signal referenced to cerebellar activity. Raw amplitude was higher in more 
superficial channels. Signals were digitally down-sampled to 1250 samples/ second and 
processed through a Hamming window-based FIR filter (filter order 200, 4-12 Hz) based on 
script for detection of hippocampal theta events published by Buzsaki et al., 2003[314]. Black 
arrow indicates channel at which theta phase reversed relative to most superficial layer. The 
reversal ‘CA1’ channel was used for time frequency analysis. Right: Representative histology 
of hippocampal slice, red arrows indicate lesion site. Schematic showing the 2 mm tetrode 
array spanning parietal association cortex (PtA) region CA1 and the dentate gyrus (DG).  
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Correct tetrode placement in the hippocampus was first confirmed by histology. Mice were 
given a terminal overdose of pentobarbital sodium anaesthetic (Euthatal
TM
) by IP injection 
and monitored for loss of surgical reflexes. Once paw withdrawal and righting reflexes were 
lost, a small current was passed through four of the tetrode sites to create a series of small 
lesions at the placement site. The brain was removed and fixed in formalin overnight before 
being transferred into 30% w/v sucrose and stored at 4°C until slicing. Brains were sliced 30 
μm thick in a cryostat and mounted onto adhesive slides before taking bright field images of 
unstained tissue. Placement site was identified as slices with the largest volume of tetrode 
lesion visible. Animals with incorrect placement were excluded from analysis.  
For hippocampal LFP, I used the depth channel I believed was recording from CA1. Theta 
phase in the hippocampus gradually shifts according to depth and reverses around the border 
of CA1 and subiculum [315, 316].  I identified the depth channel where theta reversed (see 
Fig. 5.8) and used this for subsequent power spectra analysis. Two-second hippocampal LFP 
data were selected for every position of the mouse on the maze, i.e. start, choice point, pellet 
distribution point (whether or not they received reward) and return arm. Fast Fourier 
Transforms for every time window were performed in MATLAB r2015a (MathWorks, USA) 
and then averaged to produce a mean power spectrum of the LFP of each mouse at every 
position on the maze subdivided into chosen and forced trials. All data were plotted 
using GraphPad Prism version 6.04 for Windows (GraphPad Software, La Jolla California 
USA, www.graphpad.com).  
  
138 
 
Concluding Remarks 
Throughout this thesis, I studied mouse sleep, wake and anaesthesia in both their 
natural and drug-induced forms. My first question was whether a noradrenergic arousal 
nucleus in the mouse pons, the LC, was necessary for sleep architecture, behaviour or 
dexmedetomidine anaesthesia and what its acute activation contributed to wakefulness. The 
LC is a key component of the ascending arousal network, which in Saper’s “flip-flop” sleep 
model maintains wakefulness and inhibits sleep. It is also directly inhibited by the anaesthetic 
dexmedetomidine and for many years it was assumed that LC silencing was the primary 
mechanism of action for this drug. As such it constituted an attractive common neural 
component that could be inhibited in both sleep and anaesthesia.  
Chronic silencing of the LC increased REM sleep but had little effect on other aspects 
of sleep and behaviour and had no effect on dexmedetomidine anaesthesia. Silencing the LC 
also paradoxically delayed sleep after sleep deprivation where I expected the opposite but the 
relatively small delay suggests that the LC has a minor rather than instrumental role in sleep 
drive. The LC’s role in REM however may link the early degeneration of this nucleus in 
Parkinson’s disorder and the co-morbidity of REM sleep disorders in patients with 
Parkinson’s.  Unexpectedly, activation of the LC acutely via designer drug receptors induced 
behavioural arrest during wake, which appeared to be related to inhibition of voluntary 
movement rather than loss of muscle tone associated with cataplexy or anaesthesia. This 
highlights a novel role for the LC in regulating voluntary movement during wakefulness in 
addition to its proposed role in sustaining muscle tone. It should be noted that voluntary 
spontaneous locomotion in an open field was normal in LC-silenced animals so the process 
by which LC activation or over-activation causes behavioural arrest remains to be studied.  
Secondly, I studied drug-induced wake in TASK-3 knockout and wild-type mice in 
order to dissect the role of this potassium channel in mediating wakefulness. TASK-3 is 
expressed in several arousal nuclei, including the LC, and also in the thalamus, which plays a 
role in switching between arousal states. TASK-3 knockout animals are less sensitive to 
certain anaesthetics and it is controversial whether TASK-3 opening promotes anaesthesia 
because it inhibits arousal nuclei or hyperpolarises the thalamus which results in a switch to 
burst firing and dissociation of the cortex from sensory inputs. While I confirmed that TASK-
3 knockout mice have elevated wakefulness and that antagonism of TASK-3 produces 
prolonged wake, other wake-promoting compounds were still effective in the absence of 
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TASK-3. This suggests that TASK-3 is not a necessary common target for drug-induced 
wake promotion. It is not unconceivable that TASK-3 antagonism promotes wakefulness by 
stimulating arousal nuclei or depolarising thalamic nuclei to promote high frequency tonic 
firing. Targeted knockdown of TASK-3 channels in individual regions will reveal which is 
the case and whether the same region is targeted by anaesthetics and the TASK-3 antagonist 
C23.  
Finally, accidentally, we noticed that TASK-3 knockout mice exhibited blunted 
stress-induced hyperthermia after handling revealing a role for TASK-3 in stress or its 
downstream effects on heat generation. In addition, we found a robust unreported 
hypothermic effect for C23 which suggests that central TASK-3 receptors are directly 
involved in thermoregulation. TASK-3 antagonism results in hypothermia during wake which 
starkly contrasts with the hypothermia observed during sleep and anaesthesia. The dissection 
of hypothermia mechanisms from sleep and anaesthesia is unusual and further localisation of 
the TASK-3 positive neurons that drive this process may be informative. 
 Studying sleep, anaesthesia and wakefulness in the same mouse models has been a 
productive experimental design; when manipulation affected one state but not the other, such 
as in the LC study, direct comparisons could be made. Meanwhile, monitoring temperature as 
well as EEG and EMG revealed an unexpected role for TASK-3 in thermoregulation as well 
as wakefulness. Both studies revealed the functional redundancy in sleep and anaesthesia 
mechanisms; mice can live, sleep, wake and be anaesthetised both with a silenced LC and 
without TASK-3 channels. But each revealed specialised functions in the giant neural jigsaw 
puzzle; the LC has a role in REM sleep generation and movement while TASK-3 is important 
in sleep, anaesthesia and thermoregulation. Finally, study of both revealed the limits of EEG 
in sleep and anaesthesia research; stimulation of the LC sustains wake but mice are frozen 
still while stimulation of TASK-3 promotes wake but mice are frozen cold. Both classify as 
wake but are not desirable. This, above all, reveals how finely balanced the neural orchestras 
behind restful sleep and productive wake are and how blunt our tools still are in trying to 
induce either state artificially.  
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Supplementary Methods 
Use of animals in research – the 3Rs  
Replacement 
The animal work undertaken for this thesis adhered to ethical review which justified the use 
of animals for this line of research but also took steps to implement the 3Rs: replacement, 
reduction and refinement (outlined by the National Centre for Replacement, Refinement and 
Reduction of Animals in Research). The physiological processes studied here – sleep, 
arousal, anaesthesia, and thermoregulation – are undoubtedly orchestrated by multiple organs 
and physiological systems (complex CNS signaling pathways, cardiovascular and lymph 
circulation of drugs and endogenous signaling molecules, locomotor (skeletomuscular) 
processes to effect behaviour and reflexes and others). As a result, replacement of animal 
work with mathematical modelling, cell line experiments or non-protected invertebrates such 
as worms was not considered appropriate as none of these can model consciousness and 
unconsciousness as we understand them in humans and other mammals. The two projects 
sought to understand the role of a specific brain region and specific channel by genetic 
manipulation – the reasons we could not do this on human volunteers instead of mice are 
twofold. Firstly and obviously, it would be grossly unethical to manipulate local and global 
gene expression in volunteers, especially given their hypothesized importance in sleep and 
arousal. Hypothetically, we could instead study humans with natural LC lesions or TASK-3 
deletions. The former cohort was not available to us for study (and would almost certainly not 
have a lesion anatomically restricted to the LC) and the latter does not appear to occur 
naturally in the population; Birk-Barel syndrome patients have a mutation as opposed to 
deletion of TASK-3 [280]. 
Reduction 
Our focus was therefore on reduction of animals used and refinement of the protocols where 
possible. Both studies aimed to use appropriate animal number by instrumenting each cohort 
and studying sleep, drug sensitivity, thermoregulation (in the TASK-3 project only), 
behaviour and histology of every animal with sufficient time gaps between any regulated 
procedures to allow animals to recover. Almost all animals used for electrophysiology by Dr. 
Catriona Houston were also used for behavioral, drug and sleep studies. The TASK-3 study 
required the use of littermates to determine effects of the gene while the LC-TeLC required 
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control-injected animals to determine the background phenotype. The injection and 
exogenous expression of GFP could affect LC function and the genetic background strain 
used for this study was a mix of several pure mouse strains so we felt it insufficient to 
compare our LC-TeLC mice to literature reports or previous lab data of EEG-instrumented 
C57bl6 mouse behaviour and sleep. However, given we had data for LC-GFP mice; we did 
not feel it ethically appropriate to create a control cohort for LC-hM3Dq mice. Instead we 
used the hM3Dq-LC mice as their own controls in saline-drug crossover studies.  
Refinement 
Protocols were refined to minimize animal suffering and maximize use for the data generated. 
Firstly, we aimed to use established protocols already published in the literature so that our 
data could be compared to or even pooled with existing data in the future. This included 
anaesthetic end-points such as sedation being measured as reduced locomotion or LORR in a 
rotating tube, behavioral tests and scoring of EEG/EMG into sleep stages. Secondly, we 
aimed to minimize animal suffering by providing adequate anaesthesia and analgesia during 
surgery, attentive post-operative and post-treatment care and habituation to all behavioral and 
sleep experiments that did not require novelty (such as novel object recognition); exposing 
animals to EEG tether or neurologger, to handling by the experimenter and to experimental 
rooms and arenas. We found this practice not only helpful for minimizing animal suffering 
but also feel it improved baseline animal behaviour providing a clearer comparator for 
experimentally manipulated cohorts. 
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General surgical protocol 
All the surgeries detailed here used similar pre-operative and post-operative care. Mice were 
two-three months old at the time of surgery and exceeded lower weight limits specified 
below. Before surgery, the surgical areas, i.e. abdomen and top of head, were shaved, corneal 
protectant (Lacrilube
TM
) was applied to the eyes and the animal transferred to the surgical 
area. Before attaching to the stereotaxic apparatus, the animal’s tongue was moved to one 
side using a Q tip to avoid obstruction of the airway. Once attached to anaesthetic apparatus, 
the surgical region was cleaned either with chlorhexidine (Hibiscrub
TM
) and 70% ethanol 
(Chapters 4 and 5) or with iodine (Chapter 2). Mouse anaesthesia was maintained at 
approx. 1.5% isoflurane and mouse body temperature maintained via a 36°C heat blanket. 
For EEG/LFP surgery, blunt ear bars were inserted to stabilise the skull, the skull exposed 
and cleaned as follows. An incision was made on the scalp from the midpoint between the 
eyes to the midpoint between the ears. To avoid cutting the muscle layer behind the ears, 
when lengthening the cut, the skin closer to the neck was pulled towards the scalpel. The 
perioestal membrane was pushed off the skull and the surface scrubbed carefully using a Q-
tip dipped in 3% v/v hydrogen peroxide and then wiped with a Q-tip soaked in sterile 0.9 % 
saline. The skull was blotted dry with a piece of gauze and the process repeated two more 
times, taking care to avoid contact between the peroxide and any tissue surrounding the skull. 
EEG placement was marked out using digital brain atlas for work done in Chapter 2 and 
calipers for Chapters 4 and 5. Both methods used the skull anatomical landmarks Bregma 
and Lambda for reference. After surgery, animals were kept in the sterile area with oxygen 
and the heat blanket on until they began to wake up and then transferred to a heated recovery 
box (24-26°C). 
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Viral injection and EEG surgery (Chapter 2) 
Male Gal-Cre mice, exceeding 25g, were anaesthetized with 2% isofluorane, maintained at 
1.5-2% and mounted onto a stereotaxic frame. A small region of the skull above the LC was 
exposed with a dental burr (−5.4 mm AP, ± 0.8 mm ML from Bregma, measured using digital 
brain atlas ((Angle two, Leica Microsystems)). AAV, suspended in 10% w/v mannitol, was 
carefully injected, via a 6-10 μm tip diameter pipette at a rate of 0.2 μl/ min (controlled by an 
ultra-micropump (World Precision Instruments), into three portions of the LC (three 0.5 μl 
injections at -3.6, -3.7 and -3.8 mm DV). Stainless steel screws (for EEG recordings) were 
implanted in the frontal bone (+1.5 mm AP, + 1.5 mm ML from Bregma), parietal bone (-1.5 
mm AP, -1.5 mm ML from Bregma) and occipital bone (-1 mm AP, 0 mm ML from Lambda) 
and three Teflon-coated recording electrodes placed apart beneath the nuchal muscles (for 
EMG recordings). These six recording electrodes were soldered onto a headstage which in 
turn was attached to the skull using dental cement, taking care to suture any loose skin with 
single interrupted absorbable sutures. Animals were given subcutaneous buprenorphine 
analgesic and 0.1% of antibiotic enrofloxacin (Baytril®, Bayer AG, Germany) in drinking 
water for one week. They were allowed one month recovery and their health monitored for 
the remainder of their life. 
Animal surgery for sleep-wake recordings (Chapters 4 & 5) 
Adult mice exceeding the lower weight limit of 28 g were instrumented with a cranial 
implant connected to five stainless steel cranial screws (for EEG recording) and two Teflon-
coated stainless steel wires under the nuchal trapezial muscles (for EMG recording). In 
addition, a miniature telemeter to monitor body temperature and locomotor activity was 
implanted in the abdominal cavity. Prior to surgery, mice were weighed and drug doses were 
prepared accordingly (1mg/ kg medetomidine HCl, 5 mg/ kg atipamezole, 5 mg/ kg 
carprofen, 7.5 mg / kg cefovecin, approx. 1 ml 5 % glucose / mouse). All drugs were 
formulated in sterile 5 % glucose. Mice were induced in a separate pre-operative chamber at 
approx. 2 % isoflurane (in medical oxygen), once they had lost righting reflex, injectable 
anaesthetic medetomidine was administered subcutaneously.  
Once in the surgical area, the abdominal telemeter implantation was performed first. A 2 cm 
ventral midline incision was made in the skin, cranial to umbilicus using a scalpel and the 
skin and abdominal musculature bluntly dissected 1 cm either side of the incision to facilitate 
access to the abdominal wall. The exposed abdominal muscle layer was tented up with 
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foreceps and a small incision made with a scalpel, cutting a hole along the linea alba but 
taking care not to cut the underlying viscera. Scissors were then used to extend the incision 1-
2 cm and the sterile telemeter inserted into the cavity such that the ‘bullet’ end faced towards 
the mouse’s head. The telemeter was attached to the abdominal wall from the inside using a 
single silk stitch and several finishing sutures. The muscle layer of the abdominal incision 
was closed with non-absorbable silk suture using simple interrupted sutures 3-5 mm apart to 
ensure adequate incision closure. The skin layer was closed with absorbable suture.  
The mouse was then attached to stereotaxic apparatus, the skull exposed and skull holes were 
drilled using a dental burr, 1-2 mm deep (until loss of resistance). A small quantity of 
superglue was placed on the bottom of the cranial headstage and the headstage placed just 
above Lambda so that the wire loop holes aligned with the drilled holes. The headstage was 
held in place for a few minutes with forceps to allow the glue to set. Drill holes were wiped 
with Q-tips dipped in saline to remove bone dust and each screw secured through the 
headstage wire loops and screwed ¾ way down. Whilst holding the trapezius muscle at the 
neck, tweezers were used to made two ‘tunnels’ either side of the midline and the one Teflon-
coated EMG wire guided into each so that the wire was fully secured under the muscle. Pre-
mixed acrylic was used to cover all the screws and wires on the surface of the skull and cured 
with 10-second bursts of UV light (taking care to shield the animal’s eyes from the light 
source).  Approximately 10 minutes before the end of surgery (which was roughly once 
acrylic had set), the analgesic carprofen was administered subcutaneously. A simple 
interrupted pattern of absorbable sutures was used to close the head incision around the 
protruding headstage but not all the way to the base of the implant. Vet glue was applied on 
top of the sutures to ensure adequate closure. 5% glucose and the long-acting antibiotic 
cefovecin were administered subcutaneously and isoflurane turned off. Medetomidine 
anaesthesia was reversed with a subcutaneous injection of atipamezole. Following surgery, 
animals were given a rehydration pack in addition to their dry diet and water and housed 
individually. Animals were allowed >21 days to recover from surgery before being used for 
any subsequent procedures and monitored daily for signs of ill health for the remainder of 
their life. 
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Animal surgery for local field potential recording from hippocampus (Chapter 5) 
All preoperative preparations, drug administration and dosage and postoperative care were 
identical to that described above in Animal Surgery for sleep-wake recordings, Chapter 4 
and 5. LFP animals were not implanted with a telemeter so after anaesthetic induction, mice 
were transferred straight onto the anaesthetic rig and the skull exposed and cleaned. The head 
was secured such that the skull was flat both in the anterior-posterior and medio-lateral 
directions. A needle attached to a stereotaxic arm was used to measure -1.9 mm, - 1.2 mm 
from Bregma and mark the place on the scalp with a superficial needle piercing. An 
approximately 1 mm hole was exposed in the skull using the dental burr and a surgical 
microscope to guide movement. To avoid damaging the underlying brain tissue, this exposure 
was done in a series of shallow circular drilling motions. Five additional holes were made on 
the skull for round-top screws, used to anchor the dental cement and LFP implant. The LFP 
implant was mounted on the stereotaxic arm and with the help of the microscope guided so 
that the tip of the electrode was touching the surface of the dura at -1.9, -1.2 mm from 
Bregma. The electrode was then lowered 2 mm. Bone wax was applied to cover the opening 
around the electrode and any part of the electrode still exposed. The ground and reference 
wires were wound around individual cerebellar screws and the region of wire touching the 
screws covered with conducting silver paint. The implant, wires and the screws were then 
secured to the skull with pre-mixed acrylic as described above and any loose skin sutured. 
The standard programme of post-operative care and recovery monitoring was followed. 
TASK-3 KO genotyping 
The TASK-3 KO line (129Sv/C57BL/6 background) was first introduced in 2007 [236] .  The 
TASK-3 gene was disabled by combined homologous and insertional recombination. The 
gene was successfully disabled albeit through an unintentional mechanism: four copies of 
neomycin cassette (intended as a positive selection marker for embryonic stem cell culture) 
and inverted repeats of TASK-3 exon 1 were inserted into the TASK-3 locus. The absence of 
TASK-3 transcripts in knockout animal brain was confirmed by in situ hybridisation and RT-
PCR. Levels of other K2P channel mRNA expression appeared unchanged in knockout 
cerebellum and forebrain. The knockout animals appear to breed normally and were 
maintained by crossing heterozygotes with heterozygotes on a C57BL/6 background. 
Genotype was re-confirmed using tail tips taken following animal sacrifice and kept at -20C 
until DNA extraction. DNA was extracted using a variation of the HotSHOT method [220]. 
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Briefly, the tissue was submerged in Alkaline Lysis Reagent (25 mM NaOH, 0.2 mM EDTA, 
pH 12) and heated to 95 C for 30 minutes. The solutions were allowed to cool before an equal 
volume of Neutralization Reagent (40 mM Tris-HCl, pH 5) was added to the samples and 
mixed thoroughly. A small volume of the DNA extraction was processed by PCR using 
primers flanking the 5’ loxP site (Primer 1: 5’-TCT GTC CCG CTA CCG ATC CTG C-
3’, Primer 2: 5’-TTC CGT GGG CGC AGC GGG TTC CGC-3’). In a PCR total volume 
of 25 µl; 10 µM of each primer, 1 µl DMSO, 12.5 µl 2x GoTaq Green Master mix (Promega, 
UK) was added. DNA was amplified in standard PCR conditions with 5 minutes at 95°C 
followed by 30 cycles of 1 minute at 95°C, 1 minute at 60°C and 1 minute at 72°C and a final 
extension of 5 minutes at 72°C. PCR samples were stored at 4 C until resolution on a 1.3% 
agarose gel containing 1:10000 SYBR® Safe (Invitrogen, USA) as DNA gel stain. The 
agarose gel was prepared in Tris-acetate EDTA running buffer (TAE):  40 mM Tris-acetate, 1 
mM EDTA, pH ~8.3 (we routinely prepared this as 50 x stock using 242 g L
-1
 Tris Base, 10 
% v/v 0.5 M EDTA and  57.2 ml L
-1
 glacial acetic acid). Gels were run for 1 hour at 90 V and 
bands using a Kodak DC290 camera under UV light and 535 nm WB50 emission filter. The 
wildtype fragment band was expected at 350 bp whereas in knockout animals, the additional 
presence of a neomycin cassette within the sequence resulted in a 400 bp fragment. 
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Contributors to presented data 
Several talented scientists performed experiments or analysis that I have presented here. I 
would like to fully acknowledge which work was performed by these individuals and make 
clear that I present their work with their consent and because it is vital to the discussion of the 
two projects presented here. All electrophysiology experiments on locus coeruleus brain 
slices were performed initially by Drs. Anna Zecharia and subsequently by Catriona Houston; 
the vast majority of the electrophysiology data was collected, analysed and plotted by Dr. 
Catriona Houston. My contribution to these experiments was the stereotaxic injection of 
recombinant viruses into control and experimental mice which were then used for the slice 
work. Because the electrophysiology data supports my interpretation of the tetanus toxin light 
chain effects on the locus coeruleus, I have included it in my thesis. Sleep-scoring for 
Chapter 2 was done by Dr. Valentina Ferretti and me, while for Chapters 4 and 5 was 
performed by the SCORE team at Eli Lilly headed by Dr. Wesley Seidel. I would particularly 
like to acknowledge the contribution of Andrew McCarthy and Peter Kinsley for organising 
and scoring the sleep-wake data. I have made every effort to understand the methodology 
used by the SCORE team in order to interpret the results most effectively but the time and 
great skill put into handling this data was theirs not mine. My contribution to these 
experiments was in instrumenting the knockout animals and littermates, setting them up for 
long-term sleep-wake recordings, performing the drug tests and subsequently analysing and 
plotting the data. Finally, the observation that Gal-Cre mice do not display loss of righting 
reflex to dexmedetomidine was made by Dr Valentina Ferretti and the back-crossing of the 
line with C57bl6 was majorly done by her.  
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